mdvn-10q_20160331.htm

0001564590-16-018012.txt : 20160505 0001564590-16-018012.hdr.sgml : 20160505 20160505163941 ACCESSION NUMBER: 0001564590-16-018012 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160505 DATE AS OF CHANGE: 20160505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDIVATION, INC. CENTRAL INDEX KEY: 0001011835 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133863260 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32836 FILM NUMBER: 161624482 BUSINESS ADDRESS: STREET 1: 525 MARKET STREET STREET 2: 36TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94105 BUSINESS PHONE: 415-543-3470 MAIL ADDRESS: STREET 1: 525 MARKET STREET STREET 2: 36TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94105 FORMER COMPANY: FORMER CONFORMED NAME: ORION ACQUISITION CORP II DATE OF NAME CHANGE: 19960408 10-Q 1 mdvn-10q_20160331.htm 10-Q mdvn-10q_20160331.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

COMMISSION FILE NUMBER: 001-32836

MEDIVATION, INC.

(Exact name of registrant as specified in its charter)

Delaware

13-3863260

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

identification No.)

525 Market Street, 36th floor

San Francisco, California 94105

(Address of principal executive offices) (Zip Code)

(415) 543-3470

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x		Accelerated filer	o

Non-accelerated filer	o	(Do not check if a smaller reporting company)	Smaller reporting company	o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of April 29, 2016, 164,624,777 shares of the registrant’s Common Stock, $0.01 par value per share, were outstanding.

MEDIVATION, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED MARCH 31, 2016

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION			3

	ITEM 1. FINANCIAL STATEMENTS.		3

		CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited).	3

		CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited).	4

		CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited).	5

		CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited).	6

		NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited).	7

	ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.		22

	ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.		29

	ITEM 4. CONTROLS AND PROCEDURES.		30

PART II — OTHER INFORMATION			30

	ITEM 1. LEGAL PROCEEDINGS		30

	ITEM 1A. RISK FACTORS		31

	ITEM 6. EXHIBITS.		55

PART I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

MEDIVATION, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

(unaudited)

	March 31, 2016			December 31, 2015
ASSETS
Current assets:
Cash and cash equivalents	$	317,361		$	225,853
Receivable from collaboration partner		186,593			391,558
Prepaid expenses and other current assets		24,416			15,877
Restricted cash		1,140			930
Total current assets		529,510			634,218
Property and equipment, net		59,849			58,142
Intangible assets		644,299			644,299
Deferred income tax assets		53,148			57,011
Restricted cash, net of current		11,996			12,206
Goodwill		18,643			18,643
Other non-current assets		8,037			7,072
Total assets	$	1,325,482		$	1,431,591
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable, accrued expenses and other current liabilities	$	121,995		$	186,203
Borrowings under Revolving Credit Facility		—			75,000
Contingent consideration		4,924			4,900
Current portion of build-to-suit lease obligation		110			—
Total current liabilities		127,029			266,103
Contingent consideration		268,303			262,368
Build-to-suit lease obligation, excluding current portion		17,278			17,406
Other non-current liabilities		12,658			13,035
Total liabilities		425,268			558,912
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.01 par value per share; 1,000,000 shares authorized; no shares issued and outstanding		—			—
Common stock, $0.01 par value per share; 340,000,000 shares authorized; 164,581,922 and 163,905,342 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively		1,646			1,639
Additional paid-in capital		707,870			684,841
Accumulated other comprehensive loss		(317	)		—
Retained earnings		191,015			186,199
Total stockholders’ equity		900,214			872,679
Total liabilities and stockholders’ equity	$	1,325,482		$	1,431,591

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDIVATION, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

	Three Months Ended March 31,
	2016			2015
Collaboration revenue	$	182,497		$	129,188
Operating expenses:
Research and development expenses		77,587			44,676
Selling, general and administrative expenses		96,827			83,939
Total operating expenses		174,414			128,615
Income from operations		8,083			573
Other income (expense), net:
Interest expense		(680	)		(5,608	)
Other, net		(209	)		137
Total other income (expense), net		(889	)		(5,471	)
Income (loss) before income tax (expense) benefit		7,194			(4,898	)
Income tax (expense) benefit		(2,378	)		1,780
Net income (loss)	$	4,816		$	(3,118	)
Basic net income (loss) per common share	$	0.03		$	(0.02	)
Diluted net income (loss) per common share	$	0.03		$	(0.02	)
Weighted average common shares used in the calculation of basic net income (loss) per common share		164,247			156,637
Weighted average common shares used in the calculation of diluted net income (loss) per common share		168,397			156,637

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDIVATION, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands)

(unaudited)

	Three Months Ended March 31,
	2016			2015
Net income (loss)	$	4,816		$	(3,118	)
Other comprehensive loss:
Unrealized losses on cash flow hedges, net of tax impact of $175 and $-- for the three months ended March 31, 2016 and 2015, respectively		(317	)		—
Other comprehensive loss		(317	)		—
Comprehensive income (loss)	$	4,499		$	(3,118	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDIVATION, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Three Months Ended March 31,
	2016			2015
Cash flows from operating activities:
Net income (loss)	$	4,816		$	(3,118	)
Adjustments for non-cash operating items:
Stock-based compensation		14,211			13,372
Change in fair value of contingent purchase consideration		5,959			4,000
Depreciation on property and equipment		2,416			1,531
Change in deferred income taxes		2,696			(1,402	)
Amortization of debt discount and debt issuance costs		85			3,910
Excess tax benefits from stock-based compensation		(2,490	)		—
Amortization of deferred revenue		—			(1,411	)
Other non-cash items		—			73
Changes in operating assets and liabilities:
Receivable from collaboration partner		204,965			58,124
Prepaid expenses and other current assets		(6,050	)		(520	)
Other non-current assets		(1,049	)		(1,335	)
Accounts payable, accrued expenses and other current liabilities		(26,869	)		(17,587	)
Interest payable		—			1,698
Current taxes payable		(32,565	)		—
Other non-current liabilities		(438	)		(113	)
Net cash provided by operating activities		165,687			57,222
Cash flows from investing activities:
Purchases of property and equipment		(9,328	)		(956	)
Change in restricted cash		—			(1,574	)
Net cash used in investing activities		(9,328	)		(2,530	)
Cash flows from financing activities:
Principal repayment of borrowings under Revolving Credit Facility		(75,000	)		—
Proceeds from issuance of common stock under equity incentive and stock purchase plans		7,677			11,502
Excess tax benefits from stock-based compensation		2,490			—
Reduction of build-to-suit lease obligation		(18	)		(227	)
Principal repayment of Convertible Notes		—			(8	)
Net cash (used in) provided by financing activities		(64,851	)		11,267
Net increase in cash and cash equivalents		91,508			65,959
Cash and cash equivalents at beginning of period		225,853			502,677
Cash and cash equivalents at end of period	$	317,361		$	568,636
Supplemental disclosures of cash flow information:
Non-cash investing and financing activities:
Property and equipment expenditures incurred but not yet paid	$	964		$	918
Interest capitalized during construction period for build-to-suit lease transactions		—		$	527

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDIVATION, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2016

(unaudited)

NOTE 1. DESCRIPTION OF BUSINESS

Medivation, Inc. (the “Company” or “Medivation”) is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. It has one commercial product, XTANDI® (enzalutamide) capsules, or XTANDI, through the Company’s collaboration with Astellas Pharma, Inc., or Astellas. XTANDI has received marketing approval in the United States, Europe and numerous other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer, or mCRPC, and in Japan for the treatment of patients with castration-resistant prostate cancer, or CRPC. The Company and Astellas are also conducting investigational studies of enzalutamide in prostate cancer, advanced breast cancer, and hepatocellular carcinoma. Under the Company’s collaboration agreement with Astellas, it shares equally with Astellas all profits (losses) related to U.S. net sales of XTANDI. The Company also receives royalties ranging from the low teens to the low twenties as a percentage of ex-U.S. XTANDI net sales.

The Company seeks to become a more fully-integrated biopharmaceutical company through the continued commercialization of XTANDI, the acquisition or in-license and development and commercialization of other product opportunities, and through the advancement of its own proprietary research and development programs. The Company expects that its future growth may come from both its internal research efforts, focused in oncology, neurology and other areas, and third-party business development activities, such as its acquisition of all worldwide rights to talazoparib (which is referred to as MDV3800) from BioMarin Pharmaceutical Inc., or BioMarin, in the fourth quarter of 2015 and its license of exclusive worldwide rights to pidilizumab (which is referred to as MDV9300) from CureTech, Ltd., or CureTech, in the fourth quarter of 2014.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of the Company’s financial condition, results of operations and cash flows for the periods presented, have been included. The results of operations for any interim period are not necessarily indicative of the results of operations for the full year or any other interim period.

The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2015, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, or the Annual Report, filed with the U.S. Securities and Exchange Commission, or SEC, on February 26, 2016. The consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date.

The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company operates in one business segment.

All tabular disclosures of dollar and share amounts are presented in thousands unless otherwise indicated. All per share amounts are presented at their actual amounts. The number of shares issuable under the Amended and Restated 2004 Equity Incentive Award Plan, or the Medivation Equity Incentive Plan, and the Medivation, Inc. 2013 Employee Stock Purchase Plan, or ESPP, disclosed in Note 10, “Stockholders’ Equity,” are presented at their actual amounts unless otherwise indicated. Amounts presented herein may not calculate or sum precisely due to rounding.

(b) Use of Estimates

The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that management make estimates and assumptions in certain circumstances that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and

expenses during the reporting period. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Although management believes that these estimates are reasonable, actual future results could differ materially from those estimates. In addition, had different estimates and assumptions been used, the unaudited condensed consolidated financial statements could have differed materially from what is presented.

Significant estimates and assumptions used by management principally relate to revenue recognition, including reliance on third-party information, estimating the performance periods of the Company’s deliverables under collaboration agreements, and estimating the various deductions from gross sales to calculate net sales of XTANDI. Additionally, significant estimates and assumptions used by management include those related to contingent purchase consideration, intangible assets, goodwill, convertible notes, determining whether the Company is the primary beneficiary of any variable interest entities, leases, taxes, research and development and other accruals, share-based compensation, derivatives and hedging, and the calculation of diluted net income per common share.

Reference is made to Note 2, “Summary of Significant Accounting Policies,” included in the notes to the Company’s audited consolidated financial statements included in its Annual Report. As of the date of the filing of this Quarterly Report on Form 10-Q, or Quarterly Report, there were no significant changes to the significant accounting policies described in the Company’s Annual Report, except for the addition of the Company’s accounting policies with respect to derivative instruments related to its cash flow hedging program, which commenced during the first quarter of 2016 as discussed in Note 4, “Derivative Financial Instruments,” and performance share units.

(d) Derivative Financial Instruments

The Company uses forward foreign currency exchange contracts to hedge a portion of its gross collaboration revenue exposure from royalties related to the Euro and the Japanese Yen. These derivative instruments are designated as cash flow hedges and are recognized as either assets or liabilities at fair value in the Company’s unaudited condensed consolidated balance sheets. The effective portion of changes in the fair value of these instruments is initially recorded as a component of accumulated other comprehensive income (loss) in stockholders’ equity, and subsequently reclassified into earnings when the underlying exposure is reflected in earnings. Ineffectiveness, if any, is recorded immediately in earnings as other income (expense), net. The Company classifies the cash flows from these instruments in the same category as the cash flows from the hedged items, within net cash provided by operating activities in the unaudited condensed consolidated statement of cash flows.

The Company assesses, both at inception and on an ongoing basis, whether its cash flow hedge derivative instruments are highly effective in offsetting the changes in cash flows of the hedged items. At inception and on a quarterly basis, the Company documents and asserts that the critical terms of its derivatives (i.e. notional amounts, currency rate mechanisms, and timing) match the critical terms of the hedged items for the risk being hedged. As such, the Company will assume no ineffectiveness in the hedge relationship because all of the critical terms of the hedge and hedged item are matched. If the Company determines that a forecasted transaction is no longer probable of occurring, hedge accounting will be discontinued for the affected portion of the hedge instrument. If the hedged item becomes probable of not occurring, any related gain or loss on the contract will be recognized immediately in earnings as other income (expense), net.

In assessing hedge effectiveness, the Company also considers the risk of counterparty default under the hedge contract. The Company seeks to limit its counterparty credit risk by working only with counterparties that have certain financial credit ratings. The Company does not enter into derivative contracts for speculative or trading purposes.

(e) Stock-Based Compensation

Performance Share Units

In the first quarter of 2016, the Company granted performance share units, or PSUs, to certain officers of the Company pursuant to the terms of the Medivation Equity Incentive Plan. The terms of the PSUs provide for target and maximum numbers of shares eligible to be earned based on the level of achievement of certain pre-determined revenue goals and clinical development milestones. For the PSUs tied to revenue goals, the actual number of shares of common stock that may ultimately be issued upon vest is calculated by multiplying the number of PSUs by a payout percentage ranging from 50% to 150%. For the PSUs tied to clinical development milestones, the actual number of shares of common stock that may ultimately be issued upon vest is calculated by multiplying the number of PSUs by a payout percentage of 100%. The PSUs will vest, if at all, upon certification by the Compensation Committee of the Company’s Board of Directors of the actual achievement of the performance objectives, subject to specified change of control exceptions.

Stock-based compensation expense associated with PSUs is based on the fair value of the Company’s common stock on the grant date, which equals the closing market price of the Company’s common stock on the grant date. The Company recognizes compensation expense over the vesting period of the awards that are ultimately expected to vest.

(f) New Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-09, “Compensation--Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions. Changes that may impact public companies include changes in the accounting for income taxes, specifically excess tax benefits and tax deficiencies; the classification of excess tax benefits on the statement of cash flows as an operating activity; the option for companies to make an entity-wide accounting policy election to either estimate the number of share-based payment awards that are expected to vest (current GAAP) or account for forfeitures when they occur; and the classification of employee taxes paid when an employer withholds shares for tax withholding purposes as a financing activity on the statement of cash flows. Depending on the specific item to be changed, ASU 2016-09 requires certain changes to be applied either prospectively, retrospectively, or under a modified retrospective transition method to all periods presented. The amended guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period, and early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.

In March 2016, the FASB issued ASU 2016-05, “Derivatives and Hedging (Topic 815): Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships.” ASU 2016-05 clarifies that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument under Topic 815 does not, in and of itself, require dedesignation of that hedging relationship provided that all other hedge accounting criteria continue to be met. The amended guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period, with the option to apply the amended guidance on either a prospective basis or a modified retrospective basis, and early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” ASU 2016-02 includes a lessee accounting model that recognizes two types of leases - finance leases and operating leases. The standard requires that a lessee recognize on the balance sheet a right-to-use asset and a lease liability for all leases with lease terms of more than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as either a finance or operating lease. ASU 2016-02 also requires new qualitative and quantitative disclosures for the amount, timing, and uncertainty of cash flows arising from leases. The amended guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that reporting period, and early adoption is permitted. ASU 2016-02 requires modified retrospective transition, which requires application of the guidance at the beginning of the earliest comparative period presented in the year of adoption; however, for all leases that commenced before the effective date, companies can elect not to reassess certain elements, including their lease classification or whether contracts are or contain embedded leases. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, a comprehensive new revenue recognition standard that will supersede the existing revenue recognition guidance. The new accounting guidance creates a framework by which an entity will allocate the transaction price to separate performance obligations and recognize revenue when (or as) each performance obligation is satisfied. Under the new standard, entities will be required to use judgment and make estimates, including identifying performance obligations in a contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each separate performance obligation and determining when an entity satisfies its performance obligations. The standard allows for either “full retrospective” adoption, meaning that the standard is applied to all of the periods presented with a cumulative catch-up as of the earliest period presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements with a cumulative catch-up as of the current period. In August 2015, the effective date of the new revenue standard was delayed by one year to December 15, 2017 for annual reporting periods beginning after that date. The FASB also agreed to permit early adoption of the standard, but not before the original effective date of December 15, 2016. In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” to clarify ASU 2014-09 implementation guidance on principal versus agent considerations. The Company has not yet selected a transition method and is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.

NOTE 3. COLLABORATION AGREEMENT

(a) Collaboration Agreement with Astellas

In October 2009, the Company entered into a collaboration agreement with Astellas, or the Astellas Collaboration Agreement, pursuant to which it is collaborating with Astellas to develop and commercialize XTANDI globally for all indications, dosages, and formulations of enzalutamide. Under the agreement, decision making and economic participation differs between the U.S. market and the ex-U.S. market. In the United States, decisions are generally made by consensus, pre-tax profits and losses are shared equally, and, subject to certain exceptions, development and commercialization costs (including cost of goods sold and the royalty on net sales payable to The Regents of the University of California (“UCLA” or “the Regents”) under the Company’s license agreement with UCLA) are also shared equally. The primary exceptions to equal cost sharing in the U.S. market are that each party is responsible for its own commercial full-time equivalent, or FTE, costs, and that development costs supporting marketing approvals in both the United States and either Europe or Japan are borne one-third by the Company and two-thirds by Astellas. The Company and Astellas are co-promoting XTANDI in the U.S. market, with each company providing half of the sales and medical affairs effort in support of the product. Both the Company and Astellas are entitled to receive a fee for each qualifying detail made by its respective sales representatives. Outside of the United States, decisions are generally made by Astellas and all development and commercialization costs (including cost of goods sold and the royalty on net sales payable to UCLA) are borne by Astellas. Astellas retains all ex-U.S. profits and losses, and pays the Company a tiered royalty ranging from the low teens to the low twenties as a percentage of the aggregate net sales of XTANDI outside of the United States, or ex-U.S. XTANDI net sales. Astellas has sole responsibility for promoting XTANDI outside of the United States and for recording all XTANDI net sales both inside and outside of the United States. Both the Company and Astellas have agreed not to commercialize certain other products having a similar mechanism of action (as defined by the Astellas Collaboration Agreement) as XTANDI for the treatment of prostate cancer for a specified time period, subject to certain exceptions.

Under the Astellas Collaboration Agreement, Astellas paid the Company a non-refundable, upfront cash payment of $110.0 million in the fourth quarter of 2009. The Company was also eligible to receive up to $335.0 million in development milestone payments and up to $320.0 million in sales milestone payments under the Astellas Collaboration Agreement. As of the fourth quarter of 2015, the Company had earned all of the development and sales milestone payments under the Astellas Collaboration Agreement.

The Company and Astellas are each permitted to terminate the Astellas Collaboration Agreement for an uncured material breach by the other party or for the insolvency of the other party. Astellas has a right to terminate the Astellas Collaboration Agreement unilaterally by advance written notice to the Company. Following any termination of the Astellas Collaboration Agreement in its entirety, all rights to develop and commercialize XTANDI will revert to the Company, and Astellas will grant a license to the Company to enable it to continue such development and commercialization. In addition, except in the case of a termination by Astellas for the Company’s material breach, Astellas will supply XTANDI to the Company during a specified transition period.

Unless terminated earlier by the Company or Astellas pursuant to the terms thereof, the Astellas Collaboration Agreement will remain in effect: (a) in the United States, until such time as Astellas notifies the Company that Astellas has permanently stopped selling products covered by the Astellas Collaboration Agreement in the United States; and (b) in each other country of the world, on a country-by-country basis, until such time as (i) products covered by the Astellas Collaboration Agreement cease to be protected by patents or regulatory exclusivity in such country and (ii) commercial sales of generic equivalent products have commenced in such country.

The Astellas Collaboration Agreement further provides for a standstill period during which Astellas and its Affiliates, as defined in the Astellas Collaboration Agreement, agreed to certain restrictive covenants, including that they would not, directly or indirectly (subject to certain exceptions), unless invited to do so by the Company, acquire (a) all or substantially all of the Company’s consolidated assets or (b) beneficial ownership of more than five percent of any voting securities of the Company or any subsidiary or Affiliate of the Company. The standstill period will expire in September 2016.

(b) Collaboration Revenue

Collaboration revenue was as follows:

	Three Months Ended March 31,
	2016		2015
Collaboration revenue:
Related to U.S. XTANDI net sales	$	153,793	$	112,010
Related to ex-U.S. XTANDI net sales		28,704		15,767
Related to upfront and milestone payments		—		1,411
Total	$	182,497	$	129,188

The Company is currently involved in litigation with UCLA regarding certain terms of its license agreement and other matters, which are discussed in Note 13, “Commitments and Contingencies.”

Collaboration Revenue Related to U.S. XTANDI Net Sales

Under the Astellas Collaboration Agreement, Astellas records all U.S. XTANDI net sales. The Company and Astellas share equally all pre-tax profits and losses from U.S. XTANDI net sales. Subject to certain exceptions, the Company and Astellas also share equally all XTANDI development and commercialization costs attributable to the U.S. market, including cost of goods sold and the royalty on net sales payable to UCLA under the Company’s license agreement with UCLA. The primary exceptions to 50/50 cost sharing are that each party is responsible for its own commercial FTE costs and that development costs supporting marketing approvals in both the United States and either Europe or Japan are borne one-third by the Company and two-thirds by Astellas. The Company recognizes collaboration revenue related to U.S. XTANDI net sales in the period in which such sales occur. Collaboration revenue related to U.S. XTANDI net sales consists of the Company’s share of pre-tax profits and losses from U.S. XTANDI net sales, plus reimbursement of the Company’s share of reimbursable U.S. development and commercialization costs. The Company’s collaboration revenue related to U.S. XTANDI net sales in any given period is equal to 50% of U.S. XTANDI net sales as reported by Astellas for the applicable period.

Collaboration revenue related to U.S. XTANDI net sales was as follows:

	Three Months Ended March 31,
	2016			2015
U.S. XTANDI net sales (as reported by Astellas)	$	307,586		$	224,020
Shared U.S. development and commercialization costs		(130,583	)		(110,313	)
Pre-tax U.S. profit	$	177,003		$	113,707
Medivation’s share of pre-tax U.S. profit	$	88,501		$	56,853
Reimbursement of Medivation’s share of shared U.S. costs		65,292			55,157
Collaboration revenue related to U.S. XTANDI net sales	$	153,793		$	112,010

Collaboration Revenue Related to Ex-U.S. XTANDI Net Sales

Under the Astellas Collaboration Agreement, Astellas records all ex-U.S. XTANDI net sales. Astellas is responsible for all development and commercialization costs for XTANDI outside of the United States, including cost of goods sold and the royalty on net sales payable to UCLA under the Company’s license agreement with UCLA, and pays the Company a tiered royalty ranging from the low teens to the low twenties as a percentage of ex-U.S. XTANDI net sales. The Company recognizes collaboration revenue related to ex-U.S. XTANDI net sales in the period in which such sales occur. Collaboration revenue related to ex-U.S. XTANDI net sales consists of royalties from Astellas on those sales.

Collaboration Revenue Related to Upfront and Milestone Payments

As of the fourth quarter of 2015, the Company had earned all development and sales milestone payments under the Astellas Collaboration Agreement. Collaboration revenue related to upfront and milestone payments from Astellas for the three months ended March 31, 2015 was $1.4 million, which was comprised of amortization of deferred upfront and development milestones.

Under the Astellas Collaboration Agreement, the Company and Astellas share certain development and commercialization costs (including cost of goods sold and the royalty on net sales payable to UCLA under the Company’s license agreement with UCLA) in the United States. For the three months ended March 31, 2016 and 2015, development cost-sharing payments from Astellas were $13.3 million and $13.8 million, respectively. For the three months ended March 31, 2016 and 2015, commercialization cost-sharing payments to Astellas were $18.7 million and $20.1 million, respectively. Development cost-sharing payments from Astellas are recorded as reductions in research and development, or R&D, expenses. Commercialization cost-sharing payments to Astellas are recorded as increases in selling, general, and administrative, or SG&A, expenses.

NOTE 4. DERIVATIVE FINANCIAL INSTRUMENTS

Because a significant portion of ex-U.S. sales of XTANDI have been generated in the European Union and in Japan, the royalties received from Astellas related to such sales are dependent on the value of the U.S. dollar versus the Euro and Japanese Yen. The Company also conducts certain R&D activities outside of the United States, with expenses incurred in various currencies, including the Euro and Japanese Yen, and these expenses partially offset the currency exposure related to its collaboration revenue from royalties.

In the first quarter of 2016, the Company began using forward foreign currency exchange contracts to hedge a portion of its gross collaboration royalty revenue, equal to the royalty revenue amount net of the Company’s R&D expense related to the Euro and the Japanese Yen. These derivative instruments are designated as cash flow hedges and have maturity dates of 15 months or less. The Company assesses, both at inception and on an ongoing basis, whether its cash flow hedge derivative instruments are highly effective in offsetting the changes in cash flows of the hedged items. At inception and on a quarterly basis, the Company documents and asserts that the critical terms of its derivatives (i.e. notional amounts, currency rate mechanisms, and timing) match the critical terms of the hedged items for the risk being hedged. As such, the Company will assume no ineffectiveness in the hedge relationship because all of the critical terms of the hedge and hedged items are matched. If the Company determines that a forecasted transaction is no longer probable of occurring, hedge accounting will be discontinued for the affected portion of the hedge instrument. If the hedged item becomes probable of not occurring, any related gain or loss on the contract will be recognized immediately in earnings as other income (expense), net.

The effective portion of changes in the fair value of these instruments is initially recorded as a component of accumulated other comprehensive income (loss), or OCI, in stockholders’ equity, and subsequently reclassified into earnings as collaboration revenue when the underlying exposure is reflected in collaboration revenue. All of the gains and losses related to the hedged forecasted transactions reported in accumulated OCI at March 31, 2016 are expected to be reclassified to collaboration revenue within the next 12 months. There were no amounts related to ineffectiveness for the quarter ended March 31, 2016. Additionally, the Company did not discontinue any of its cash flow hedges during the three months ended March 31, 2016.

As of March 31, 2016, the Company had an average derivative USD equivalent notional amount on its open contracts of $5.4 million. The Company plans to enter into approximately eight foreign currency forward contracts per quarter covering a rolling four-quarter period.

The obligations of the Company under its foreign exchange contracts are secured obligations under the terms of the Company’s senior secured credit facility. In addition, the Company‘s foreign exchange contracts are subject to standard International Swaps and Derivatives Association (ISDA) master agreements which provide for various events of default, including a cross default to the Company’s senior secured credit facility. If an event of default or termination event where the Company is the defaulting party occurs, the counterparties to these contracts could request immediate payment on the derivatives. The aggregate fair value of all foreign exchange contracts with credit-risk-related contingent features that are in a liability position as of March 31, 2016, is $0.5 million. In addition, the agreements governing such contracts permit the Company, subject to applicable requirements, to net settle transactions of the same currency with a single net amount payable by one party to the other.

While all of the Company’s derivative contracts allow the right to offset assets or liabilities, it is the Company’s policy to present its derivatives on a gross basis in the unaudited condensed consolidated balance sheets. The following table summarizes the classification and fair values of derivative instruments on the Company’s unaudited condensed consolidated balance sheet:

	March 31, 2016
	Asset Derivatives			Liability Derivatives
	Classification	Fair Value		Classification	Fair Value
Derivatives designated as hedges:
Foreign currency exchange contracts	Other current assets		—	Other current liabilities	$	(431	)
Foreign currency exchange contracts	Other non-current assets		—	Other non-current liabilities		(61	)
Total derivatives			—		$	(492	)

The following table summarizes the effect of the Company’s foreign currency exchange contracts on its unaudited condensed consolidated financial statements:

	Three Months Ended March 31, 2016
Derivatives designated as hedges:
Gains (losses) recognized in accumulated OCI (effective portion)	$	(492	)
Gains (losses) reclassified from accumulated OCI into collaboration revenue (effective portion)		—
Gains (losses) recognized in other income (expense), net		—

As of March 31, 2016, the Company held one type of financial instrument – derivative contracts related to foreign currency exchange contracts. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on our unaudited condensed consolidated balance sheet:

As of March 31, 2016
Offsetting of Derivative Assets/Liabilities
									Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/Liabilities			Gross Amounts Offset in the Condensed Consolidated Balance Sheet		Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet			Derivative Financial Instruments		Cash Collateral Received/Pledged		Net Amount (Legal Offset)
Derivative assets		—			—		—			—		—		—
Derivative liabilities	$	(492	)		—	$	(492	)		—		—	$	(492	)

NOTE 5. INTANGIBLE ASSETS AND GOODWILL

Intangible assets consist of in-process research and development, or IPR&D, acquired from business acquisitions. The Company accounts for IPR&D as indefinite-lived intangible assets until regulatory approval or discontinuation of the related R&D efforts. Upon obtaining regulatory approval, the Company reclassifies the IPR&D as a definite-lived intangible asset and determines the economic life for amortization purposes. The Company assesses the impairment of indefinite-lived intangible assets and goodwill on an annual basis or more frequently whenever events or changes in circumstances may indicate that the carrying value might not be recoverable.

The following table summarizes the Company’s indefinite-lived intangible assets as of March 31, 2016 and December 31, 2015:

	Carrying
	Amount
Indefinite-lived intangible asset – MDV3800	$	573,299
Indefinite-lived intangible asset – MDV9300		71,000
Total	$	644,299

The carrying amount of goodwill was $18.6 million as of March 31, 2016 and December 31, 2015.

NOTE 6. NET INCOME (LOSS) PER COMMON SHARE

The computation of basic net income (loss) per common share is based on the weighted-average number of common shares outstanding during each period. The computation of diluted net income (loss) per common share is based on the weighted-average number of common shares outstanding during the period plus, when their effect is dilutive, incremental shares consisting of shares subject to stock options, restricted stock units, performance share units, stock appreciation rights, ESPP shares, warrants, and shares issuable upon conversion of convertible debt.

In periods where the Company reports a net loss, all common stock equivalents are deemed anti-dilutive such that basic net loss per common share and diluted net loss per common share are equal.

For the three months ended March 31, 2016, employee stock-based awards to purchase approximately 4.2 million shares of the Company’s common stock were excluded from the computation of diluted net income per common share because their effect would have been anti-dilutive. For the three months ended March 31, 2015, approximately 22.8 million potentially dilutive common shares were excluded from the diluted net loss per common share computation because such securities had an anti-dilutive effect on net loss per common share due to the Company’s net loss for the period.

The following table reconciles the numerator and denominator used to calculate diluted net income (loss) per common share:

	Three Months Ended March 31,
	2016		2015
Numerator:
Net income (loss)	$	4,816	$	(3,118	)
Denominator:
Weighted-average common shares, basic		164,247		156,637
Dilutive effect of common stock equivalents		4,150		—
Weighted-average common shares, diluted		168,397		156,637

NOTE 7. BUILD-TO-SUIT LEASE OBLIGATION

In the fourth quarter of 2013, the Company entered into a property lease for approximately 52,000 square feet of space located in San Francisco, California. In the second quarter of 2015, the Company entered into an amended lease agreement to reduce the amount of leased space at this property to approximately 44,000 square feet. The lease agreement expires in August 2024, and the Company has an option to extend the lease term for up to an additional five years.

The Company was deemed, for accounting purposes only, to be the owner of the entire project including the building shell, even though it was not the legal owner. In connection with the Company’s accounting for this transaction, the Company capitalized $14.5 million as a build-to-suit property within property and equipment, net, and recognized a corresponding build-to-suit lease obligation for the same amount. The Company also recognized, as an additional build-to-suit lease property and obligation, structural tenant improvements totaling $3.6 million for amounts paid by the landlord and $3.5 million for capitalized interest during the construction period through 2015. As a result of the amended agreement, the Company surrendered a portion of the property totaling approximately 8,000 square feet to the lessor. Accordingly, the Company derecognized a portion of the build-to-suit asset totaling $3.2 million and a portion of the build-to-suit lease obligation totaling $3.2 million during 2015 related to the portion of the property that was surrendered to the lessor.

During the first quarter of 2016, construction on the property was substantially completed and the property was placed in service. As such, the Company evaluated its lease to determine whether it had met the requirements for sale-leaseback accounting, including evaluating whether all risks of ownership have been transferred back to the landlord, as evidenced by a lack of continuing involvement in the leased property. The Company determined that the construction project did not qualify for sale-leaseback accounting and will instead be accounted for as a financing lease, given the Company’s expected continuing involvement after the conclusion of the construction period. As a result, the building asset remains on the Company’s unaudited condensed consolidated balance sheets at its historical cost of $18.4 million and the Company began depreciating the asset over its estimated useful life in the first quarter of 2016. Additionally, the Company is allocating its monthly lease payments between land rent, which is recorded as an operating lease expense, interest expense, and reduction of the related lease obligation. As of March 31, 2016, the total amount of the build-to-suit lease obligation was $17.4 million, of which $17.3 million was classified as a non-current liability on the unaudited condensed consolidated balance sheets. The Company expects to derecognize the build-to-suit lease asset and lease obligation at the end of the lease term.

Expected future lease payments under the build-to-suit lease as of March 31, 2016 are included in Note 13, “Commitments and Contingencies.”

NOTE 8. OTHER BALANCE SHEET ITEMS

(a) Property and Equipment, Net

Property and equipment, net, consisted of the following:

	March 31, 2016			December 31, 2015
Leasehold improvements	$	22,615		$	19,074
Build-to-suit property		18,371			18,371
Computer equipment and software		17,300			16,083
Furniture and fixtures		6,014			5,714
Construction in progress		12,806			14,440
Laboratory equipment		1,447			748
		78,553			74,430
Less: Accumulated depreciation		(18,704	)		(16,288	)
Total	$	59,849		$	58,142

(b) Accounts Payable, Accrued Expenses and Other Current Liabilities

Accounts payable, accrued expenses and other current liabilities consisted of the following:

	March 31, 2016		December 31, 2015
Clinical and preclinical	$	45,635	$	48,975
Accounts payable		23,791		22,696
Payroll and payroll-related		15,988		29,215
Royalties payable		21,015		20,665
Accrued professional services and other current liabilities		15,566		14,282
Taxes payable		—		32,565
Other payable to licensor		—		17,500
Interest payable		—		305
Total	$	121,995	$	186,203

Accounts payable represents short-term liabilities for which the Company has received and processed a vendor invoice prior to the end of the reporting period. Accrued expenses and other current liabilities represent, among other things, compensation and related benefits to employees, royalties due to licensors of technologies, estimated amounts due to third-party vendors for services rendered prior to the end of the reporting period, invoices received from third-party vendors that have not yet been processed, taxes payable, interest payable and other accrued items.

NOTE 9. DEBT

(a) Revolving Credit Facility

In October 2015, the Company entered into an amendment and restatement of its original credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders from time to time party thereto (the “Lenders”), providing for: (i) a five-year $300 million revolving loan facility (the “Revolving Credit Facility”); and (ii) an uncommitted accordion facility subject to the satisfaction of certain conditions (collectively, the “Senior Secured Credit Facility”). The Revolving Credit Facility includes a $50 million multicurrency sub-facility, a $20 million letter of credit sub-facility and a $10 million swing line loan sub-facility.

Loans under the Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR rate, plus an applicable margin ranging from 1.75% to 2.50% per annum, based upon the secured leverage ratio (as defined in the Credit Agreement) or (b) the prime lending rate, plus an applicable margin ranging from 0.75% to 1.50% per annum, based upon the senior secured net leverage ratio (as defined in the Credit Agreement). In October 2015, the Company borrowed $75.0 million under the Revolving Credit Facility, which the Company repaid in January 2016. The interest rate for this borrowing was 2.1250% and was applied on an actual/360 day basis. There were no balances outstanding under the Revolving Credit Facility at March 31, 2016.

The obligations under the Credit Agreement and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) thereunder are and will be guaranteed by the Company and each of the Company’s existing and subsequently

acquired or organized direct and indirect domestic subsidiaries (other than certain immaterial domestic subsidiaries, certain Domestic Foreign Holding Companies, and certain domestic subsidiaries whose equity interests are owned directly or indirectly by certain foreign subsidiaries) (collectively, the “Loan Parties”). The obligations under the Credit Agreement and any such swap and banking services obligations are secured, subject to customary permitted liens and other agreed upon exceptions, by a perfected security interest in (i) all tangible and intangible assets of the Loan Parties, except for certain customary excluded assets, and (ii) all of the capital stock owned by the Loan Parties thereunder (limited, in the case of the stock of certain non-U.S. subsidiaries of the Company and Domestic Foreign Holding Companies, to 65% of the capital stock of such subsidiaries).

The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions. Under the terms of the Credit Agreement, the Company is required to comply with a maximum senior secured net leverage ratio and minimum interest coverage ratio covenants. At March 31, 2016, the Company was in compliance with these covenants.

In accordance with ASU 2015-15, the Company deferred $1.7 million of debt issuance costs associated with the Revolving Credit Facility, including underwriting, legal and accounting fees, and is amortizing this amount ratably over the five-year access period of the facility. Amortization of the debt issuance costs is recorded as non-cash interest expense on the unaudited condensed consolidated statements of operations.

(b) Convertible Notes Due 2017

In March 2012, the Company issued $258.8 million aggregate principal amount of the Convertible Notes. The Company was required to pay interest semi-annually in arrears on April 1 and October 1 of each year. The Convertible Notes were convertible upon the occurrence of certain conditions into shares of the Company’s common stock.

During 2015, the Company settled all of its Convertible Notes. During the second quarter of 2015, the Company settled a total of $91.0 million aggregate principal amount of the Convertible Notes through a combination of $92.1 million in cash and 2,099,358 shares of its common stock. During the third quarter of 2015, the Company settled a total of $167.8 million aggregate principal amount of the Convertible Notes through a combination of $167.8 million in cash and 3,539,218 shares of its common stock. The Company recorded a non-cash loss on extinguishment of the Convertible Notes of $7.9 million and $13.2 million in the second and third quarters of 2015, respectively, which was included in other income (expense), net, on the condensed consolidated statements of operations. Forfeited accrued interest payable totaling $1.7 million was reclassified to additional paid-in capital during 2015. Upon settlement, the Convertible Notes were no longer outstanding, interest ceased to accrue thereon, and all rights of the holders of the Convertible Notes ceased to exist.

NOTE 10. STOCKHOLDERS’ EQUITY

(a) Stock Purchase Rights

All shares of the Company’s common stock, if issued prior to the termination by the Company of its rights agreement, dated as of December 4, 2006, include stock purchase rights. The rights are exercisable only if a person or group acquires twenty percent or more of the Company’s common stock or announces a tender or exchange offer which would result in ownership of twenty percent or more of the Company’s common stock. Following the acquisition of twenty percent or more of the Company’s common stock, the holders of the rights, other than the acquiring person or group, may purchase Medivation common stock at half of its fair market value. In the event of a merger or other acquisition of the Company, the holders of the rights, other than the acquiring person or group, may purchase shares of the acquiring entity at half of their fair market value. The rights were not exercisable at March 31, 2016.

(b) Medivation Equity Incentive Plan

The Medivation Equity Incentive Plan provides for the issuance of options and other stock-based awards, including stock appreciation rights, restricted stock units and performance share units. The vesting of all outstanding awards under the Medivation Equity Incentive Plan will accelerate, and all such awards will become immediately exercisable, upon a “change of control” of Medivation, as defined in the Medivation Equity Incentive Plan.

In 2015, the Company’s stockholders approved an amendment and restatement of the Medivation Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the Medivation Equity Incentive Plan from 42,300,000 to 47,700,000. As of March 31, 2016, approximately 5.7 million shares were available for issuance under the Medivation Equity Incentive Plan.

Performance Share Units

The Company granted 129,150 target number of PSUs during the first quarter of 2016 to certain officers of the Company pursuant to the terms of the Medivation Equity Incentive Plan. The terms of the PSUs provide for target and maximum numbers of shares eligible to be earned based on the level of achievement of certain pre-determined revenue goals and clinical development milestones. For the PSUs tied to revenue goals, the actual number of shares of common stock that may ultimately be issued upon vest is calculated by multiplying the number of PSUs by a payout percentage ranging from 50% to 150%. For the PSUs tied to clinical development milestones, the actual number of shares of common stock that may ultimately be issued upon vest is calculated by multiplying the number of PSUs by a payout percentage of 100%.

The PSUs will vest, if at all, upon certification by the Compensation Committee of the Company’s Board of Directors, or the Committee, of the actual achievement of the performance objectives, subject to specified change of control exceptions. Each recipient of a PSU must remain an employee of the Company through the date the Committee determines actual performance has been achieved in order to earn the shares eligible under the award. For a portion of the PSUs tied to revenue goals, each recipient must remain an employee of the Company for one year after the initial date the Committee determined actual performance was achieved in order to earn that particular portion of the shares eligible under the award. Stock-based compensation expense associated with PSUs is based on the fair value of the Company’s common stock on the grant date, which equals the closing market price of the Company’s common stock on the grant date. The Company recognizes compensation expense over the vesting period of the awards that are ultimately expected to vest.

The Company’s ESPP permits eligible employees to purchase shares of the Company’s common stock through payroll deductions at the lower of 85% of the fair market value of the common stock at the beginning or end of a purchase period. Eligible employee purchases are limited on an annual basis to $25,000 in accordance with Section 423 of the Internal Revenue Code. The number of shares of common stock authorized for issuance under the ESPP is 6,000,000 shares. As of March 31, 2016, a total of 397,536 shares have been issued under the ESPP.

(d) Stock-Based Compensation

Stock-based compensation expense was as follows:

	Three Months Ended March 31,
	2016		2015
Stock-based compensation expense recognized as:
R&D expense	$	6,037	$	5,811
SG&A expense		8,174		7,561
Total	$	14,211	$	13,372

NOTE 11. INCOME TAXES

The Company calculates its quarterly income tax provision in accordance with the guidance provided by ASC 740-270, “Interim Income Tax Accounting,” whereby the Company forecasts its estimated annual effective tax rate and then applies that rate to its year-to-date pre-tax book income (loss). Income tax expense for the three months ended March 31, 2016 was $2.4 million. The provision for income taxes was lower than the tax computed at the U.S. federal statutory rate due primarily to the Federal research and development credit, partially offset by state income taxes, non-deductible officers’ compensation and non-deductible stock-based compensation. Income tax benefit for the three months ended March 31, 2015 was $1.8 million.

The effective tax rate was 33.1% and 36.3% for the three months ended March 31, 2016 and 2015, respectively. The decrease in the effective tax rate for the three months ended March 31, 2016 as compared to the prior year period was due to the Federal research and development tax credit which was permanently reinstated in the fourth quarter of 2015.

For the three months ended March 31, 2016, the Company reduced its current Federal and state taxes payable by $2.5 million related to excess tax benefits from stock-based compensation, increasing additional paid-in capital.

The Company records a valuation allowance to reduce deferred tax assets to reflect the net amount that is more likely than not to be realized. Based upon the weight of available evidence at December 31, 2014, the Company determined that it was more likely than not that a portion of its deferred tax assets would be realizable and consequently released the valuation allowance against Federal and certain state net deferred tax assets during the fourth quarter of 2014. The decision to reverse a portion of the valuation allowance was

made after management considered all available evidence, both positive and negative, including but not limited to the historical operating results, income or loss in recent periods, cumulative income in recent years, forecasted earnings, forecasted future taxable income, and significant risk and uncertainty related to forecasts. The release of the valuation allowance resulted in the recognition of certain deferred net tax assets and a decrease to income tax expense.

The future effective tax rate is subject to volatility and may be materially impacted by various internal and external factors. These factors may include, but are not limited to, the amount of income tax benefits and charges from: interpretations of existing tax laws; changes in tax laws and rates; future levels of research and development expenditures; changes in the mix of earnings in countries with differing statutory tax rates in which the Company may conduct business; changes in the valuation of deferred tax assets and liabilities; state income taxes; the tax impact of stock-based compensation; accounting for uncertain tax positions; closure of statute of limitations or settlement of tax audits; changes in estimates of prior years’ items; tax costs for acquisition-related items; changes in accounting standards; non-deductible officers’ compensation; limitations on the utilization of net operating losses and tax credits due to changes in ownership; and overall levels of income before taxes.

NOTE 12. FAIR VALUE DISCLOSURES

The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis:

			Fair Value Measurements Using:
	Fair Value		Level 1		Level 2		Level 3
March 31, 2016:
Current liabilities:
Foreign currency derivative contracts	$	431		—	$	431		—
Contingent consideration	$	4,924		—		—	$	4,924
Non-current liabilities:
Foreign currency derivative contracts	$	61		—	$	61		—
Contingent consideration	$	268,303		—		—	$	268,303
December 31, 2015:
Current liabilities:
Contingent consideration	$	4,900		—		—	$	4,900
Non-current liabilities:
Contingent consideration	$	262,368		—		—	$	262,368

The Company estimates the fair values of Level 2 assets or liabilities, including foreign currency derivative contracts, by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly, or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar assets, issuer credit spreads, benchmark yields, foreign currency rates, London Interbank Offered Rates (LIBOR), and other observable inputs. The Company validates the prices provided by its third-party pricing sources by understanding the models used, obtaining market values from other pricing sources, and/or analyzing pricing data in certain instances. For additional information regarding the Company’s foreign currency derivative transactions, see Note 4, “Derivative Financial Instruments.”

In connection with the acquisitions of MDV3800 and MDV9300, the Company recorded contingent consideration liabilities pertaining to amounts potentially payable to BioMarin and CureTech, respectively. The fair value of contingent consideration is considered a Level 3 liability and was estimated utilizing a model with key assumptions that included estimated revenues or completion of certain development, regulatory and sales milestone targets during the earn-out period, volatility, and estimated discount rates corresponding to the periods of expected payments. The estimated fair value of the contingent consideration liability is measured at each reporting date based on significant inputs not observable in the market. The Company assesses these estimates on an ongoing basis as additional data impacting the assumptions is obtained. Changes in the estimated fair value of contingent consideration are reflected as non-cash adjustments to operating expenses in the unaudited condensed consolidated statements of operations.

During the three months ended March 31, 2016, the Company recorded fair value adjustments of $0.5 million and $2.5 million as increases to R&D and SG&A expenses, respectively, related to the BioMarin contingent consideration liability. During the three months ended March 31, 2016, the Company also recorded fair value adjustments of $0.6 million and $2.3 million as increases to R&D and SG&A expenses, respectively, related to the CureTech contingent consideration liability. During the three months ended March 31, 2015, the Company recorded fair value adjustments of $1.0 million and $3.0 million as increases to R&D and SG&A expenses, respectively, related to the CureTech contingent consideration liability. All of these adjustments were primarily due to the time value of money.

BioMarin is entitled to contingent payments totaling up to $160.0 million upon the achievement of defined regulatory and sales-based milestones, and mid-single digit royalties on net sales of products that contain MDV3800 during the royalty term specified in the related purchase agreement. CureTech is entitled to contingent payments totaling up to $85.0 million upon attainment of certain development and regulatory milestones, up to $245.0 million upon the achievement of certain annual worldwide net sales thresholds, and tiered royalties ranging from 5% to 11% on annual worldwide net sales. CureTech is also entitled to a $5.0 million milestone payment upon completion of the Manufacturing Technology Transfer as described in Note 13, “Commitments and Contingencies.”

Contingent consideration may change significantly as development progresses and additional data is obtained that will affect the Company’s assumptions regarding probabilities of successful achievement of related milestones used to estimate the fair value of the liability and the timing in which they are expected to be achieved. Updates to these assumptions could have a significant impact on our results of operations. For example, a significant increase in the probability of achieving a milestone would result in a significantly higher fair value measurement, while a significant increase in the expected timing of achieving a milestone would result in a significantly lower fair value measurement. Considerable judgment is required to interpret the market data used to develop the assumptions. The estimates of fair value may not be indicative of amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques could result in materially different fair value estimates.

There were no transfers between Level 1 and Level 2 financial instruments during the three months ended March 31, 2016. The following table includes a roll-forward of the fair value of Level 3 financial instruments for the period presented:

	Three Months Ended March 31, 2016
Contingent consideration (current and non-current):
Balance at beginning of period	$	267,268
Amounts acquired or issued		—
Net change in fair value		5,959
Settlements		—
Transfers in and/or out of Level 3		—
Balance at end of period	$	273,227

The following table presents the total balance of the Company’s other financial instruments that are not measured at fair value on a recurring basis:

			Fair Value Measurements Using:
	Total Balance		Level 1		Level 2		Level 3
March 31, 2016:
Assets:
Bank deposits (included in “Cash and cash equivalents”)	$	317,361	$	317,361		—		—
December 31, 2015:
Assets:
Bank deposits (included in “Cash and cash equivalents”)	$	225,853	$	225,853		—		—
Liabilities:
Borrowings under Revolving Credit Facility	$	75,000	$	75,000		—		—

Due to their short-term maturities, the Company believes that the fair value of its bank deposits, receivable from collaboration partner, accounts payable and accrued expenses, short-term borrowings under the Revolving Credit Facility, and other current assets and liabilities approximate their carrying value.

NOTE 13. COMMITMENTS AND CONTINGENCIES

(a) Lease Obligations

The Company leases approximately 158,000 square feet of office space, including approximately 143,000 square feet of office space at its corporate headquarters, pursuant to operating lease agreements expiring at various dates through December 2019. The Company has the option to extend the lease term of its corporate headquarters, which expires in June 2019, for an additional five years.

Future operating lease obligations as of March 31, 2016 are as follows:

Years Ending December 31,	Operating Leases
Remainder of 2016	$	7,028
2017		9,542
2018		9,743
2019		5,065
2020		—
2021 and thereafter		—
Total minimum lease payments	$	31,378

The Company is considered the “accounting owner” for a build-to-suit property and has recorded a build-to-suit lease obligation on its unaudited condensed consolidated balance sheets. Additional information regarding the build-to-suit lease obligation is included in Note 7, “Build-To-Suit Lease Obligation.”

Expected future lease payments under the build-to-suit lease as of March 31, 2016 are as follows:

Years Ending December 31,	Expected Cash Payments Under Build- To-Suit Lease Obligation
Remainder of 2016	$	1,639
2017		2,244
2018		2,311
2019		2,380
2020		2,452
2021 and thereafter		9,627
Total minimum lease payments	$	20,653

(b) License Agreement with UCLA

Under an August 2005 license agreement with UCLA, the Company’s subsidiary Medivation Prostate Therapeutics, Inc., or MPT, holds an exclusive worldwide license under several UCLA patents and patent applications covering XTANDI and related compounds. Under the Astellas Collaboration Agreement, the Company granted Astellas a sublicense under the patent rights licensed to it by UCLA.

The Company is required to pay UCLA (a) an annual maintenance fee, (b) $2.8 million in aggregate milestone payments upon achievement of certain development and regulatory milestone events with respect to XTANDI (all of which has been paid as of March 31, 2016), (c) ten percent of all Sublicensing Income, as defined in the agreement, which the Company earns under the Astellas Collaboration Agreement, and (d) a four percent royalty on global net sales of XTANDI, as defined. Under the terms of the Astellas Collaboration Agreement, the Company shares this royalty obligation equally with Astellas with respect to sales in the United States, and Astellas is responsible for this entire royalty obligation with respect to sales outside of the United States. The Company is currently involved in litigation with UCLA, which is discussed in the section titled “Litigation” below.

UCLA may terminate the agreement if the Company does not meet a general obligation to diligently proceed with the development, manufacturing and sale of licensed products, or if it commits any other uncured material breach of the agreement. The Company may terminate the agreement at any time upon advance written notice to UCLA. If neither party terminates the agreement early, the agreement will continue in force until the expiration of the last-to-expire patent on a country-by-country basis.

Manufacturing Services and Supply Agreements

Manufacturing Technology Transfer, as defined. In accordance with the terms of the MSA, the Company is also responsible for providing Manufacturing Funding totaling up to $19.3 million for clinical trial materials of MDV9300 over the three-year term of the MSA, of which $9.0 million has been paid through March 31, 2016. The Manufacturing Funding is contingent upon the successful achievement of the requirements set forth in the Manufacturing Plan, and any such amounts may be reduced or eliminated by the Company under the terms of the MSA.

Development and Manufacturing Services Agreement

During the fourth quarter of 2014, the Company entered into a Development and Manufacturing Services Agreement with a third-party clinical manufacturing organization. The term of the agreement is for the longer of (i) a period of five years or (ii) through the completion of the Services, as defined. Under the current statement of work under this agreement, as amended, the Company intends to transfer the current manufacturing process of MDV9300 from CureTech to this third party, further scale up and production of Phase 3 clinical trial material of MDV9300 from this entity’s manufacturing facility. The estimated total consideration payable under the current statement of work, as amended, is approximately $15.2 million, of which approximately $6.2 million has been paid through March 31, 2016.

(d) Litigation

The Company is party to legal proceedings, investigations, and claims in the ordinary course of its business, including the matters described below. The Company records accruals for outstanding legal matters when it believes that it is both probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in significant legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. To the extent new information is obtained and the Company’s views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company’s accrued liabilities would be recorded in the period in which such determination is made. In addition, in accordance with the relevant authoritative guidance, for matters for which the likelihood of material loss is at least reasonably possible, the Company provides disclosure of the possible loss or range of loss; however, if a reasonable estimate cannot be made, the Company will provide disclosure to that effect. Gain contingencies, if any, are recorded when they are realized.

In May 2011, the Company filed a lawsuit in San Francisco Superior Court against the Regents of the University of California, or the Regents, and one of its professors, alleging breach of contract and fraud claims, among others. The Company’s allegations in this lawsuit include that it has exclusive commercial rights to apalutamide, an investigational drug originally known as ARN-509 (previously also referred to as JNJ-56021927, or JNJ-927), which is currently being developed by Aragon Pharmaceuticals, or Aragon. In August 2013, Johnson & Johnson and Aragon completed a transaction in which Johnson & Johnson acquired all apalutamide assets owned by Aragon. The Company sought remedies including a declaration that it is the proper licensee of apalutamide, contractual remedies conferring to it exclusive patent license rights regarding apalutamide, and other equitable and monetary relief. On August 7, 2012, the Regents filed a cross-complaint against the Company seeking declaratory relief that the Regents are entitled to ten percent of any sales milestone payments under the Astellas Collaboration Agreement.

On December 20, 2012, and January 25, 2013, the Court granted summary judgment motions filed by defendants Regents and Aragon, resulting in dismissal of all claims against Regents and Aragon, but denied such motions filed by the remaining Regents professor. On April 15, 2013, the Company filed a Notice of Appeal seeking appeal of the judgment in favor of Aragon, which is now wholly-owned by Johnson & Johnson. The bench trial of the Regent’s cross-complaint against the Company was conducted in July 2013, and on January 15, 2014, the Court entered a judgment in the cross-complaint in favor of Regents. The Company appealed this judgment on February 13, 2014 along with the December 2012 summary judgment order in favor of Regents. The jury trial of the Company’s breach of contract and fraud claims against the remaining Regents professor was conducted in October and November 2013. On November 15, 2013, the jury rendered a verdict in the case, finding in favor of the Company on one of the breach of contract claims, and in favor of the Regents professor on the fraud claims. The Company appealed the resulting judgment on the fraud claims. All appeals from this matter were consolidated, oral arguments were heard on February 23, 2016, and the matter was submitted. A decision of the appellate court is required to be rendered within 90 days of when the matter is submitted. On March 8, 2016, the Court’s submission was vacated, on its own order, stating that “further consideration of the merits of the issues raised on appeal is required.” The Company awaits further instructions from the Court.

On April 11, 2014, the Regents filed a complaint against the Company in which the Regents allege that the “Operating Profits” the Company has received (and will continue to receive) from Astellas, as a result of the Astellas Collaboration Agreement, constitute Sublicensing Income under the license agreement between the Company and the Regents and that the Company and its subsidiary, MPT, have failed to pay the Regents ten percent of such Operating Profits. The Company denies the Regents’ allegations and is vigorously defending the litigation. The Company is currently awaiting a trial date to be set by the Courts.

While the Company believes it has meritorious positions with respect to the claims above and intends to advance its positions in these lawsuits vigorously, including on appeal, the process of resolving matters through litigation or other means is inherently uncertain, and it is not possible to predict the ultimate resolution of any such proceeding. The actual costs of defending the Company’s position may be significant, and the Company may not prevail.

NOTE 14. SUBSEQUENT EVENT

On April 28, 2016, the Company confirmed that it had received an unsolicited, non-binding proposal from Sanofi to acquire all outstanding shares of Medivation common stock for $52.50 in cash, which followed a private letter received by the Company from Sanofi on April 15, 2016. On April 29, 2016, the Company announced that its Board of Directors, after consultation with its financial and legal advisors, unanimously determined that the unsolicited proposal from Sanofi to acquire Medivation for $52.50 per share in cash substantially undervalues Medivation and is not in the best interests of the Company and its stockholders.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2015, included in our Annual Report on Form 10-K for the year ended December 31, 2015, or Annual Report. The following discussion and analysis contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We intend that these forward-looking statements be subject to the safe harbors created by those provisions. Forward-looking statements are generally written in the future tense and/or are preceded by words such as “may,” “should,” “could,” “expect,” “suggest,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” or similar words, or negatives of such terms or other variations on such terms of comparable terminology. These forward-looking statements include, but are not limited to, statements regarding the commercialization of XTANDI® (enzalutamide) capsules, or XTANDI, the continuation and success of our collaboration with Astellas Pharma, Inc., or Astellas, the timing, progress and results of our clinical trials, and our future drug development activities, including those with respect to talazoparib (which is referred to as MDV3800) and pidilizumab (which is referred to as MDV9300). The forward-looking statements contained in this Quarterly Report on Form 10-Q, or Quarterly Report, involve a number of risks, uncertainties and assumptions, many of which are outside of our control. Factors that could cause actual results to differ materially from projected results include, but are not limited to, those discussed in “Risk Factors” in Item 1A of Part II below. Readers are expressly advised to review and consider those Risk Factors. Although we believe that the assumptions underlying the forward-looking statements contained in this Quarterly Report are reasonable, any of the assumptions could be inaccurate, and therefore there can be no assurance that the results anticipated by such statements will occur. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that the results or conditions described in such statements or our objectives and plans will be achieved. Furthermore, past financial or operations performance is not necessarily indicative of future performance. We disclaim any intention or obligation to update, supplement or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Overview

We are a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. We have one commercial product, XTANDI® (enzalutamide) capsules, or XTANDI, through our collaboration with Astellas Pharma, Inc., or Astellas. XTANDI has received marketing approval in the United States, Europe and numerous other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer, or mCRPC, and in Japan for the treatment of patients with castration-resistant prostate cancer, or CRPC. We and Astellas are also conducting investigational studies of enzalutamide in prostate cancer, advanced breast cancer, and hepatocellular carcinoma. Under our collaboration agreement with Astellas, we share equally with Astellas all profits (losses) related to U.S. net sales of XTANDI. We also receive royalties ranging from the low teens to the low twenties as a percentage of ex-U.S. XTANDI net sales.

We seek to become a more fully-integrated biopharmaceutical company through the continued commercialization of XTANDI, the acquisition or in-license and development and commercialization of other product opportunities, and through the advancement of our own proprietary research and development programs. We expect that our future growth may come from both our internal research efforts, focused in oncology, neurology and other areas, and third-party business development activities, such as our acquisition of all worldwide rights to talazoparib (which we refer to as MDV3800) from BioMarin Pharmaceutical Inc., or BioMarin, in the fourth quarter of 2015 and our license of exclusive worldwide rights to pidilizumab (which we refer to as MDV9300) from CureTech, Ltd., or CureTech, in the fourth quarter of 2014.

2016 Clinical and Business Highlights

The following summarizes our recent clinical and business highlights:

•

In April 2016, we announced that data from a Phase 2 investigator-sponsored study of enzalutamide was presented at the American Association for Cancer Research Annual Meeting 2016, or AACR, by the study’s lead investigator Ravi Madan, M.D., Clinical Director, Genitourinary Malignancies Branch at the National Cancer Institute. The primary objective of the study was to evaluate the effect of a short-course of enzalutamide (three months) alone or in combination with a therapeutic cancer vaccine (PROSTVAC®) on prostate specific antigen kinetics four months after completing enzalutamide. Preliminary data from a 12-patient subset demonstrated that treatment with enzalutamide alone resulted in potential immune-activating properties in patients with non-metastatic castration sensitive prostate cancer.

•

In April 2016, we announced that Phase 1 data from an investigator-sponsored study of talazoparib in combination with low-dose chemotherapy was presented during a Clinical Trials Mini-Symposium at AACR by the study’s lead investigator Zev A. Wainberg, M.D., Associate Professor of Medicine at UCLA and Co-Director of the UCLA GI Oncology Program. Data from the 40 patient trial demonstrated that combination treatment with talazoparib and low-dose chemotherapy resulted in stable disease or an objective response in 23 of 40 heavily pretreated patients with a variety of advanced cancers (clinical benefit rate of 58%). Most notably, objective responses were seen in four of seven (57%) heavily pretreated non-BRCA-mutated ovarian cancer patients when talazoparib was used in combination with either low-dose temozolomide or low-dose irinotecan. Six of seven individuals (86%) with non-BRCA ovarian cancer had clinical benefit (four partial responses and two stable disease through the first 16 weeks of study) and had a reduction in CA 125 levels by 50% or greater.

The Phase 1 investigator-sponsored study evaluated escalating doses of talazoparib (≥ 0.5 mg given orally once daily) with either temozolomide (≥ 25 mg/m2 given orally on days 1-5; Arm A) or irinotecan (≥ 25 mg/m2 given by intravenous infusion every two weeks; Arm B) every 28 days in patients with advanced malignancies. Study participants ranged in age from 21 to 77 years (median: 57 years) and had received one to fifteen prior chemotherapy regimens (median: 6). The primary endpoint of the study was the determination of the maximum tolerated dose. Secondary endpoints included pharmacokinetics, tumor response and biomarkers. The most common grade 3/4 adverse events (≥ 5%) observed in patients treated with talazoparib plus temozolomide were neutropenia (28%), anemia (33%), and thrombocytopenia (33%). Among those treated with talazoparib plus irinotecan, the most common adverse events were thrombocytopenia (13%), anemia (27%) and neutropenia (31%). No significant pharmacokinetic interactions were observed between talazoparib and either temozolomide or irinotecan.

•

In April 2016, we announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, had issued a positive opinion recommending approval of a type II variation to include data from the head-to-head TERRAIN trial of enzalutamide versus bicalutamide in the European label for XTANDI. The CHMP’s positive recommendation does not change indications or contraindications, and the update to the Summary of Product Characteristics, or SmPC, took effect immediately and is applicable in all of the 28 member states of the European Union.

•

In March 2016, the first patient was enrolled in the Phase 3 ARCHES trial to evaluate the efficacy and safety of enzalutamide with androgen deprivation therapy versus placebo with androgen deprivation therapy in metastatic hormone sensitive prostate cancer, or mHSPC, patients. The global, randomized, double-blind, placebo-controlled study aims to enroll approximately 1,100 patients with mHSPC at approximately 250 centers globally. The primary endpoint of the trial is radiographic progression-free survival, or rPFS, defined as the time from randomization to the first objective evidence of radiographic disease progression as assessed by central review or death, whichever occurs first.

•

In February 2016, the U.S. Food and Drug Administration, or FDA, accepted for review a supplemental New Drug Application, or sNDA, for XTANDI in mCRPC, which includes findings from the Phase 2 TERRAIN and STRIVE studies, to update the relevant clinical sections within the current indication. XTANDI is approved by the FDA for the treatment of patients with mCRPC. The Prescription Drug User Fee Act, or PDUFA, goal date for a decision by the FDA is October 22, 2016.

•

Results from the Phase 2 STRIVE trial of enzalutamide compared to bicalutamide in men with CRPC were published in the Journal of Clinical Oncology.

•

Results from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic CRPC were published in Lancet Oncology.

•

In January 2016, we entered into a collaboration agreement with NanoString Technologies, Inc., or NanoString, and our partner Astellas to translate our gene expression profile into a companion diagnostic assay using NanoString’s nCounter® Dx Analysis System for potential use as a companion diagnostic test for enzalutamide for triple negative breast cancer, or TNBC.

2016 Financial Highlights

•

Net sales of XTANDI as reported by Astellas and collaboration revenue related to net sales of XTANDI are summarized in the table below (dollars in millions; amounts may not calculate or sum precisely due to rounding):

	Three Months Ended March 31,
	2016			2015
Worldwide net sales of XTANDI (as reported by Astellas)	$	547		$	357
Increase year-over-year	$	190
Percentage change		53	%

U.S. XTANDI net sales (as reported by Astellas)	$	308		$	224
Increase year-over-year	$	84
Percentage change		37	%

Ex-U.S. XTANDI net sales (as reported by Astellas)	$	240		$	133
Increase year-over-year	$	107
Percentage change		80	%

Collaboration revenue	$	182		$	129
Increase year-over-year	$	53
Percentage change		41	%

•

Total operating expenses for the three months ended March 31, 2016 were $174.4 million, an increase of $45.8 million, or 36%, from the three months ended March 31, 2015. Operating expenses included non-cash stock-based compensation expense of $14.2 million and $13.4 million for the three months ended March 31, 2016 and 2015, respectively. Operating expenses for the three months ended March 31, 2016 and 2015 also included non-cash expense of $6.0 million and $4.0 million, respectively, related to fair value adjustments for contingent purchase consideration.

•

Cash and cash equivalents were $317.4 million at March 31, 2016, an increase of $91.5 million, or 41%, from $225.9 million at December 31, 2015. During the first quarter of 2016, we collected the 2015 collaboration receivable balance from Astellas, which included a $175.0 million sales milestone payment, and utilized $75.0 million of cash to repay our borrowing under our five-year $300.0 million revolving loan facility (the “Revolving Credit Facility”).

Critical Accounting Policies and the Use of Estimates

The preparation of our consolidated financial statements and related footnotes requires us to make estimates, assumptions and judgments in certain circumstances that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We have based our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We have discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from these estimates under different assumptions or conditions. A detailed description of our significant accounting policies is included in the footnotes to our audited consolidated financial statements included in our Annual Report.

We have identified our most critical accounting policies and estimates upon which our financial statements depend as those relating to: revenue recognition, including reliance on third-party information, estimating the various deductions from gross sales used to calculate net sales of XTANDI, and estimating the performance periods of our deliverables under collaboration agreements; business combinations, including estimates related to goodwill, intangible assets and contingent consideration; stock-based compensation; research and development expenses and accruals; litigation; convertible notes; leases, including build-to-suit lease arrangements; the calculation of diluted net income per common share; and income taxes. As of March 31, 2016, there have been no significant or material changes to our critical accounting policies or estimates from that disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in our Annual Report.

Results of Operations

Collaboration Revenue

We have a collaboration agreement with Astellas pursuant to which we are collaborating with Astellas to develop and commercialize XTANDI globally. The terms of the collaboration agreement are described in Note 3, “Collaboration Agreement,” to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report. Collaboration revenue consists of three components: (a) collaboration revenue related to U.S. XTANDI net sales; (b) collaboration revenue related to ex-U.S. XTANDI net sales; and (c) collaboration revenue related to upfront and milestone payments.

Collaboration revenue was as follows (in thousands):

	Three Months Ended March 31,
	2016		2015
Collaboration revenue:
Related to U.S. XTANDI net sales	$	153,793	$	112,010
Related to ex-U.S. XTANDI net sales		28,704		15,767
Related to upfront and milestone payments		—		1,411
Total	$	182,497	$	129,188

We are currently involved in litigation with UCLA regarding certain terms of our license agreement and other matters, which are discussed in Part II, Item 1, “Legal Proceedings.”

Collaboration Revenue Related to U.S. XTANDI Net Sales

Collaboration revenue related to U.S. XTANDI net sales was as follows (in thousands):

	Three Months Ended March 31,
	2016			2015
U.S. XTANDI net sales (as reported by Astellas)	$	307,586		$	224,020
Shared U.S. development and commercialization costs		(130,583	)		(110,313	)
Pre-tax U.S. profit	$	177,003		$	113,707
Medivation’s share of pre-tax U.S. profit	$	88,501		$	56,853
Reimbursement of Medivation’s share of shared U.S. costs		65,292			55,157
Collaboration revenue related to U.S. XTANDI net sales	$	153,793		$	112,010

U.S. net sales of XTANDI (as reported by Astellas) for the three months ended March 31, 2016 were $307.6 million, an increase of $83.6 million, or 37%, compared with net sales for the prior year period. The majority of the increase was due to higher sales volumes with a minor increase resulting from changes in price elements. The increase in price elements includes a net favorable adjustment of $4.2 million for the three months ended March 31, 2016 related to changes in prior period estimates of deductions against gross sales.

In the fourth quarter of 2015, we experienced cyclical buying patterns of XTANDI in the U.S. by the Astellas distribution channel partners. Specifically, fourth quarter 2015 U.S. XTANDI net sales (as reported by Astellas) included approximately one-half week of additional channel partner inventory. As a result, the fourth quarter 2015 channel partner inventory levels were reduced in the first quarter of 2016. In addition, the estimated gross-to-net sales discount applied by Astellas in the first quarter of 2016 was higher than the fourth quarter of 2015 because of the impact of Medicare Part D coverage gap in the new calendar year.

Collaboration revenue related to U.S. XTANDI net sales for the three months ended March 31, 2016 was $153.8 million, an increase of $41.8 million, or 37%, from the prior year. The increase in the first quarter of 2016 was the result of an increase in our share of pre-tax U.S. profit in the collaboration with Astellas as well as an increase in their reimbursement of our shared U.S. costs.

Collaboration Revenue Related to Ex-U.S. XTANDI Net Sales

Net sales of XTANDI outside of the United States (as reported by Astellas) were approximately $240.0 million and approximately $133.0 million for the three months ended March 31, 2016 and 2015, respectively. Collaboration revenue attributable to ex-U.S. XTANDI net sales was $28.7 million and $15.8 million for the three months ended March 31, 2016 and 2015, respectively.

Net sales of XTANDI outside of the United States (as reported by Astellas) in the first quarter of 2016 increased approximately 80% compared to net sales in the first quarter of 2015. Changes in foreign currency exchange rates reduced the U.S. dollar equivalent of such first quarter 2016 net sales (as reported by Astellas) by approximately 1% compared to the first quarter of 2015.

Collaboration Revenue Related to Upfront and Milestone Payments

As of the fourth quarter of 2015, we had earned all development and sales milestone payments under the Astellas Collaboration Agreement. Collaboration revenue related to upfront and milestone payments from Astellas for the three months ended March 31, 2015 was $1.4 million, which was comprised of amortization of deferred upfront and development milestones.

Research and Development Expenses

Research and development, or R&D, expenses were as follows (dollars in thousands):

	Three Months Ended March 31,
	2016			2015
Research and development expenses	$	77,587		$	44,676
Percentage change		74	%

R&D expenses increased by $32.9 million, or 74%, to $77.6 million for the three months ended March 31, 2016, from $44.7 million for the prior year period. The increase was primarily due to a $23.5 million increase in third-party clinical and preclinical development costs as a result of increased activities, including direct expenses associated with our MDV3800 and enzalutamide programs, a $6.4 million increase in personnel-related costs and a $3.0 million increase in facilities and information technology costs. The higher MDV3800 expenses were primarily due to the ongoing Phase 3 EMBRACA trial and the planned initiation of additional clinical studies in multiple tumor types.

Under the Astellas Collaboration Agreement, we and Astellas share certain development costs in the United States. Development cost-sharing payments from Astellas were $13.3 million and $13.8 million for the three months ended March 31, 2016 and 2015, respectively. Development cost-sharing payments from Astellas are recorded as reductions in R&D expenses.

We were engaged in four R&D programs during the periods presented: (1) the development of enzalutamide for the treatment of prostate cancer, advanced breast cancer, and hepatocellular carcinoma; (2) the development of MDV3800; (3) the development of MDV9300; and (4) multiple proprietary research and drug discovery projects. R&D costs are identified as either directly allocable to one of our R&D programs or indirect costs, with only direct costs being tracked by specific program. Direct costs consist primarily of clinical, preclinical, and drug discovery costs, cost of supplying drug substance and drug product for use in clinical and preclinical studies, including clinical manufacturing costs, upfront and development milestone payments under license agreements, non-cash fair value adjustments related to contingent purchase consideration, non-cash in-process research and development, or IPR&D, impairment charges, personnel costs, contract research organization fees, and other contracted services pertaining to specific clinical and preclinical studies. Indirect costs consist of corporate overhead costs and other administrative and support costs. The following table summarizes the direct costs attributable to each program and total indirect costs (in thousands):

	Three Months Ended March 31,
	2016		2015
Direct costs:
XTANDI (enzalutamide) program	$	24,552	$	19,385
MDV3800 program		15,427		—
MDV9300 program		8,741		5,700
Early-stage programs		20,033		13,766
Total direct costs		68,753		38,851
Indirect costs		8,834		5,825
Total	$	77,587	$	44,676

Our R&D programs may be subject to change from time to time as we evaluate our priorities and available resources.

For a detailed discussion of the risks and uncertainties associated with the timing and cost of completing a product development plan, see Part II, Item 1A, “Risk Factors—Risks Related to Our Future Product Development Candidates” of this Quarterly Report.

Selling, General and Administrative Expenses

Selling, general and administrative, or SG&A, expenses were as follows (dollars in thousands):

	Three Months Ended March 31,
	2016			2015
Selling, general and administrative expenses	$	96,827		$	83,939
Percentage change		15	%

SG&A expenses increased by $12.9 million, or 15%, to $96.8 million for the three months ended March 31, 2016, from $83.9 million for the prior year period. The increase was primarily due to higher personnel-related costs and higher sales, marketing and medical affairs costs, including certain collaboration expenses incurred by Astellas that do not recur to the same degree in subsequent quarters of the year. These increases were partially offset by accrued payments of $5.9 million to UCLA associated with potential milestone payments from Astellas recognized during the three months ended March 31, 2015. SG&A expenses for the three months ended March 31, 2016 included non-cash fair value adjustments of $4.8 million for contingent purchase consideration related to our BioMarin and CureTech acquisitions, which were recorded as increases to SG&A expenses. SG&A expenses for the three months ended March 31, 2015 included a non-cash fair value adjustment of $3.0 million for contingent purchase consideration related to our CureTech acquisition, which was recorded as an increase to SG&A expenses. We also incurred $1.5 million of higher royalty expenses in the first quarter of 2016 compared to the prior year period as a result of an increase in net sales of XTANDI.

Under our collaboration with Astellas, we are responsible for fifty percent of the cost of goods sold and the royalty payable to UCLA on U.S. net sales of XTANDI. Our share of these items is included in SG&A expenses in our unaudited condensed consolidated statements of operations. As such, those components of our reported SG&A expenses will fluctuate in correlation with net sales of XTANDI in the United States.

Under the Astellas Collaboration Agreement, we and Astellas share certain commercialization costs in the United States. Commercialization cost-sharing payments to Astellas were $18.7 million and $20.1 million for the three months ended March 31, 2016 and 2015, respectively. Commercialization cost-sharing payments to Astellas are recorded as increases in SG&A expenses.

Other Income (Expense), Net

The components of other income (expense), net were as follows (in thousands):

	Three Months Ended March 31,
	2016			2015
Other income (expense), net:
Coupon interest expense	$	(595	)	$	(1,698	)
Non-cash amortization of debt discount and issuance costs		(85	)		(3,910	)
Other, net		(209	)		137
Total	$	(889	)	$	(5,471	)

Other income (expense), net consists of cash interest expense and non-cash interest expense and the impact of changes in foreign exchange rates on our foreign currency-denominated payables, which were not significant.

Income Tax (Expense) Benefit

Income tax (expense) benefit and the effective income tax rate were as follows (dollars in thousands):

	Three Months Ended March 31,
	2016			2015
Income tax (expense) benefit	$	(2,378	)	$	1,780
Effective income tax rate		33.1	%		36.3	%

Income tax expense for the three months ended March 31, 2016 was $2.4 million. The provision for income taxes was lower than the tax computed at the U.S. federal statutory rate for the 2016 period due primarily to the Federal research and development credit, partially offset by state income taxes, non-deductible officers’ compensation and non-deductible stock-based compensation. Income tax benefit for the three months ended March 31, 2015 was $1.8 million. The provision for income taxes was higher than the

tax computed at the U.S. federal statutory rate for the 2015 period due primarily to state income taxes and non-deductible stock-based compensation.

Our effective tax rate was 33.1% for the three months ended March 31, 2016. Our effective tax rate was 36.3% for three months ended March 31, 2015. The decrease in the effective tax rate for the three months ended March 31, 2016 as compared to the prior year period was primarily due to the Federal research and development tax credit that was permanently reinstated in the fourth quarter of 2015.

During the three months ended March 31, 2016, we reduced our current Federal and state taxes payable by $2.5 million related to excess tax benefits from stock-based compensation, offsetting additional paid-in capital.

The future effective tax rate is subject to volatility and may be materially impacted by various internal and external factors. These factors may include, but are not limited to, the amount of income tax benefits and charges from: interpretations of existing tax laws; changes in tax laws and rates; future levels of research and development expenditures; changes in the mix of earnings in countries with differing statutory tax rates in which we may conduct business; changes in the valuation of deferred tax assets and liabilities; state income taxes; the tax impact of stock-based compensation; accounting for uncertain tax positions; closure of statute of limitations or settlement of tax audits; changes in estimates of prior years’ items; tax costs for acquisition-related items; changes in accounting standards; non-deductible officers’ compensation; limitations on the utilization of net operating losses and tax credits due to changes in ownership; and overall levels of income before taxes.

Liquidity and Capital Resources

Our principal source of liquidity is cash generated from our collaboration agreement with Astellas, which is described elsewhere in this Quarterly Report.

At March 31, 2016, we had cash and cash equivalents of $317.4 million, compared with $225.9 million at December 31, 2015. At March 31, 2016, our collaboration receivable from Astellas was $186.6 million, compared with $391.6 million at December 31, 2015. Based on our current expectations, we believe our net current assets, amounts that are available under our Revolving Credit Facility, and our projected cash flows will be sufficient to fund our currently planned operations for at least the next twelve months. This estimate is based on a number of assumptions that may prove to be wrong. In addition, we may choose to raise additional funds in the form of equity, debt, or otherwise due to market conditions or strategic considerations even if we believe we have sufficient funds for our current and future operating plans. For example, we may choose to raise additional capital to fund business development activities, and for other general corporate purposes. For a detailed discussion of the risks and uncertainties associated with our sources of liquidity and access to capital, see Part II, Item 1A, “Risk Factors—Risks Related to the Operation of Our Business.”

In October 2015, we entered into an amendment and restatement of our original credit agreement (the “Credit Agreement”) described elsewhere in this Quarterly Report. The Credit Agreement provides for (i) a five-year $300.0 million Revolving Credit Facility; and (ii) an uncommitted accordion facility subject to the satisfaction of certain conditions (collectively, the “Senior Secured Credit Facility”). The Revolving Credit Facility includes a $50.0 million multicurrency sub-facility, a $20.0 million letter of credit sub-facility, and a $10.0 million swing line loan sub-facility. In October 2015, we borrowed $75.0 million under the Revolving Credit Facility, which we repaid in January 2016. There were no balances outstanding under the Revolving Credit Facility at March 31, 2016.

Cash Flow Analysis

The following table summarizes our cash flows (in thousands):

	Three Months Ended March 31,
	2016			2015
Net cash provided by (used in):
Operating activities	$	165,687		$	57,222
Investing activities		(9,328	)		(2,530	)
Financing activities		(64,851	)		11,267
Net change in cash and cash equivalents	$	91,508		$	65,959

Net cash provided by operating activities totaled $165.7 million for the three months ended March 31, 2016, which consisted of our net income of $4.8 million, non-cash items of $22.9 million and positive changes in our operating assets and liabilities of $138.0 million, which included the collection of a $175.0 million sales milestone payment from Astellas, partially offset by cash utilized in operations that arose in the ordinary course of business.

Net cash provided by operating activities totaled $57.2 million for the three months ended March 31, 2015, which consisted of positive changes in our operating assets and liabilities of $40.3 million and our net loss of $3.1 million adjusted for non-cash items of $20.1 million. Net cash provided by operating activities was primarily driven by collaboration revenue related to U.S. XTANDI net sales, royalties on ex-U.S. XTANDI net sales and sales milestone payments received from Astellas during 2015, partially offset by cash utilized in operations that arose in the ordinary course of business.

Net cash used in investing activities totaled $9.3 million for three months ended March 31, 2016, and consisted of capital expenditures. Net cash used in investing activities totaled $2.5 million for the three months ended March 31, 2015, and consisted of an increase in letters of credit collateralized by restricted cash to secure various leases of $1.6 million and capital expenditures of $1.0 million.

Net cash used in financing activities totaled $64.9 million for the three months ended March 31, 2016, and consisted primarily of the repayment of our borrowing under the Revolving Credit Facility of $75.0 million, partially offset by proceeds from the issuance of common stock under equity incentive and stock purchase plans of $7.7 million and excess tax benefits from stock-based compensation of $2.5 million. Net cash provided by financing activities totaled $11.3 million for the three months ended March 31, 2015, and primarily consisted of proceeds from the issuance of common stock under equity incentive and stock purchase plans.

Commitments and Contingencies

There have been no significant changes in our contractual cash obligations, commercial commitments and contingencies since December 31, 2015, as disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in our Annual Report.

Off-Balance Sheet Arrangements

We are involved with a variable interest entity, or VIE, that performs contract research for us. We have not consolidated this entity because we do not have the power to direct the activities that most significantly impact the VIE’s economic performance and, thus, we are not considered the primary beneficiary of the VIE.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Market risk is the exposure to loss resulting from changes in interest rates, foreign currency exchange rates, commodity prices and equity prices. There were no material changes to our market risk exposures from those disclosed in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report except for our foreign currency exchange risk as discussed below.

Foreign Currency Exchange Risk

Under the Astellas Collaboration Agreement, Astellas records all ex-U.S. XTANDI sales and pays us a tiered royalty ranging from the low teens to the low twenties as a percentage of such sales. The royalties we receive from Astellas on net sales of XTANDI outside of the United States are calculated by converting the respective countries’ XTANDI net sales in local currency to U.S. dollars. The royalties are paid to us in U.S. dollars on a quarterly basis. To date, a significant portion of ex-U.S. sales of XTANDI have been generated in the European Union and in Japan. Therefore, the royalties we receive from Astellas related to ex-U.S. sales of XTANDI are dependent on the value of the U.S. dollar versus the Euro and Japanese Yen. A strengthening of the U.S. dollar compared to current exchange rates would likely result in lower collaboration revenue related to ex-U.S. XTANDI sales. We also conduct certain R&D activities outside of the United States, with expenses incurred in various currencies, including the Euro and Japanese Yen, and these expenses partially offset the currency exposure related to our collaboration revenue from royalties.

In the first quarter of 2016, we began using forward foreign currency exchange contracts to hedge a portion of our gross collaboration royalty revenue, equal to the royalty revenue amount net of our R&D expense related to the Euro and the Japanese Yen. As of March 31, 2016, we had open foreign currency forward contracts with notional amounts of $43.0 million. A hypothetical 10% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates at March 31, 2016 would have resulted in a reduction in fair value of these contracts of approximately $4.0 million on this date and, if realized, would negatively affect earnings over the remaining life of the contracts.

Foreign exchange gains and losses recorded in our unaudited condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015 were not significant.

ITEM 4.

CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is communicated to our management, including our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable, but not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet the reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

As required by Rule 13a-15(b) or Rule 15d-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer) of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2016. Based on the foregoing, our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer) concluded that our disclosure controls and procedures were effective as of March 31, 2016 at the reasonable assurance level.

Changes in Internal Controls

There were no changes in our internal control over financial reporting during the three months ended March 31, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We are involved in legal proceedings, investigations, and claims in the ordinary course of our business, including the matters described below.

In May 2011, we filed a lawsuit in San Francisco Superior Court against the Regents of the University of California, and one of its professors, alleging breach of contract and fraud claims, among others. Our allegations in this lawsuit include that we have exclusive commercial rights to apalutamide, an investigational drug originally known as ARN-509 (previously also referred to as JNJ-56021927, or JNJ-927), which is currently being developed by Aragon Pharmaceuticals, or Aragon. In August 2013, Johnson & Johnson and Aragon completed a transaction in which Johnson & Johnson acquired all apalutamide assets owned by Aragon. We sought remedies including a declaration that we are the proper licensee of apalutamide, contractual remedies conferring to us exclusive patent license rights regarding apalutamide, and other equitable and monetary relief. On August 7, 2012, the Regents filed a cross-complaint against us seeking declaratory relief that the Regents are entitled to ten percent of any sales milestone payments under the Astellas Collaboration Agreement.

On December 20, 2012, and January 25, 2013, the Court granted summary judgment motions filed by defendants Regents and Aragon, resulting in dismissal of all claims against Regents and Aragon, but denied such motions filed by the remaining Regents professor. On April 15, 2013, we filed a Notice of Appeal seeking appeal of the judgment in favor of Aragon, which is now wholly-owned by Johnson & Johnson. The bench trial of the Regent’s cross-complaint against us was conducted in July 2013, and on January 15, 2014, the Court entered a judgment in the cross-complaint in favor of Regents. We appealed this judgment on February 13, 2014 along with the December 2012 summary judgment order in favor of Regents. The jury trial of our breach of contract and fraud claims against the remaining Regents professor was conducted in October and November 2013. On November 15, 2013, the jury rendered a verdict in the case, finding in our favor on one of the breach of contract claims, and in favor of the Regents professor on the fraud claims. We appealed the resulting judgment on the fraud claims. All appeals from this matter were consolidated, oral arguments were heard on February 23, 2016, and the matter was submitted. A decision of the appellate court is required to be rendered within 90 days of when the matter is submitted. On March 8, 2016, the Court’s submission was vacated, on its own order, stating that “further consideration of the merits of the issues raised on appeal is required.” We await further instructions from the Court.

On April 11, 2014, the Regents filed a complaint against us in which the Regents allege that the “Operating Profits” we have received (and will continue to receive) from Astellas, as a result of the Astellas Collaboration Agreement, constitute Sublicensing Income under the license agreement between us and the Regents and that we and our subsidiary, Medivation Prostate Therapeutics, Inc., have failed to pay the Regents ten percent of such Operating Profits. We deny the Regents’ allegations and are vigorously defending the litigation. We are currently awaiting a trial date to be set by the Courts.

While we believe we have meritorious positions with respect to the claims above and intend to advance our positions in these lawsuits vigorously, including on appeal, the process of resolving matters through litigation or other means is inherently uncertain, and it is not possible to predict the ultimate resolution of any such proceeding. The actual costs of defending our position may be significant, and we may not prevail.

ITEM 1A.

RISK FACTORS

Risks facing our business have not changed substantively from those discussed in our Annual Report on Form 10-K for the year ended December 31, 2015, except for those risk factors below designated by an asterisk (*). Our business faces significant risks, some of which are set forth below to enable readers to assess, and be appropriately apprised of, many of the risks and uncertainties applicable to the forward-looking statements made in this Quarterly Report. You should carefully consider these risk factors as each of these risks could adversely affect our business, operating results, cash flows and financial condition. If any of the events or circumstances described in the following risk factors actually occurs, our business may suffer and the trading price of our common stock could decline and our financial condition or results of operations could be harmed. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. These risks should be read in conjunction with the other information set forth in this Quarterly Report. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us, or that we currently believe to be immaterial, may also adversely affect our business.

Risks Related to XTANDI® (enzalutamide) capsules

We and Astellas may not be able to further commercialize XTANDI in the United States, and may fail to continue to generate significant revenue from the sale of XTANDI in the United States. XTANDI may fail to obtain regulatory approval and reimbursement, to be successfully commercialized and to generate significant revenue outside the United States.

We only have one commercial product, XTANDI® (enzalutamide) capsules, or XTANDI, which is approved in the United States to treat men with metastatic castration-resistant prostate cancer, or mCRPC. However, the further commercialization of XTANDI in the United States for the treatment of mCRPC and any other patient populations for which XTANDI is being developed and may subsequently be approved, may not be successful for a number of reasons, including:

•

we and our collaboration partner, Astellas Pharma, Inc., or Astellas, may not be able to establish or demonstrate in the medical community the safety and efficacy of XTANDI and its potential advantages over, and side effects compared to, competing therapeutics and products currently in clinical development for each applicable patient population;

•

our limited experience in marketing XTANDI to urologists;

•

reimbursement and coverage policies of government and private payors such as Medicare, Medicaid, insurance companies, health maintenance organizations and other plan administrators;

•

the price of XTANDI as compared to alternative treatment options;

•

changes or increases in regulatory restrictions;

•

changes to the label for XTANDI that further restrict how we and Astellas market XTANDI, including as a result of routine pharmacovigilance activities and/or data collected from the safety study in patients with known risk factor(s) for seizure that the FDA required us to undertake as a post-marketing requirement or from any other ongoing or future studies;

•

we and Astellas may not have adequate financial or other resources to successfully commercialize XTANDI; and

•

we and Astellas may not be able to obtain adequate commercial supplies of XTANDI to meet demand or at an acceptable cost.

If the further commercialization of XTANDI in the United States is unsuccessful, our ability to generate revenue from product sales and maintain profitability would be adversely affected and our business could be severely negatively impacted.

XTANDI has received marketing approval in the European Union (or Europe, or EU) for the treatment of patients with mCRPC and in Japan for the treatment of patients with castration-resistant prostate cancer, and numerous other countries worldwide for the

treatment of patients with mCRPC. Additional marketing applications for the mCRPC indication are under review in numerous other countries. Unless we and Astellas can obtain additional regulatory approval and reimbursement of XTANDI outside the United States, Japan and the EU, Astellas’ ability to successfully commercialize XTANDI further and our ability to generate additional revenue from XTANDI worldwide, could be significantly limited.

XTANDI may fail to effectively compete commercially with other approved products and other products in development.

There are a number of currently marketed therapies for advanced prostate cancer that compete directly with XTANDI. In addition, several companies are currently developing products or are expected to be marketing products in the near future that compete or may compete directly with XTANDI in its currently approved indication for mCRPC and any other indication for which enzalutamide may be subsequently approved. Our current and future competitors are generally large pharmaceutical companies with considerably greater financial, human, and development and commercialization resources and experiences than ours, including Johnson & Johnson, Sanofi, and Bayer Pharma AG. Some competitive drugs already have acquired substantial shares in these markets or are generic which may make it more difficult for us to compete successfully in these markets notwithstanding any positive results that we may generate from our current or potential future clinical trials for enzalutamide. Also, intense competition from products and compounds in development could impact our ability to successfully conduct upstream clinical trials, as trials may become more difficult to enroll, or complete successfully, as patients may have more treatment options with demonstrated efficacy and safety. Factors upon which XTANDI would have to compete successfully include efficacy, safety, price and cost effectiveness. We cannot guarantee that we and Astellas will be able to compete successfully in the context of any of these factors.

*Pricing pressure from third parties and price competition could substantially impact Astellas’ or our ability to generate revenue from XTANDI and, therefore, negatively impact our business.

The realized price of XTANDI could be subject to pricing pressure from aggressive competitive pricing activity and managed care organizations and institutional purchasers, who use cost considerations to restrict the sale of preferred drugs that their physicians may prescribe. To the extent that payors believe similar lower-priced, branded or generic competitor products may be suitable alternatives for patients, we and our partner Astellas may consider reducing the price of XTANDI or be subject to formulary restrictions, which could result in a loss of sales revenue and/or market share. Additionally, XTANDI currently competes against products and could compete in the future with products marketed by some of the world’s largest and most experienced pharmaceutical companies, such as Johnson & Johnson, who have more resources and greater flexibility to engage in aggressive price competition in order to gain revenues and market share. It is uncertain whether we and Astellas could successfully compete with such competition and our failure to compete or a decision to reduce the price of XTANDI in order to compete could severely impact our business.

Moreover, non-profit groups have recently petitioned the U.S. federal government to exercise their “march-in” rights under the Bayh-Dole Act due to the difference in price of XTANDI in the U.S. versus abroad since certain patents which cover XTANDI were allegedly developed with federal funding. In March 2016, the National Institutes of Health, or NIH, reiterated its continuing position that drug pricing does not meet the statutory requirements justifying use of its march-in authority. Subsequently, several members of Congress, including presidential candidate Bernie Sanders, requested that the U.S. Department of Health and Human Services and NIH hold public hearings to determine if we and our partner Astellas have not met the statutory requirement to make XTANDI available to U.S. residents on reasonable terms. While the government has yet to exercise its march-in rights in response to pricing pressures or shortage problems, it may do so in the future which would significantly negatively impact our ability to generate revenue from XTANDI.

Competition from other approved products, including those that mechanistically operate similarly to XTANDI, could negatively impact the expected use or duration of therapy of XTANDI, and impact our ability to generate revenue.

We are competing and will continue to compete against drugs that operate similarly to XTANDI. If XTANDI is unable to successfully compete for a position in the prostate cancer treatment paradigm ahead of drugs like Zytiga and/or potentially apalutamide (formerly JNJ-56021927, or JNJ-927, and ARN-509), which are now being investigated in Phase 3 clinical studies in earlier stage prostate cancer, sales of XTANDI may be negatively impacted. In addition, the availability of multiple other approved agents to treat the same patients being treated with XTANDI could cause treating physicians to switch patients off of XTANDI and onto competing therapies more quickly than would otherwise be the case, which could also negatively impact XTANDI net sales.

Competition from generic products could potentially harm our business and result in a decrease in our revenue.

Like other branded pharmaceutical companies, we face competition from generic products that could potentially harm our business and result in a decrease in our revenue. Such competition may arise from the loss or expiration of intellectual property rights on enzalutamide or a competitor product, or the approval by the FDA of a generic of our product or a competitor product, such as Zytiga, any of which could adversely affect our business by putting downward pressure on the price and market share of XTANDI. Generic products for the treatment of prostate cancer that have already been approved by the FDA, e.g., Casodex, are

generally sold at a lower price than branded drugs. Furthermore, Abbreviated New Drug Applications (ANDAs) requesting approval for generic versions of Zytiga were submitted to the FDA on April 28, 2015. See the risk factor below entitled, “Risks Related to the Pharmaceutical Industry, Including the Activities of Medivation, Inc.— If the FDA or other applicable regulatory authorities approve generic products that compete with any of our products or product candidates, the sales of our products or product candidates may be adversely affected,” for additional information regarding general risks related to generic and biosimilar competition in our industry.

We have recently increased our promotional efforts and focus in the United States to include urologists as well as oncologists. If we are not successful in marketing XTANDI to these physician audiences, the commercial potential of XTANDI may not be realized.

We have recently increased promotional efforts in the United States to include urologists as well as oncologists as a result of the expanded label of XTANDI in the United States to treat mCRPC patients who have not yet received chemotherapy (September 2014). Our efforts include expanding and dividing our sales force into urology- and oncology-focused teams. Failure to successfully commercialize XTANDI to urologists and oncologists would have a negative impact on our business and future prospects.

We are dependent upon our collaborative relationship with Astellas to further develop, fund, manufacture and commercialize XTANDI, and if such relationship is unsuccessful, or if Astellas terminates our collaboration agreement with them, it could negatively impact our ability to conduct our business and generate revenue from XTANDI.

Under our collaboration agreement with Astellas, Astellas is responsible for developing, seeking regulatory approval for, and commercializing XTANDI outside the United States and is responsible globally for all manufacture of product for both clinical and commercial purposes. We and Astellas are jointly responsible for commercializing XTANDI in the United States. We and Astellas share equally the costs (subject to certain exceptions), profits and losses arising from development and commercialization of XTANDI in the United States. For clinical trials useful both in the United States and in Europe or Japan, we are responsible for one-third of the total costs and Astellas is responsible for the remaining two-thirds. We are subject to a number of risks associated with our dependence on our collaborative relationship with Astellas, including:

•

Astellas’ right to terminate the collaboration agreement with us on limited notice for convenience (subject to certain limitations), or for other reasons specified in the collaboration agreement;

•

the need for us to identify and secure on commercially reasonable terms the services of third parties to perform key activities currently performed by Astellas in the event that Astellas were to terminate its collaboration with us, including development and commercialization activities outside of the United States and manufacturing activities globally;

•

adverse decisions by Astellas regarding the amount and timing of resource expenditures for the commercialization of XTANDI;

•

adverse decisions by Astellas regarding whether or not to initiate claims or litigation against third parties for infringement of proprietary rights protecting XTANDI or to determine the scope and validity of proprietary rights covering XTANDI or proprietary rights held by competitors;

•

failure by Astellas to negotiate favorable coverage determinations and adequate reimbursement rates with third-party payors;

•

decisions by Astellas to prioritize other of its present or future products more highly than XTANDI for either development and/or commercial purposes;

•

possible disagreements with Astellas as to the timing, nature and extent of our development plans, including clinical trials or regulatory approval strategy, which if we disagree could significantly delay or halt development of XTANDI; and

•

the financial returns to us, if any, under our collaboration agreement with Astellas, depend in large part on the generation of product sales, and if Astellas fails to perform or satisfy its obligations to us, the development or commercialization of XTANDI would be delayed or may not occur and our business and prospects could be materially and adversely affected.

Due to these factors and other possible disagreements with Astellas, we may be delayed or prevented from further developing, manufacturing or commercializing XTANDI or we may become involved in litigation or arbitration, which would be time consuming and expensive. For example, we understand that Astellas has not made a final decision on the phase 3 clinical trial evaluating enzalutamide in triple negative breast cancer.

If Astellas were to terminate our collaborative relationship unilaterally, we would need to undertake development and commercialization activities for XTANDI solely at our own expense and/or seek one or more other partners for some or all of these activities, worldwide. If we pursued these activities on our own, it would significantly increase our capital and infrastructure requirements, might limit the indications we are able to pursue for XTANDI, and could prevent us from effectively commercializing XTANDI. If we sought to find one or more other pharmaceutical company partners for some or all of these activities, we may not be

successful in such efforts, or they may result in collaborations that have us expending greater funds and efforts than our current relationship with Astellas.

*We are dependent on third-party manufacturers for commercial supply of XTANDI and for clinical trial materials and if we fail to receive such adequate supplies, global sales of XTANDI could be limited and clinical trials could be delayed.

We require adequate supplies of enzalutamide for commercial supply of XTANDI, and for use in clinical trials. Under our collaboration agreement, Astellas has the responsibility to manufacture commercial supplies of XTANDI for all markets and provide material for clinical studies. Astellas fulfills its manufacturing and supply obligations largely through third-party contract manufacturers. Consequently, we are, and expect to remain, dependent on Astellas and its contract manufacturers for commercial and clinical trial materials. If Astellas cannot provide the materials on a timely basis due to, for example, raw materials availability, quality issues or failure of the contracting facilities to perform or comply with current good manufacturing practices, or cGMP, it could result in decreased sales or put at risk ongoing clinical studies. If Astellas or its contract manufacturers do not perform, we may be forced to incur additional expenses, delays, or both, to arrange or take responsibility for contract manufacturers to manufacture or package XTANDI or enzalutamide on our behalf, as we do not have any internal manufacturing or packaging capabilities.

We also rely on our own third-party vendors for clinical supplies. If clinical supplies cannot be provided on a timely basis it could put at risk our sponsored clinical studies with XTANDI or enzalutamide.

In some instances, we and Astellas are dependent on third-party suppliers of raw materials, intermediates or finished goods of commercial supplies of XTANDI and clinical trial materials. If any of these suppliers or subcontractors fails to meet our or Astellas’ needs, we may not have readily available alternatives. If we or Astellas experience a material supplier or subcontractor inability to supply, our ability to satisfactorily and timely complete our clinical trial or delivery obligations could be negatively impacted which could result in reduced sales, termination of contracts and damages to our relationships with clinical trial sites and the medical community. We could also incur additional costs to address and resolve such an issue. Any of these events could have a negative impact on our results of operations and financial condition.

We are dependent on Astellas to distribute and sell XTANDI, and if Astellas fails to adequately perform these activities, our business would be negatively impacted.

Under our collaboration agreement with Astellas, we and Astellas have the right to jointly promote XTANDI to customers in the United States. However, Astellas has the sole right to distribute and sell XTANDI to customers in the United States and the sole right to promote, distribute and sell XTANDI to customers outside the United States. We are thus partially dependent on Astellas to successfully promote XTANDI in the United States, and solely dependent on Astellas to successfully distribute and sell XTANDI in the United States and to promote, distribute and sell XTANDI outside of the United States. In the United States, we depend on customer support from specialty pharmaceutical distributors and wholesalers in Astellas’ network. Astellas has contracted with a limited number of specialty pharmaceutical distributors and wholesalers to deliver XTANDI to end users. The use of specialty pharmacies and wholesalers requires significant coordination with Astellas’ sales and marketing, medical affairs, regulatory affairs, legal and finance organizations and involves risks, including but not limited to risks that these specialty pharmacies and wholesalers will:

•

not provide Astellas accurate or timely information regarding their inventories, patient- or account-level data or safety complaints regarding XTANDI;

•

not effectively sell or support XTANDI;

•

not devote the resources necessary to sell XTANDI in the volumes and within the timeframes that we expect; or

•

cease operations.

We generally do not have control over the resource or degree of effort that any of the specialty pharmacies and distributors may devote to XTANDI, and if their performance is substandard, this will adversely affect sales of XTANDI. If Astellas’ network of specialty pharmacies and distributors fails to adequately perform, it could negatively impact sales of XTANDI, which would negatively impact our business, results of our operations, cash flows and liquidity.

XTANDI may not be commercially successful if not widely covered and appropriately reimbursed by third-party payors, and we are dependent upon Astellas for the execution of third-party payor access and reimbursement strategies for XTANDI.

Our ability to successfully commercialize XTANDI for its approved indications depends, in part, on the extent to which coverage and adequate reimbursement for XTANDI is available from government and health administration authorities, private health insurers, managed care programs and other third-party payors, both in the United States and globally.

In addition, even if third-party payors ultimately elect to cover and reimburse XTANDI, most payors will not reimburse 100% of the cost, but rather require patients to pay a portion of the cost through a co-payment. Thus, even if reimbursement is available, the percentage of drug cost required to be borne by patients may make use of XTANDI financially difficult or impossible for certain patients, which would have a negative impact on sales of XTANDI. For example, in the United States there exists a coverage gap, or “donut hole”, in the Medicare Part D coverage for prescription medications for participants, which renews annually each January 1st. While in the donut hole, Medicare Part D participants, including many patients in XTANDI’s approved indication, may have to pay out-of-pocket a substantial portion of their prescription drug costs, which may discourage physicians from prescribing or patients from accessing XTANDI. It is increasingly difficult to obtain coverage and adequate reimbursement levels from third-party payors, and we may be unable to achieve these objectives. Moreover, our commercial prospects would be further weakened if payors approve coverage for XTANDI only as second- or later-line treatments, or if they place XTANDI in tiers requiring unacceptably high patient co-payments. Since launch, several third-party payors have included in their coverage criteria use of XTANDI after patient treatment on Zytiga plus prednisone or if there is a contra-indication to prednisone or Zytiga. These coverage situations may persist even with expanded indications for XTANDI. Because XTANDI works via a similar molecular signaling pathway as Zytiga does, patients who have already failed treatment with Zytiga may not have as strong a response on XTANDI as would patients who are Zytiga-naïve. Failure to overturn coverage decisions or stop additional coverage decisions could materially harm our (or our partner’s) ability to successfully market XTANDI in the United States. Achieving coverage and acceptable reimbursement levels typically involves negotiating with individual payors and is a time-consuming and costly process. Therefore, obtaining acceptable coverage and reimbursement from one payor does not guarantee similar acceptable coverage or reimbursement from another payor. Additionally, even if favorable coverage and adequate reimbursement levels are achieved, the payor may change its decision in the future. We are dependent upon Astellas globally for the achievement of such coverage and acceptable reimbursement, and for negotiation with individual payors.

We and Astellas are required to undertake certain studies to comply with post-marketing requirements or commitments in the EU and the United States, which could result in adverse modifications to XTANDI’s existing labeling, and risk XTANDI’s ability to obtain additional regulatory approvals for additional patient populations.

In the EU, we and Astellas are required to collect efficacy data on mCRPC patients previously treated with Zytiga to determine XTANDI’s efficacy response in such patients, which we do not expect to be as good as in patients naïve to Zytiga, and anticipate that these results may be available as early as 2016. In the United States, we and Astellas are required to conduct an open-label safety study of XTANDI in patients with known risk factor(s) for seizure and to report the results of that study to the FDA in 2019. If the results of this study reveal unacceptable safety risks, this could result in decreased commercial utilization of XTANDI for mCRPC patients in the United States and in the EU, failure to obtain approval in other indications, and modifications to the existing label for XTANDI, including potentially a boxed warning, or additional clinical testing. Any one or more of these outcomes would seriously harm our business. Additionally, we could receive additional post-marketing requirements as we seek approval of XTANDI in additional patient populations. Failure to conduct the post-marketing requirements or commitments in a timely manner may result in withdrawal of approval for XTANDI and substantial civil and/or criminal penalties.

*If significant patient safety issues were to arise for XTANDI or our other product candidates, our future sales may be reduced, adversely affecting our results of operations.

The data supporting the marketing approvals for our products and forming the basis for the safety warnings in our product labels were obtained in controlled clinical trials of limited duration and, in some cases, from post-approval use. As our products are used over longer periods of time by many patients with underlying health problems, taking numerous other medicines, we expect to continue to find new issues such as safety, resistance or drug interactions of XTANDI or in other products, which may require us to provide additional warnings or contraindications on our labels or narrow our approved indications, each of which could reduce the market acceptance of these products. For example, in 2015, based upon routine pharmacovigilance review and signal detection, we and Astellas submitted a label change to the FDA after identifying two post-marketing reports of posterior reversible encephalopathy syndrome, or PRES, in patients receiving XTANDI. PRES is a neurological disorder which can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging, or MRI. Because PRES was reported voluntarily from a post-marketing population of uncertain size, it is not possible to reliably estimate the frequency or establish a causal relationship to XTANDI. Discontinue XTANDI in patients who develop PRES.

Regulatory authorities have been moving towards heightened pharmacovigilance, including requests for additional post-approval analyses to detect possible safety signals, and more transparent pharmacovigilance, such as making additional stand-alone safety information directly available to the public through websites and other means, e.g., periodic safety update report summaries, risk management plan summaries and various adverse event data. Safety information, without the appropriate context and expertise, may be misinterpreted and lead to misperception or legal action which may potentially cause our product sales or stock price to decline.

Further, if serious safety, resistance or drug interaction issues arise with XTANDI, product sales could be limited or halted by us or by regulatory authorities and our results of operations would be adversely affected.

XTANDI and any other product candidates that may receive regulatory approval in the future will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense as well as significant penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products and product candidates.

We are required to monitor the safety and efficacy of XTANDI and any other products candidates that are approved by the FDA. In addition, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for any approved products, such as XTANDI, will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration and listing, as well as continued compliance with current good clinical practices, or cGCP, for any clinical trials that we conduct post-approval. We and our contract manufacturers will be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMP. We must also comply with requirements concerning advertising and promotion for XTANDI and any other product candidates for which we obtain marketing approval in the future. Promotional communications with respect to prescription drugs, including biologics, are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved labeling. Thus, we will not be able to promote XTANDI or any other products candidates for which we might obtain approval in the future for indications or uses for which they are not approved. Later discovery of previously unknown problems with XTANDI or any other product candidate for which we might obtain approval in the future, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:

•

restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;

•

restrictions on such products’ manufacturing processes;

•

restrictions on the marketing of a product;

•

restrictions on product distribution;

•

requirements to conduct post-marketing clinical trials;

•

untitled or warning letters;

•

withdrawal of the products from the market;

•

refusal to approve pending applications or supplements to approved applications that we submit;

•

recall of products;

•

fines, restitution or disgorgement of profits or revenue;

•

suspension or withdrawal of regulatory approvals;

•

refusal to permit the import or export of our products;

•

product seizure;

•

injunctions;

•

imposition of civil penalties; or

•

criminal prosecution.

The FDA’s and other regulatory authorities’ policies may change and additional government regulations may be enacted that could affect the marketing of XTANDI or prevent, limit or delay regulatory approval of our other product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not sustain profitability.

If we are unable to successfully develop enzalutamide for breast cancer with a suitable diagnostic, we may not be able to obtain regulatory approval for enzalutamide for breast cancer or realize the full potential for enzalutamide.

We may initiate a Phase 3 clinical trial evaluating enzalutamide in triple negative breast cancer, or TNBC. A key element of our strategy to develop enzalutamide in TNBC is the use of a companion diagnostic to identify patients with TNBC appropriate for treatment with enzalutamide. Patients whose tumors test positive for a gene expression profile may be more likely to respond to

treatment with enzalutamide; patients whose tumors test negative may not be responsive to treatment with enzalutamide. Both regulatory approval and, if approval is obtained, successful commercialization of enzalutamide in TNBC will, therefore, likely depend on our successful development of such a companion diagnostic.

We and Astellas have entered into a collaboration with NanoString Technologies, Inc. to translate our gene expression signature algorithm into a companion diagnostic assay using NanoString’s nCounter Dx Analysis System. However, we may encounter difficulties in developing enzalutamide for TNBC and/or developing the companion diagnostic for clinical, regulatory and/or commercial reasons including issues related to analytical validation, reproducibility or clinical validation.

Companion diagnostics are subject to regulation by the FDA as a medical device and require separate regulatory clearance prior to commercialization. Companion diagnostics are also subject to regulation by foreign regulatory authorities and such regulations may change or new regulations may be enacted during our development of the companion diagnostic. We may be unable to alter our development program in time to comply with the revised or new regulations, or we may only be able to do so by expending greater funds and efforts, and any delay or failure to obtain regulatory approval could delay or prevent the approval of enzalutamide for TNBC.

Risks Related to our License and Manufacturing and Supply Agreement with CureTech, Ltd.

The clinical molecule MDV9300 we licensed from CureTech is a biologic molecule, and we do not have long-standing experience or expertise in the development, manufacture, or commercialization of biologic molecules.

Under the license agreement, we are responsible for all development, manufacturing, and commercialization activities for MDV9300 for all indications, including in oncology. We have limited history, experience, or expertise in the development, manufacturing and commercialization, including regulatory interactions, commercial manufacturing, and distribution of biologic molecules, like MDV9300.

The successful development, testing, manufacturing and commercialization of biologics involves a long, expensive, and uncertain process. There are unique risks and uncertainties with biologics, including:

•

The development, manufacturing and marketing of biologics are subject to regulation by the FDA, the European Medicines Agency or EMA, and other regulatory bodies. These regulations are often more complex and extensive than the regulations applicable to other pharmaceutical products;

•

Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies to handle living cells. Each lot of an approved biologic must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing biologics requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. For MDV9300, we plan to implement changes in manufacturing site and to improve the manufacturing process to provide for larger manufacturing lot sizes, as well as the critical analytical assays. Comparability data will be required to support these changes; and

•

The use of biologically derived ingredients can lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. Any of these events could result in substantial costs.

We are currently dependent on CureTech to produce clinical supply of MDV9300 that meets global regulatory standards and CureTech is dependent on its suppliers for sufficient quantities of raw materials, starting materials, and supplies. If CureTech fails to manufacture clinical supply of MDV9300 in sufficient quantities or fails to source raw or starting materials or supplies in sufficient quantities, our ability to conduct clinical trials could be further delayed or otherwise negatively impacted.

Our failure to successfully develop, manufacture, or commercialize MDV9300 could significantly impact our ability to generate value from the License Agreement with CureTech.

*Our Phase 2 clinical trial of MDV9300 in DLBCL has been delayed, which could result in increased cost and could delay, prevent or limit our ability to generate value from and realize the commercial potential of MDV9300.

In early January 2016, we advised the FDA of our conclusion that MDV9300 does not bind PD-1, and the agency placed the investigational new drug applications, or INDs, on clinical hold and requested that we revise our characterization of MDV9300 in the related investigator brochure, protocols and informed consent documents. We submitted the revised documents in early February 2016, and the FDA lifted the clinical hold in March 2016. We intend to submit an amendment to our INDs for MDV9300 to modify

the production process to better support our planned clinical activities in the first half of 2016 and intend that patients in our Phase 2 DLBCL trial will be treated with MDV9300 manufactured in accordance with the amended IND. We do not intend to proceed with the trial until MDV9300 manufactured in accordance with the amended INDs is available. These circumstances contributed to a delay in the DLBCL trial and to a partial impairment charge recorded in the fourth quarter of 2015, and it is possible they could contribute to further delays or increased costs that could prevent or limit our ability to generate value from and realize the commercial potential of MDV9300.

*If we are unable to determine the binding target for MDV9300, we may fail to successfully develop MDV9300 for DLBCL, multiple myeloma or any other indication, and we may not be able to obtain regulatory approval or realize the full potential for MDV9300.

Although the molecule was originally understood to work primarily via PD-1 (Programmed Death-1) binding, our work as well as that of others has also suggested other potential binding activity. During 2015, we conducted testing and characterization work to better identify the binding target and, in late December 2015, we concluded that MDV9300 does not bind PD-1. While we intend to continue work to identify the binding target and thereafter develop a target-specific release assay, these activities are time consuming, expensive and there is no assurance that we will be successful since the binding mechanism is currently unknown. Furthermore, there can be no assurance that we will not experience additional development issues in the future which may cause further delays or unanticipated costs, or that we will be able to solve such development issues. Our failure to identify the binding target for MDV9300 or to develop a target-specific release assay would significantly impact our ability to obtain regulatory approval and could materially harm our business.

The development and commercialization of MDV9300 may face strong competition from other immuno-oncology agents that have already received marketing approval and are being developed for additional indications by larger companies with substantial resources and relatively more experience developing, manufacturing, and commercializing biologic molecules.

The immuno-oncology field is competitively crowded with more than 100 immuno-oncology agents, including biologic molecules, vaccines, modified T-cells, and adjuvants, currently approved and on the market or in development for various tumor types and patient populations by larger more experienced companies than ours, such as Bristol Myers Squibb, Roche, AstraZeneca, Pfizer and Merck. This competitive environment could compromise our ability to develop MDV9300 by limiting the availability of clinical trial investigators, sites, and/or appropriate clinical patients, which could slow, delay or limit the progress of MDV9300’s development. Even if we are able to successfully develop MDV9300 and obtain regulatory approval for it in an oncology indication, the competition from already approved immuno-oncology molecules and other agents in the same or similar oncology indications could significantly limit our ability to generate revenue from MDV9300. While we have some experience developing and in certain aspects of the commercialization of small molecule products, we may be required to hire additional qualified employees with experience developing, manufacturing, and commercializing, including regulatory interactions, commercial manufacturing, and distributing biological molecules, like MDV9300. Many of our competitors are large, multinational pharmaceutical and biotechnology companies with considerably more resources and experience with biological molecules than us.

Risks Related to Our Future Product Development Candidates

Our business strategy depends on our ability to identify and acquire additional product candidates. We may never acquire or identify such product candidates for reasons that may not be in our control, or are otherwise unforeseen or unforeseeable to us.

A key component of our business strategy is to diversify our product development risk by identifying and acquiring new product opportunities for development. However, we may not be able to identify promising new technologies. In addition, the competition to acquire promising biomedical technologies is fierce, and many of our competitors are large, multinational pharmaceutical, biotechnology and medical device companies with considerably more financial, development and commercialization resources and experience than we have. Thus, even if we succeed in identifying promising technologies, we may not be able to compete against our larger competitors with considerably more financial resources or we may not be able to acquire rights to them on acceptable terms or at all. If we are unable to identify and acquire new technologies, we will be unable to diversify our product risk. We believe that any such failure would have a significant negative impact on our prospects.

*Pharmaceutical and biological product candidates require extensive, time-consuming and expensive preclinical and clinical testing to establish safety and efficacy, and to obtain regulatory approval. If we are unable to successfully develop and test our product candidates, we will not be successful.

The research and development of pharmaceuticals and biological products is an extremely risky industry. Only a small percentage of product candidates that enter the development process ever receive regulatory approval. The process of conducting the preclinical and clinical testing required to establish safety and efficacy and obtain regulatory approval is expensive and uncertain and

takes many years. If we are unable to complete preclinical or clinical trials of current or future product candidates, due to safety concerns with a product candidate, or if the results of these trials are not satisfactory to convince regulatory authorities of their safety or efficacy, we will not be able to obtain regulatory approval for commercialization. As more product candidates within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change.

We cannot be certain if any of our product candidates will be approved by regulatory authorities. Furthermore, even if we are able to obtain regulatory approvals for any of our product candidates, those approvals may be for indications that are not as broad as desired or may contain other limitations that would adversely affect our ability to generate revenue from sales of those products. Moreover, if we are not able to differentiate our product against other approved products within the same class of drugs, or if any of the other circumstances described above occur, our business would be materially harmed and our ability to generate revenue from that class of drugs would be severely impaired.

Enrollment and retention of patients in clinical trials of enzalutamide and other product candidates are expensive and time-consuming processes, could be made more difficult or rendered impossible by competing treatments or clinical trials of competing drugs in the same or other indications, and could result in significant delays, cost overruns, or both, in our product development activities, or in the failure of such activities.

We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data with respect to the study drug, the number and nature of competing treatments and ongoing clinical trials of competing drugs for the same indication, the proximity of patients to clinical sites and the eligibility criteria for the study. Furthermore, any negative results we may report in clinical trials of enzalutamide or any potential future product candidates may make it difficult or impossible to recruit and retain patients in other clinical studies of that same product candidate. Delays or failures in planned patient enrollment and/or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop enzalutamide or any product candidates, or could render further development impossible.

Our reliance on third parties for the operation of our business may result in material delays, cost overruns and/or quality deficiencies in our development programs.

We currently rely on third parties to perform key product development tasks, such as laboratories to conduct preclinical testing, clinical research organizations to help us manage our clinical studies, investigators and investigative sites who conduct the clinical trials, and contract manufacturing organizations to manufacture our product candidates at appropriate scale for preclinical and clinical trials. In addition, we currently rely on Astellas and its third party vendors to supply commercial quantities of XTANDI. To manage our business successfully, we will need to identify, engage and properly manage qualified third parties that will perform these development and manufacturing activities. For example, we need to monitor the activities of our vendors closely to ensure that they are performing their tasks correctly, on time, on budget and in compliance with strictly enforced regulatory standards. We need to monitor investigators who participate in our clinical trials to ensure that they are conducting the trial in compliance with the protocol, cGCP and all applicable laws. Our ability to identify and retain key vendors, investigators and investigative sites with the requisite knowledge is critical to our business and the failure to do so could negatively impact our business. Because all of our key vendors perform services for other clients in addition to us, we also need to ensure that they are appropriately prioritizing our projects. If we fail to manage our key vendors well, we could incur material delays, cost overruns or quality deficiencies in our development and commercialization programs, as well as other material disruptions to our business.

Patient safety issues may arise from investigator-sponsored research with our product candidates, which may adversely affect our development program for such product candidates.

We are committed to improving patient care through research that advances the medical and scientific knowledge of XTANDI and our product candidates. In support of this commitment, we, in collaboration with our partner Astellas, have established an investigator-sponsored research program as a mechanism for independent researchers to seek support for preclinical and clinical research studies with enzalutamide. We also provide support for investigator-sponsored research with MDV3800 and MDV9300. However, because we are not the sponsor of investigator-sponsored research studies, we cannot control how such studies are conducted. If new patient safety issues arise from use of our product candidates in these investigator-sponsored research studies, our development programs may be adversely affected which could impact our business and the results of our operations.

Risks Related to the Operation of our Business

We may incur substantial costs in the foreseeable future as we continue our development and commercialization activities and may not maintain or increase profitability on a quarterly or annual basis.

We have incurred significant costs principally from funding our research and development activities, from general and administrative expenses and from our XTANDI commercialization activities. We may incur substantial costs in the foreseeable future as we continue to finance the commercialization of XTANDI in the U.S. market, preclinical and clinical studies of enzalutamide, MDV3800, MDV9300 and early stage programs, potential business development activities, and our corporate overhead costs, which could impact our ability to maintain or increase profitability on a quarterly or annual basis. Our ability to generate revenue sufficient to offset these costs in order to maintain or increase profitability on a quarterly or annual basis is dependent on our ability, alone or with collaboration partners, to successfully commercialize products for which we receive marketing approval.

Our operating results are unpredictable and may fluctuate. If our operating results are below the expectations of securities analysts or investors, the market value of our common stock could decline.

Our operating results are difficult to predict and will likely fluctuate from quarter to quarter and year to year. Due to the competitive market for mCRPC therapies, XTANDI net sales will be difficult to predict from period to period. As a result, you should not rely on XTANDI net sales results in any period as being indicative of future performance and sales of XTANDI may be below the expectation of securities analysts or investors in the future. Additionally, you should not place undue reliance on the forward-looking statements about expectations for future XTANDI net sales from our partner Astellas, as we may not agree with such statements, or from us, as XTANDI net sales results are difficult to predict. We believe that our quarterly and annual results of operations may be affected by a variety of factors, including:

•

the price and level of demand for XTANDI;

•

the extent to which coverage and reimbursement for XTANDI is available from government and health administration authorities, private health insurers, managed care programs and other third-party payors;

•

the timing, cost and level of investment in our and Astellas’ sales and marketing efforts to support XTANDI sales;

•

the timing, cost and level of investment in our research and development activities involving XTANDI and our product candidates;

•

the cost of manufacturing XTANDI, and the amount of legally mandated discounts to government entities, other discounts and rebates, product returns and other gross-to-net deductions;

•

the risk/benefit profile, cost and reimbursement of existing and potential future branded and generic drugs which compete with XTANDI;

•

the timeliness and accuracy of financial information we receive from Astellas regarding XTANDI net sales globally, and shared U.S. development and commercialization costs for XTANDI incurred by Astellas, including the accuracy of the estimates Astellas uses in calculating any such financial information including for gross-to-net revenue adjustments;

•

inventory levels at pharmaceutical wholesalers and distributors;

•

expenditures that we will or may incur to acquire or develop additional technologies, product candidates and products; and

•

the impact of fluctuations in foreign currency exchange rates.

In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award, and recognize the cost as a non-cash operating expense over the employee’s requisite service period. As the variables that we use as a basis for valuing these awards change over time, including our underlying stock price and stock price volatility, the magnitude of the non-cash expense that we must recognize may vary significantly.

We are required to evaluate the fair value of intangible assets, including in-process research and development, or IPR&D, for impairment at least annually or more frequently if impairment indicators exist. These assets are initially measured at fair value and therefore any change to our assumptions used in the valuations could potentially lead to impairment. Some of the more common potential risks leading to impairment include competition, earlier than expected loss of exclusivity, pricing pressures, adverse regulatory changes or clinical trial results, delay or failure to obtain regulatory approval and additional development costs, inability to achieve expected synergies, higher operating costs, changes in tax laws and other macro-economic changes. If any of these or similar issues arise during development, we may need to re-evaluate our IPR&D and incur a non-cash impairment charge, adversely affecting our consolidated results of operations.

Additionally, each reporting period, we revalue contingent consideration obligations associated with business acquisitions to their fair value and record increases in fair value as non-cash contingent consideration expense and decreases in fair value as non-cash

contingent consideration income. Changes in contingent consideration result from changes in assumptions regarding the probability of successful achievement of related milestones, the estimated timing in which the milestones may be achieved and the discount rates used to estimate the fair value of the liability. Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our estimates.

For these and other reasons, it is difficult for us to accurately forecast future profits or losses. As a result, it is possible that in some quarters our operating results could be below the expectations of securities analysts or investors.

Sales fluctuations of XTANDI as a result of inventory levels at Astellas’ customers (such as pharmaceutical wholesalers and distributors) may cause our revenue to fluctuate, which could adversely affect our financial results and the market value of our common stock.

The pharmaceutical wholesalers and distributors with whom Astellas has entered into inventory management agreements make estimates to determine end user demand and may not always be effective in matching their inventory levels to actual end user demand. As a result, changes in inventory levels held by those wholesalers and distributors can cause our operating results to fluctuate unexpectedly if sales of XTANDI to these wholesalers do not match end user demand. Adverse changes in economic conditions or other factors may cause wholesalers and distributors to reduce their inventories of XTANDI. As inventory of XTANDI in the distribution channel fluctuates from quarter to quarter, we may see corresponding fluctuations in reported collaboration revenue from XTANDI net sales.

*A significant and growing amount of the collaboration revenue we generate is in currency other than U.S. dollars, primarily the Euro and the Japanese yen, thereby exposing us to foreign currency exchange rate risk.

A significant and growing amount of our collaboration revenue is generated from royalties on ex-U.S. net sales of XTANDI. The royalties we receive from Astellas on net sales of XTANDI outside of the United States are calculated by converting the respective countries’ XTANDI net sales in local currency to U.S. dollars for payment to us on a quarterly basis. A strengthening of the U.S. dollar relative to current currency exchange rates would result in lower collaboration revenue related to ex-U.S. XTANDI net sales than otherwise would have been reported by us and paid to us.

Beginning in the first quarter of 2016, we implemented a policy to hedge a portion of our exposure to fluctuating currency rates for the Euro and the Japanese yen in order to mitigate unexpected short-term volatility of such rates. Depending on the size of the exposures and the relative movements of exchange rates, if we fail to effectively hedge our exposures, we could experience adverse effects on our reported financial results.

*If we fail to attract and keep senior management personnel, we may be unable to successfully develop our product candidates, identify and acquire promising new technologies, conduct our clinical trials, and commercialize our products, and our business could be harmed.

Our future success depends upon the continued services of our executive officers and our ability to attract, retain, and motivate highly qualified management to oversee our business. None of our executive officers is bound by an employment agreement for any specific term, and they may terminate their employment at any time. We are particularly dependent on the continued services of David Hung, M.D., our president and chief executive officer and a member of our board of directors. Dr. Hung identified enzalutamide for acquisition and has primary responsibility for identifying and evaluating other potential product candidates. We believe that Dr. Hung’s services in this capacity would be difficult to replace.

Although we have not historically experienced unique difficulties attracting and retaining qualified employees, we could experience such problems in the future. Competition for qualified personnel in the biotechnology and pharmaceutical fields is intense, especially in the San Francisco Bay Area. Recent acquisition interest in the company from third parties may make it harder for us to effectively compete for such talent because of perceived uncertainty regarding the company’s future. If we are unable to attract and retain qualified personnel on acceptable terms, or there is a significant turnover in our senior management or among our employees as a result of the uncertainty created by the acquisition interest, we may face challenges to our inability to recruit and hire additional personnel which could impair the successful commercialization of XTANDI, delay or prevent continued development activities for enzalutamide, MDV3800, MDV9300 and other product candidates, delay or prevent the transfer and integration of MDV3800 into our business and adversely affect or preclude the identification and acquisition of new product candidates, any of which events could harm our business.

*We may encounter difficulty managing our growth and expanding our operations successfully.

Our business has experienced significant growth, which we expect will continue as we expand our commercialization efforts for XTANDI, seek to advance our product candidates through clinical trials, and integrate the acquisition of MDV3800 and other

potential business development activities. We expect that we will need to expand our development, regulatory, manufacturing, and commercial capabilities in concert with contracting with third parties to provide certain of these activities for us. To that end, we must be able to hire, train and integrate additional personnel effectively in order to manage our commercialization and development activities, which may be difficult if we are impeded from doing so because of acquisition interest in the company from third parties and uncertainty regarding the company’s future.

Our failure to accomplish any of these tasks could prevent us from successfully growing our company. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. If we are not able to effectively manage the expansion of our operations, it may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. In addition, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Thus, our future financial performance and our ability to develop and commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively.

We will need to expand our organization to successfully commercialize our un-partnered product candidates outside of the United States in some degree, and we may experience difficulties, which could disrupt our operations and harm our business.

We have no experience marketing or selling outside of the United States. To successfully commercialize MDV3800, MDV9300, or any other products that emerge from our development programs, we will need to build or otherwise secure these capabilities from third parties. Developing a commercial infrastructure outside the United States is a significant undertaking that requires substantial financial and managerial resources. We may need to establish internal marketing and sales capabilities for several major ex-U.S. geographies to reach the commercial potential of MDV3800, MDV9300, or any other products that result from our development programs. Such expansion would require attracting, retaining and motivating the necessary skilled personnel and, in addition, it may require significant capital and operating expenditures. As a result, such activity may divert human and financial resources from other projects, such as the development or acquisition of additional product candidates. If we encounter unexpected or unforeseen delays in establishing a commercial infrastructure outside the United States, for example, it may negatively impact our ability to launch a commercial product or it may increase the cost and number of resources required for successful commercialization. In addition, it may negatively impact the future financial performance of our business and our ability to generate sufficient revenue to sustain our business. In the future, as a result of these financial and execution risks of expanding geographically ourselves, we may choose to partner with others who have existing capability to commercialize these products.

Debt and lease obligations could adversely affect our financial condition. In addition, we may not have sufficient funds to service our debt and lease obligations when payments are due.

At March 31, 2016, we had approximately $52.0 million of minimum lease commitments. We have incurred in the past, and may incur in the future, additional indebtedness to meet our financing needs, including for example in connection with business development activities and for other general corporate purposes. Substantial indebtedness could have significant effects on our business, results of operations and financial condition. For example, it could:

•

make it more difficult for us to satisfy our financial obligations, including with respect to our debt and lease obligations;

•

increase our vulnerability to general adverse economic, industry and competitive conditions;

•

reduce the availability of our cash resources to fund our operations because we will be required to dedicate a substantial portion of our cash resources to the payment of principal and interest on our indebtedness and lease payments;

•

limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;

•

place us at a competitive disadvantage compared to our competitors that are less highly leveraged and that, therefore, may be able to take advantage of opportunities that our leverage prevents us from exploring; and

•

limit our ability to obtain financing.

Each of these factors may have a material and adverse effect on our financial condition and viability.

With the acquisition of new product candidates in recent periods, we may need additional funds to support our operations, and such funding may not be available to us on acceptable terms, or at all, which would force us to delay, scale back or eliminate some or all of our currently-planned development programs and other operations, to restructure or refinance our indebtedness, or to determine to do any combination of the foregoing. Raising additional capital may subject us to unfavorable terms or conditions, may cause dilution to our existing stockholders, or may restrict our operations or require us to relinquish rights to our product candidates and technologies.

We require significant capital to fund our operations. We have historically funded our operations primarily through public offerings of our common stock, the issuance of the Convertible Notes (which we redeemed in July 2015 and are no longer outstanding), and from the upfront, milestone, and cost-sharing payments under agreements with our current and former collaboration partners, from collaboration revenue related to XTANDI net sales and, more recently and to a lesser extent, from short-term borrowings under a Revolving Credit Facility. At March 31, 2016, we had cash and cash equivalents totaling $317.4 million available to fund our operations. We expect to devote substantial financial resources to our future operations. Based on our current expectations, we believe our current capital resources, amounts available to us under our Revolving Credit Facility, and projected operating and other cash flows will be sufficient to fund our currently planned operations for at least the next twelve months. This estimate is based on a number of assumptions that may prove to be wrong, including assumptions regarding the amount and timing of net sales of XTANDI, potential XTANDI approvals in new markets and for other indications, and potential receipt of profit sharing and royalty payments under our Astellas Collaboration Agreement, causing us to exhaust our available cash, cash equivalents, and short-term investments sooner than anticipated. For example, we may be required or choose to seek additional funds for the commercialization of XTANDI in the United States, to expand our preclinical and clinical development activities for enzalutamide, MDV3800, MDV9300 and other existing or potential future product candidates, to fund business acquisitions, investments or to in-license technologies, particularly if we face challenges or delays in connection with our clinical trials, and to maintain minimum cash balances that we deem reasonable and prudent. Our ability to raise additional funds on acceptable terms will be dependent on the climate of worldwide capital markets, which could be challenging for companies such as ours.

We may be constrained by our obligations under the Revolving Credit Facility to operate our business to its full potential.

The terms of our Revolving Credit Facility contain customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions. Furthermore, under the terms of the Revolving Credit Facility, we are required to comply with a maximum senior secured net leverage ratio and minimum interest coverage ratio covenants. These terms may restrict our ability to operate our business in the manner we deem most effective or desirable, and may restrict our ability to fund our operations through new public offerings of our common stock or strengthen our candidate development pipeline through acquisitions or in-licenses which cause us to exceed our maximum senior secured net leverage ratio.

Failure to comply with the representations and warranties or affirmative and negative covenants could constitute an event of default which, if continued beyond the cure period, would allow the Administrative Agent (as defined in the Revolving Credit Facility), at the request of or with the consent of the Lenders holding a majority of the loans and commitments under the facility, to terminate the commitments of the Lenders to make further loans and declare all the obligations of the Loan Parties under the Revolving Credit Facility to be immediately due and payable, either of which would harm our business.

We may have additional tax liabilities.

We are subject to income taxes in various jurisdictions. Significant judgment is required in determining our provision for income taxes and other tax liabilities. Our effective income tax rate in the future is subject to volatility and could be adversely affected by a number of factors, including interpretations of existing tax laws, changes in tax laws and rates, future levels of research and development expenditures, changes in the mix of earnings in countries with differing statutory tax rates in which we may conduct business, changes in the valuation of deferred tax assets and liabilities, state income taxes, the tax impact of stock-based compensation, changes in estimates of prior years’ items, tax costs for acquisition-related items, changes in accounting standards, non-deductible officers’ compensation, limitations on the utilization of net operating losses and tax credits due to changes in ownership, and overall levels of income before taxes. The impact of our income tax provision resulting from these items may be significant and could have a negative impact on our net income.

We are also subject to non-income based taxes, such as payroll, sales, use, net worth, property, and goods and services taxes in the United States. We may have additional exposure to non-income based tax liabilities.

We are regularly subject to audits by tax authorities in the jurisdictions in which we conduct business. Although we believe our tax positions are reasonable, the final outcome of tax audits and related litigation could be materially different than that reflected in our historical income tax provisions and accruals, and we could be subject to assessments of additional taxes and/or substantial fines or penalties. The resolution of any audits or litigation could have an adverse effect on our financial position and results of operations.

We and our subsidiaries are engaged in a number of intercompany transactions. Although we believe that these transactions reflect arm’s length terms and that proper transfer pricing documentation is in place, which should be respected for tax purposes, the transfer prices and terms and conditions of such transactions may be scrutinized by tax authorities, which could result in additional tax and/or penalties becoming due.

Intellectual property protection for our product candidates is crucial to our business, and is subject to a significant degree of legal risk, particularly in the life sciences industry.

The success of our business will depend in part on our ability to obtain and maintain intellectual property protection, primarily patent protection for the XTANDI product and any potential future product candidates, as well as successfully asserting and defending these patents against third-party challenges. We and/or our collaborators will only be able to protect the XTANDI product and our potential future product candidates from unauthorized commercialization by third parties to the extent that valid and enforceable patents or trade secrets cover them. Furthermore, future protection of our proprietary rights is uncertain because legal means may afford only limited protection and may not adequately protect our rights or permit us or our potential future collaborators to gain or keep our competitive advantage.

The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. Further, changes in either the patent laws or in interpretations of patent laws in the United States or other countries may diminish the value of our intellectual property rights. Accordingly, we cannot predict the breadth of claims that may be granted or enforced for our patents or for third-party patents that we have licensed. For example:

•

we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents;

•

we or our licensors might not have been the first to file patent applications for these inventions;

•

others may independently develop similar or alternative technologies or duplicate any of our technologies;

•

it is possible that none of our pending patent applications or the pending patent applications of our licensors will result in issued patents;

•

our issued patents and future issued patents, or those of our licensors, may not provide a basis for protecting commercially viable products, may not provide us with any competitive advantages, or may be challenged by third parties and invalidated or rendered unenforceable; and

•

we may not develop additional proprietary technologies or product candidates that are patentable.

Further, even if we can obtain protection for and defend the intellectual property position of the XTANDI product or any potential future product candidates, we or any of our potential future collaborators still may not be able to exclude competitors from developing or marketing competing drugs. Should this occur, we and our potential future collaborators may not generate any revenues or profits from the XTANDI product or any potential future product candidates or our revenue or profits would be significantly decreased.

We could become subject to litigation or other challenges regarding intellectual property rights, which could divert management attention, cause us to incur significant costs, prevent us from selling or using the challenged technology and/or subject us to competition by lower priced generic products.

During the course of obtaining patent protection, we may receive rejections from national patent offices or be subject to pre-grant opposition proceedings instituted by third parties. Even after a patent is granted and issued by the national patent office, many countries allow post-grant opposition proceedings. In the U.S., these post-grant opposition proceedings include inter partes review whereby a third party can seek to challenge and invalidate an issued patent in an administrative proceeding before the U.S. Patent and Trademark Office, rather than through litigation in court, which is often lengthier and costlier. Our patents and patent applications, or those of our licensors, could face other challenges, such as interference proceedings, opposition proceedings, re-examination proceedings, derivation proceedings and pre-grant submissions. Any such challenge, if successful, could result in the invalidation of, or in a narrowing of the scope of, any of our patents and patent applications subject to the challenge. Any such challenges, regardless of their success, would likely be time-consuming and expensive to defend and resolve and would divert our management’s time and attention.

Generic and other pharmaceutical manufacturers are and have been very aggressive in challenging the validity of patents held by proprietary pharmaceutical companies, especially if these patents are commercially significant. Pursuant to the provisions of the Hatch-Waxman Act, the XTANDI patents listed in the FDA “Orange Book” could be challenged by generic manufacturers as early as four years from the initial approval of the XTANDI product in the United States, which occurred on August 31, 2012. Companies seeking approval to market a generic version of a reference drug may also seek to challenge the validity of patents listed in the Orange

Book or other patents covering such reference drug by filing petitions for inter partes review with the U.S. Patent and Trademark Office. If a generic pharmaceutical company or other third party were able to successfully invalidate any of our present or future patents, the XTANDI product and any potential future product candidates that may ultimately receive marketing approval could face additional competition from lower-priced generic products that would result in significant price and revenue erosion and have a significantly negative impact on the commercial viability of the affected product candidate(s).

In addition, we may be a party to litigation to protect our intellectual property or to defend our activities in response to alleged infringement of a third party’s intellectual property. These claims and any resulting lawsuit, if successful, could subject us to significant liability for damages and invalidation, or a narrowing of the scope, of our proprietary rights. These lawsuits, regardless of their success, would likely be time-consuming and expensive to litigate and resolve and would divert management time and attention. Any potential intellectual property litigation also could force us or our potential licensees to do one or more of the following:

•

discontinue our products that use or are covered by the challenged intellectual property; or

•

obtain from the owner of the allegedly infringed intellectual property right a license to sell or use the relevant technology, which license may not be available on reasonable terms, or at all.

If we or our potential licensees are forced to take any of these actions, our business may be seriously harmed. Although we carry general liability insurance, our insurance does not cover potential claims of this type.

We may in the future initiate claims or litigation against third parties for infringement to protect our proprietary rights or to determine the scope and validity of our proprietary rights or the proprietary rights of competitors. These claims could result in costly litigation and the diversion of our technical and management personnel and we may not prevail in making these claims.

We rely on license agreements for certain aspects of our product candidates and our technology, and failure to meet our obligations under those agreements could severely negatively impact our business, and ability to generate revenue.

We have entered into agreements with third-party commercial and academic institutions to license intellectual property rights and technology. For example, we have a license agreement with UCLA pursuant to which we were granted exclusive worldwide rights to certain UCLA patents related to XTANDI and a family of related compounds. Some of these license agreements, including our license agreement with UCLA, contain diligence and milestone-based termination provisions, in which case our failure to meet any agreed upon diligence requirements or milestones may allow the licensor to terminate the agreement. If our licensors terminate our license agreements or if we are unable to maintain the exclusivity of our exclusive license agreements, we may be unable to continue to develop and commercialize XTANDI or any potential future product candidates based on licensed intellectual property rights and technology.

In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.

From time to time we may be required to license technology from additional third parties to further develop XTANDI and any future product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents based on biological activities or required to manufacture our product candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop any of our product candidates could cause us to abandon any related development efforts, which could seriously harm our business and operations.

We may become involved in disputes with Astellas, NanoString or any potential future collaborators over intellectual property ownership, and publications by our research collaborators and scientific advisors could impair our ability to obtain patent protection or protect our proprietary information, which, in either case, could have a significant impact on our business.

Inventions discovered under research, material transfer or other such collaboration agreements, including the Astellas Collaboration Agreement or NanoString collaboration agreement, may become jointly owned by us and the other party(ies) to such agreements in some cases and the exclusive property of one of the parties in other cases. Under some circumstances, it may be difficult to determine who owns a particular invention, or whether it is jointly owned, and disputes could arise regarding ownership of those inventions. These disputes could be costly and time consuming and an unfavorable outcome could have a significant adverse effect on our business if we were not able to protect or license rights to these inventions. In addition, our research collaborators and scientific advisors generally have contractual rights to publish our data and other proprietary information, subject to our prior review. Publications by our research collaborators and scientific advisors containing such information, either with our permission or in contravention of the terms of their agreements with us, may impair our ability to obtain patent protection or protect our proprietary information, which could significantly harm our business.

Trade secrets may not provide adequate protection for our business and technology.

We also rely on trade secrets to protect our technology, especially where we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. While we use reasonable efforts to protect our trade secrets, our or any potential collaborators’ employees, consultants, contractors or scientific and other advisors may unintentionally or willfully disclose our information to competitors. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, our enforcement efforts would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, if our competitors independently develop equivalent knowledge, methods or know-how, it will be more difficult or impossible for us to enforce our rights and our business could be harmed.

Significant disruptions of information technology systems or breaches of data security could adversely affect our business.

Our business is increasingly dependent on critical, complex and interdependent information technology systems to record and maintain financial, clinical trial, safety, laboratory and other corporate records. The size and complexity of our computerized information systems make them vulnerable to breakdown, malicious intrusion, catastrophic events, computer viruses, and human error. We have experienced at least one successful intrusion into our computer systems, and although it did not have a material adverse effect on our operations, there can be no assurance of a similar result in the future as cyberattacks are increasing in their frequency, sophistication and intensity.

We have developed systems and processes that are designed to protect our information and prevent data loss and other security breaches, including systems and processes designed to reduce the impact of a security breach; however, such measures cannot provide absolute security, and we have taken and are continually taking additional security measures to protect against any future intrusion, including employee training. Moreover, the prevalent use of mobile devices that access our systems and confidential information and our relationships with third-party vendors, who may or could have access to our confidential information, increases the risk of data security breaches.

A data or security breach of our systems, or that of our third-party vendors, such as third-party clinical research organizations, third-party clinical manufacturing organization, clinical trial sites, and administrators of our corporate employee benefit plans or of our current and potential future collaboration partners, could lead to public exposure of personal information of our employees, clinical trial patients, customers and other business partners, modification of or prevent us from accessing our clinical trial databases, or the loss of trade secrets or other intellectual property.

If we or our third-party vendors or business partners experience significant data security breaches, we could suffer harm to our reputation, be compelled to comply with federal and/or state breach notification laws and foreign law equivalents, be subjected to liability under laws and regulations that protect personal data, be subjected to mandatory corrective action or government enforcement action, need to verify the correctness of clinical trial database contents, or be exposed to litigation claims. In addition, because these breaches and other inappropriate access can be difficult to detect, any delay in identifying them may lead to increased harm of the type described above. Prolonged disruption would divert management’s attention and could result in a delay to the development of our product candidate.

While we do carry some insurance for these types of claims, our insurance may not be sufficient in type or amount.

Risks generally associated with our company-wide implementation of an enterprise resource planning (ERP) system may adversely affect our business and results of operations or the effectiveness of our internal controls over financial reporting.

We commenced implementation of a company-wide ERP system to upgrade certain existing business, operational, and financial processes. ERP implementations are typically complex and time-consuming projects that may require substantial time and resources to complete. Our results of operations could be adversely affected if we experience delays or cost overruns during the ERP implementation process, or if the ERP system or associated process changes do not give rise to the benefits that we expect.

Risks Related to the Pharmaceutical Industry, Including the Activities of Medivation, Inc.

*Our industry is highly regulated by the FDA and comparable foreign regulatory agencies. We must comply with extensive, strictly enforced regulatory requirements to develop, obtain, and maintain marketing approval for any of our product candidates.

Securing FDA approval requires the submission of extensive preclinical and clinical data and supporting information for each therapeutic indication to establish the product candidate’s safety and efficacy for its intended use. It takes years to complete the testing of a new drug, biologic or medical device and development delays and/or failure can occur at any stage of testing. Any of our present

and future clinical trials may be delayed, halted or approval of any of our products may be delayed or may not be obtained due to any of the following:

•

any preclinical test or clinical trial may fail to produce safety and efficacy results satisfactory to the FDA or foreign regulatory authorities;

•

preclinical and clinical data can be interpreted in different ways, which could delay, limit or prevent regulatory approval;

•

negative or inconclusive results from a preclinical test or clinical trial could cause a preclinical study or clinical trial to be repeated, even if other studies or trials relating to the program are ongoing or have been completed and were successful;

•

adverse medical events during a clinical trial could cause a program to be terminated. For example, we recently terminated our development of MDV4463 following a serious adverse event which met the criteria for drug-induced liver injury per the FDA’s 2009 Guidance for Industry. While we will continue to monitor subjects who received MDV4463, we have suspended our clinical studies of MDV4463 and do not intend to further investigate it.

•

the FDA or foreign regulatory authorities can place a clinical hold on a trial if, among other reasons, it finds that patients enrolled in the trial are or would be exposed to an unreasonable and significant risk of illness or injury;

•

the facilities that we utilize, or the processes or facilities of third-party vendors, including without limitation the contract manufacturers who will be manufacturing drug substance and drug product for us or any potential collaborators, may not complete successful inspections by the FDA or foreign regulatory authorities; and

•

we may encounter delays or rejections based on changes in FDA policies or the policies of foreign regulatory authorities during the period in which we develop a product candidate or the period required for review of any final regulatory approval before we are able to market any product candidate.

In addition, information generated during the clinical trial process is susceptible to varying interpretations that could delay, limit, or prevent regulatory approval at any stage of the approval process. Moreover, early positive preclinical or clinical trial results may not be replicated in later clinical trials. Failure to demonstrate adequately the quality, safety and efficacy of any of our product candidates would delay or prevent regulatory approval of the applicable product candidate. There can be no assurance that if clinical trials are completed, either we or our collaborative partners will submit applications for required authorizations to manufacture or market potential products or that any such application will be reviewed and approved by appropriate regulatory authorities in a timely manner, if at all.

*We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. Prosecutions under such laws have increased in recent years and we may become subject to such litigation. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.

Commercialization of drugs and biologics that receive FDA approval are subject, directly or indirectly, to various state and federal fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and federal False Claims Act and the state law equivalents of such laws. These laws may impact, among other things, our sales, marketing, and education programs.

The federal Anti-Kickback Statute prohibits persons and entities from knowingly and willingly soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. The Anti-Kickback Statute is broad, and despite a series of narrow regulatory safe harbors and statutory exceptions, prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. A focus of the Office of Inspector General, or OIG, of the U.S. Department of Health and Human Services has been financial assistance programs which provide financial assistance to patients who cannot afford their cost-sharing obligations for life saving prescription drugs. Grants made by pharmaceutical companies, including by us through our partner Astellas, to independent charities and non-profit organizations may be subsequently determined by the OIG to be an indirect remuneration to induce the recommendation or to arrange for the purchase of the pharmaceutical company’s product. Penalties for violations of the federal Anti-Kickback Statute include, among other things, criminal and administrative penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, including private insurance programs.

The federal False Claims Act prohibits persons and entities from knowingly filing, or causing to be filed, a false claim, or the knowing use of false statements, to obtain payment from the federal government. Suits filed under the False Claims Act, known as “qui tam” actions, can be brought by any individual on behalf of the government, and such individuals, commonly known as “whistleblowers,” may share in a proportion of any amounts paid by the entity to the government in fines or settlement. The frequency of filing qui tam actions has increased significantly in recent years, causing greater numbers of biotechnology and pharmaceutical

companies to have to defend False Claims Act actions. When it is determined that an entity has violated the False Claims Act, the entity may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Various states have also enacted laws modeled after the federal False Claims Act. Although we have developed, implemented, and continue to improve a program for compliance with all federal and state laws, we cannot guarantee that our compliance program will be sufficient or effective, that our employees will comply with our policies and that our employees will notify us of any violation of our policies, that we will have the ability to take appropriate and timely corrective action in response to any such violation, or that we will make decisions and take actions that will necessarily limit or avoid liability for whistleblower claims that individuals, such as employees or former employees, may bring against us or that governmental authorities may prosecute against us based on information provided by individuals. If one or more individuals bring a whistleblower claim against us or if a governmental authority prosecutes a claim against us on the basis of information provided by one or more individuals, and if we are found liable and a fine, injunction, Corporate Integrity Agreement and/or similar government oversight program is imposed on us or we agree to pay a fine or accept an injunction, Corporate Integrity Agreement and/or similar government oversight program in settlement of the claim, they could have a material adverse effect on our financial condition and impair or prevent us from conducting our business. In addition, the costs and fees associated with defending a whistleblower claim would be significant.

We may also be subject to federal criminal healthcare fraud statutes that were created by the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH. The HIPAA health care fraud statute prohibits, among other things, knowingly and willfully executing, or attempting to execute a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment, and/or exclusion from government sponsored programs. The HIPAA false statements statute prohibits, among other things, knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation in connection with the delivery of or payment for healthcare benefits, items or services. A violation of this statute is a felony and may result in fines and/or imprisonment.

We, and our business activities, are also subject to the federal Physician Payments Sunshine Act, which is within the Patient Protection and Affordable Care Act, as amended by the Health Care Education and Reconciliation Act, (collectively, “PPACA”). The federal Physician Payments Sunshine Act, and its implementing regulations, require certain manufacturers of drugs, devices, biological, and medical supplies for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program (with certain exceptions) to report annually information related to certain payments or other transfers of value provided to physicians and teaching hospitals and other healthcare providers. In addition, there has been a recent trend of increased federal and state regulation on payments made to physicians. Certain states mandate implementation of commercial compliance programs, impose restrictions on drug manufacturer marketing practices, and/or the tracking and reporting of gifts, compensation and remuneration to physicians.

We are unable to predict whether we could be subject to actions under any of these or other fraud and abuse laws, or the impact of such actions. If we are found to be in violation of any of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from government healthcare reimbursement programs and the curtailment or restructuring of our operations, any of which could have a material adverse effect on our business and results of operations.

We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and other worldwide anti-bribery laws.

We are subject to the U.S. Foreign Corrupt Practices Act, or FCPA, which generally prohibits companies and their intermediaries from making payments to non-U.S. government officials for purpose of obtaining or retaining business or securing any other improper advantage. We are also subject to similar anti-bribery laws in the jurisdictions in which we operate. Failure to comply with the FCPA or related laws governing the conduct of business with foreign government entities could disrupt our business and lead to severe criminal and civil penalties, including criminal and civil fines, denial of government reimbursement for our products and exclusion from participation in government healthcare programs. Other remedial measures could include further changes or enhancements to our procedures, policies, and controls and potential personnel changes and/or disciplinary actions, any of which could have a material adverse impact on our business, financial condition, results of operations and liquidity. We could also be affected by any allegation that we, or any third-party vendors that we rely on to perform key product development tasks, violated such laws.

If the FDA or other applicable regulatory authorities approve generic products that compete with any of our products or product candidates, the sales of our products or product candidates may be adversely affected.

Once an NDA is approved, the product covered thereby becomes a “listed drug” which, in turn can be relied upon by potential competitors in support of an approval of an ANDA or 505(b)(2) application. U.S. laws and other applicable policies provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an ANDA or other application for a

generic substitute. These manufacturers might only be required to conduct a relatively inexpensive study to show that their product has the same active ingredient(s), dosage form, strength, route of administration, and conditions of use, or labeling, as our product or product candidate and that the generic product is bioequivalent to ours, meaning it is absorbed in the body at the same rate and to the same extent as our product or product candidate. These generic equivalents, which must meet the same quality standards as branded pharmaceuticals, would be significantly less costly than ours to bring to market and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic competitor, a significant percentage of sales of any branded product is typically lost to the generic product. Accordingly, competition from generic equivalents to our products or product candidates would materially adversely impact our revenues, profitability and cash flows and substantially limit our ability to obtain a return on the investments that we have made in our product candidates.

To the extent that we receive regulatory approval to market biological products in the future, we will face competition from biosimilar products. A growing number of companies have announced their intention to develop biosimilar products, some of which could potentially compete with our product candidates. Because of the abbreviated pathway for approval of biosimilars in the United State and abroad, we may in the future face greater competition from biosimilar products. This additional competition could have a material adverse effect on our business and results of operations.

Healthcare reform initiatives and other third party cost-containment pressures could cause us to sell our products at lower prices, resulting in decreased revenues.

The United States and some foreign jurisdictions have enacted or are considering enacting a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to profitably sell XTANDI and other product candidates should they receive marketing approval. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.

In March 2010, the PPACA became law in the United States. PPACA substantially changed and will continue to change the way healthcare is financed by both governmental and private insurers and significantly affects the pharmaceutical industry. The provisions of PPACA most relevant to the pharmaceutical industry include:

•

an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain governmental health care programs, not including orphan drug sales;

•

an increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for branded and generic drugs, respectively;

•

Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers’ outpatient drugs to be covered under Medicare Part D;

•

extension of manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;

•

expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals with income at or below 133% of the Federal Poverty Level beginning in 2014, thereby potentially increasing manufacturers’ Medicaid rebate liability;

•

expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;

•

a new requirement to report certain financial arrangements with physicians and teaching hospitals, as defined in PPACA and its implementing regulations, including reporting any payment or “transfers of value” made or distributed to physicians and teaching hospitals, and reporting any ownership and investment interests held by physicians and their immediate family members and applicable group purchasing organizations;

•

expansion of health care fraud and abuse laws, including the federal False Claims Act and Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;

•

a licensure framework for follow-on biologic products; and

•

a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.

We anticipate that the PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria or maximum monthly out-of-pocket costs for patients, either of which could put additional downward

pressure on the price that we receive for any approved product, and could seriously harm our business. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. If we fail to successfully secure and maintain adequate coverage and reimbursement of our products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our products and expected revenue and profitability which would have a material adverse effect on our business, results of operations and financial condition. In addition, we will face competition from other approved drugs against which we compete, and the marketers of such other drugs are likely to be significantly larger than us and therefore enjoy significantly more negotiating leverage with respect to the individual payors than we may have.

*We could experience adverse outcomes under existing litigation or become subject to product liability or other litigation, which could harm our ability to efficiently and effectively conduct our business, and, if successful, could materially and adversely harm our business and financial condition as a result of the costs of liabilities that may be imposed thereby.

Our business exposes us to the risk of product liability claims that is inherent in the development, manufacturing, distribution and sale of pharmaceutical products. If XTANDI, MDV3800, MDV9300 or any other potential future product candidate harms people, or is alleged to be harmful, we may be subject to costly and damaging product liability claims brought against us by clinical trial participants, consumers, health care providers, corporate partners or others. We have product liability insurance covering commercial sales of XTANDI and our ongoing clinical trials. However, the amount of insurance we maintain may not be adequate to cover all liabilities that we may incur. If we are unable to obtain insurance at an acceptable cost or otherwise protect against potential product liability claims, we may be exposed to significant litigation costs and liabilities, which may materially and adversely affect our business and financial position. If we are sued for injuries allegedly caused by XTANDI, MDV3800, MDV9300 or any other of our current or future product candidates, our litigation costs and liability could exceed our total assets and our ability to pay. Regardless of merit or eventual outcome, liability claims may result in:

•

decreased demand for XTANDI and any potential future product candidate that we may develop;

•

injury to our reputation;

•

withdrawal of clinical trial participants;

•

significant costs to defend the related litigation;

•

substantial monetary awards to trial participants or patients;

•

loss of revenue; and

•

the inability to commercialize any other products that we may develop.

In addition, we may from time to time become involved in various lawsuits and legal proceedings which arise in the ordinary course of our business, such as our litigation with the Regents of the University of California, or Regents. See Part II, Item 1, “Legal Proceedings” for additional information on this litigation. Any litigation to which we are subject could require significant involvement of our senior management and may divert management’s attention from our business and operations. An adverse result in any existing litigation, including our litigation with the Regents, or litigation costs associated with any existing or new litigation that may arise from time to time, such as a result of our rejection of the unsolicited proposal from Sanofi to acquire all of our outstanding shares for $52.50 per share, may adversely impact our operating results or financial condition.

Risks Related to Business Acquisitions, Licenses, Investments and Strategic Alliances

We may not be able to successfully integrate MDV3800, MDV9300 or any other potential future product candidates we may acquire or we may otherwise fail to realize their full potential.

A key component of our business strategy is to diversify our product development risk by identifying and acquiring new product opportunities for development such as our recent acquisition of MDV3800 from BioMarin and our earlier license of MDV9300 from CureTech. However, we cannot ensure that we will be able to manage the risks associated with the transfer of development, regulatory and manufacturing activities for the ongoing clinical trials of MDV3800 from BioMarin to us or manage the risks associated with integrating MDV3800 and MDV9300 into our existing business and infrastructure. We may encounter unexpected difficulties during the transfer, integration or further development of MDV3800 or MDV9300, any of which may cause us to expend greater funds and efforts or may slow, delay or limit the progress of MDV3800’s or MDV9300’s development. Unexpected difficulties may further be disruptive to our ongoing development efforts, put a strain on our existing personnel, infrastructure and business and divert management’s time and attention.

For MDV3800, other companies, such as AstraZeneca, Clovis Oncology, AbbVie, and Tesaro are developing PARP inhibitors for various oncology indications, some of which have already been approved and on the market and others which are further along in development than MDV3800, both of which could limit our development opportunities for MDV3800. The competitive environment

could further compromise our ability to successfully enroll the ongoing clinical trial by limiting the availability of clinical trial investigators, sites and/or patients which could slow, delay or limit the progress of MDV3800’s development.

As a result of these or other problems and risks, we may never receive regulatory approval for MDV3800 or MDV9300, we may not realize the full potential or we may never generate significant value or revenues from these assets.

Business acquisitions, licenses, investments and strategic alliances could disrupt our operations and may expose us to increased costs and unexpected liabilities.

We may acquire or make investments in other companies, enter into other strategic relationships, or in-license technologies, such as our acquisition of MDV3800 and license of MDV9300. To do so, we may use cash, issue equity that could dilute our current stockholders, or incur debt or assume indebtedness. These transactions involve numerous risks, including but not limited to:

•

difficulty integrating acquired technologies, products, operations, and personnel with our existing business;

•

diversion of management’s attention in connection with both negotiating the acquisition or license and integrating the business;

•

strain on managerial and operational resources;

•

difficulty implementing and maintaining effective internal control over financial reporting at businesses that we acquire, particularly if they are not located near our existing operations;

•

exposure to unforeseen liabilities of acquired companies or companies in which we invest;

•

potential costly and time-consuming litigation, including stockholder lawsuits;

•

potential issuance of securities to equity holders of the company being acquired which may have a dilutive effect on our stockholders;

•

the need to incur additional debt or use our existing cash balances; and

•

the requirement to record potentially significant additional future non-cash operating costs for the amortization of intangible assets and potential future impairment or write-down of intangible assets and/or goodwill as well as potentially significant non-cash adjustments to contingent consideration liabilities which would be recorded within operating expenses.

As a result of these or other problems and risks, businesses we acquire or invest in may not produce the revenues, earnings or business synergies that we anticipated, acquired or licensed technologies may not result in regulatory approvals, and acquired or licensed commercial products may not perform as expected. As a result, we may incur higher costs and realize lower revenues than we had anticipated. We cannot assure you that any acquisitions or investments we have made or may make in the future will be successfully identified and completed or that, if completed, the acquired business, licenses, investments, products, or technologies will generate sufficient revenue to offset the negative costs or other negative effects on our business. Failure to manage effectively our growth through acquisition or in-licensing transactions could adversely affect our growth prospects, business, results of operations, financial condition, and cash flow.

Funding may not be available for us to make acquisitions, investments, strategic alliances or in-license technologies in order to grow our business.

We have made and anticipate that we may continue to engage in strategic transactions to grow our business through acquisitions, investments, strategic alliances or in-licensing of technologies. In particular, we may choose to partner in certain geographies to commercialize our successful product candidates. Our growth plans rely, in part, on the successful identification and completion of these various strategic transactions. At any particular time, we may need to raise substantial additional cash or issue additional equity to finance such transactions, in addition to any amounts available from operations or under our Revolving Credit Facility. There is no assurance that we will be able to secure additional funding on acceptable terms, or at all, or obtain stockholder approvals necessary to issue additional equity to finance such transactions. If we are unsuccessful in obtaining financing, our business would be adversely affected.

Our consolidated financial statements may be impacted in future periods based on the accuracy of our valuations of our acquired businesses and other agreements.

Certain of our asset acquisition or license agreements may be accounted for as a business combination. Accounting for business combinations may involve complex and subjective valuations of the assets and liabilities recorded, and in some instances contingent consideration, which is recorded in our consolidated financial statements pursuant to the standards applicable for business

combinations in accordance with accounting principles generally accepted in the United States. Differences between the inputs and assumptions used in the valuations and actual results experienced at a later date could have a material effect on our consolidated financial statements in future periods.

We have substantial intangible assets and goodwill as a result of the acquisition of MDV3800 from BioMarin and the license of MDV9300 from CureTech. A significant impairment or write-down of intangible assets and/or goodwill would have a material adverse effect on our consolidated financial statements.

We are required to perform an annual, or in certain situations a more frequent, assessment of intangible assets and goodwill for possible impairment for accounting purposes. We recorded significant intangible assets and goodwill as a result of the CureTech and BioMarin transactions during the years ended December 31, 2014 and 2015, respectively. At March 31, 2016, we had intangible assets and goodwill of approximately $662.9 million, or approximately 50% of our total assets. During the fourth quarter of 2015, we recorded a $30.0 million impairment charge related to our IPR&D asset for MDV9300. If our development activities with respect to IPR&D for acquired product candidates are not successful in future periods, we may be required to incur further non-cash impairment charges that could materially adversely affect our consolidated results of operations or our recorded assets and liabilities.

Risks Related to Ownership of Our Common Stock

*Our stock price has been and may continue to be volatile and our stockholders’ investment in our common stock could decline in value.

The market prices for our securities and those of other life sciences companies have been highly volatile and often unrelated or disproportionate to the operating performance of those companies, and may continue to be highly volatile in the future. There has been particular volatility in the market prices of securities of life sciences companies because of problems or successes in a given market segment or because investor interest has shifted to other segments. These broad market and industry factors may cause the market price of our common stock to decline, regardless of our operating performance. We have no control over this volatility and can only focus our efforts on our own operations, and even these may be affected due to the state of the capital markets.

The following factors, in addition to other risk factors described herein, may have a significant impact on the market price of our common stock:

•

comments made by securities analysts, including changes in their recommendations;

•

speculation in the press or by securities market participants about a potential business combination, the possibility of an unsolicited hostile tender offer or other strategic transactions affecting us or other companies in our industry;

•

selling by existing stockholders and short-sellers;

•

sales of our common stock by our directors, officers or significant stockholders, including sales effected pursuant to predetermined trading plans adopted under the safe-harbor afforded by Rule 10b5-1;

•

negative opinions that are misleading and/or inaccurate regarding our business, management or future prospects published by certain market participants intent on putting downward pressure on the price of our common stock;

•

lack of volume of stock trading leading to low liquidity;

•

announcements by us of financing transactions and/or future sales of equity or debt securities;

•

the recruitment or departure of key management personnel;

•

our ability to meet the expectations of investors and securities analysts related to collaboration revenue generated from net sales of XTANDI, including the timing and amount thereof, and other financial metrics;

•

changes in our financial guidance or financial estimates by any securities analysts who might cover our company, or our failure to meet our financial guidance or estimates made by securities analysts;

•

variations in our quarterly financial results or those of companies that are perceived to be similar to us;

•

new products, product candidates or uses for existing products or technologies introduced or announced by our competitors and the timing of these introductions and announcements;

•

the progress and results of preclinical studies and clinical trials of our product candidates conducted by us, Astellas or any future collaborative partners or licensees, if any, and any delays in enrolling a sufficient number of patients to complete clinical trials of our product candidates;

•

developments concerning our collaboration with Astellas or any future collaborations;

•

our dependence on third parties, including Astellas, clinical manufacturing organizations and clinical research organizations, clinical trial sponsors and clinical investigators;

•

legislative or regulatory developments in the United States or other countries affecting XTANDI or product candidates, including those of our competitors, including the passage of laws, rules or regulations relating to healthcare and reimbursement or the public announcement of inquiries or lobbying relating to these subjects;

•

developments or disputes concerning patent applications, issued patents or other proprietary rights;

•

the receipt or failure to receive funding necessary to conduct our business;

•

changes in the market valuations of other companies in our industry;

•

litigation; and

•

general economic, industry and market conditions and other factors that may be unrelated to our operating performance, including market conditions in the pharmaceutical and biotechnology sectors.

These factors and fluctuations, as well as political and other market conditions, may adversely affect the market price of our common stock. Securities-related class action litigation is often brought against a company following periods of volatility in the market price of its securities or offers by third parties to acquire the outstanding shares of a company. Securities-related litigation, whether with or without merit, could result in substantial costs and divert management’s attention and financial resources, which could harm our business and financial condition, as well as the market price of our common stock. Additionally, volatility or lack of positive performance in our stock price may adversely affect our ability to retain or recruit key employees, all of whom have been or will be granted equity awards as a part of their compensation.

If our operating results are below the expectations of securities analysts, the market price of our common stock could decline.

Various securities analysts follow our financial results and issue reports on us. These reports include information about our historical financial results, our projected development expenses, as well as the analysts’ estimates of our future performance. The analysts’ estimates are based upon their own opinions and are often different from our estimates or expectations. We expect our projected development expenses to increase as we advance our product pipeline and grow our infrastructure. While management believes these expenses are an investment in the company’s long-term prospects, such expenses could substantially reduce our near-term earnings below the expectations of security analysts. If our operating results are below their expectations, the market value of our common stock could decline, perhaps substantially.

We do not intend to pay cash dividends on our common stock for the foreseeable future.

We do not expect for the foreseeable future to pay cash dividends on our common stock. Any future determination to pay cash dividends on or repurchase shares of our common stock will be at the discretion of our board of directors and will depend upon, among other factors, our success in completing sales or partnerships of our programs, our results of operations, financial condition, capital requirements, contractual restrictions (such as our Revolving Credit Facility) and applicable law.

*Provisions of our corporate charter documents, our stockholder rights plan and Delaware law could make it more difficult for a third party to acquire us, even if the offer may be considered beneficial by our stockholders.

Provisions of the Delaware General Corporation Law could discourage potential acquisition proposals and could delay, deter or prevent a change in control. The anti-takeover provisions of the Delaware General Corporation Law impose various impediments to the ability of a third party to acquire control of us, even if a change in control would be beneficial to our existing stockholders. Specifically, Section 203 of the Delaware General Corporation Law, unless its application has been waived, provides certain default anti-takeover protections in connection with transactions between us and an “interested stockholder.” Generally, Section 203 prohibits stockholders who, alone or together with their affiliates and associates, own more than 15% of the subject company from engaging in certain business combinations for a period of three years following the date that the stockholder became an interested stockholder of such subject company without approval of the board or the vote of two-thirds of the shares held by the independent stockholders. Our board of directors has also adopted a stockholder rights plan, or “poison pill,” which would significantly dilute the ownership of a hostile acquirer. Additionally, provisions of our amended and restated certificate of incorporation and bylaws could deter, delay or prevent a third party from acquiring us. For instance, our board also has the authority to issue, in certain circumstances, without stockholder approval, preferred stock with such terms as the board of directors may determine. We believe that these provisions benefit our stockholders, although they may in certain circumstances make it more difficult or time consuming for an acquirer to effect a change of control or an acquisition of the company.

We may issue additional shares of our common stock or instruments convertible into shares of our common stock, which could cause our stock price to fall and cause dilution to existing stockholders. In addition, a sale of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to decline significantly.

We may from time to time issue additional shares of common stock or other instruments convertible into, or exchangeable or exercisable for, shares of our common stock, including in connection with potential in-licensing and acquisition transactions. The issuance of additional shares of our common stock would dilute the ownership interests of existing holders of our common stock.

The issuance of a substantial number of shares of our common stock, the sale of a substantial number of shares of our common stock that were previously restricted from sale in the public market, or the perception that these issuances or sales might occur, could depress the market price of our common stock. As a result, investors may not be able to sell their shares of our securities at a price equal to or above the price they paid to acquire them.

Furthermore, the issuance of additional shares of our common stock, or the perception that such issuances might occur, could impair our ability to raise capital through the sale of additional equity securities.

We rely on Astellas to timely deliver important financial information relating to net sales of XTANDI. In the event that this information is inaccurate, incomplete, or not timely, we may not be able to timely or fully meet our financial reporting obligations as required by the SEC.

Under the Astellas Collaboration Agreement, Astellas has exclusive control over the flow of information relating to net sales of XTANDI that we are dependent upon to meet our SEC reporting obligations. Astellas is required under the Astellas Collaboration Agreement to provide us with timely and accurate financial data related to net sales of XTANDI so that we may meet our reporting obligations under federal securities laws. In the event that Astellas fails to provide us with timely and accurate information, we may incur significant liability with respect to federal securities laws, our internal controls and procedures under the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, may be inadequate, and we could be required to record adjustments in future periods, any of which could adversely affect the market price of our common stock and subject us to securities litigation.

To the extent that we create any joint ventures or have any variable interest entities for which we are required to consolidate, we would need to rely on those entities to timely deliver important financial information to us. In the event that the financial information is inaccurate, incomplete, or not timely, we would not be able to meet our financial reporting obligations as required by the SEC.

While we currently do not have any joint ventures or variable interest entities that we are required to consolidate, to the extent we create such joint ventures or variable interest entities for which we would be required to consolidate and the financial statements of such entities are not prepared by us, we will not have direct control over their financial statement preparation. As a result, we will, for our financial reporting, depend on what these entities report to us, which could result in us adding monitoring and audit processes, which could increase the difficulty of implementing and maintaining adequate controls over our financial processes and reporting in the future. This may be particularly true when such entities do not have sophisticated financial accounting processes in place, or where we are entering into new relationships at a rapid pace, straining our integration capacity. Additionally, if we do not receive the information from the joint venture or variable interest entity on a timely basis, this could cause delays in our external reporting obligations as required by the SEC.

Changes in, or interpretations of, accounting principles could have a significant impact on our financial position and results of operations.

We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. These principles are subject to interpretation by the SEC and various other bodies formed to interpret and create appropriate accounting principles. A change in these principles can have a significant effect on our reported results and may even retroactively affect previously reported transactions.

For example, the Financial Accounting Standards Board, or FASB, is currently working together with the International Accounting Standards Board, or IASB, on several projects to further align accounting principles and facilitate more comparable financial reporting between companies who are required to follow U.S. GAAP under SEC regulations and those who are required to follow International Financial Reporting Standards outside of the United States. These efforts by the FASB and the IASB may result in different accounting principles under U.S. GAAP that may result in materially different financial results for us in areas including, but not limited to, principles for recognizing revenue and lease accounting.

Failure to maintain effective internal control over financial reporting in accordance with the Sarbanes-Oxley Act could have a material adverse effect on our stock price.

Section 404 of the Sarbanes-Oxley Act and the related rules and regulations of the SEC require an annual management assessment of the effectiveness of our internal control over financial reporting and a report by our independent registered public accounting firm attesting to the effectiveness of our internal control over financial reporting at the end of the fiscal year. If we fail to maintain the adequacy of our internal control over financial reporting, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective control over financial reporting in accordance with the Sarbanes-Oxley Act and the related rules and regulations of the SEC. If we cannot in the future favorably assess, or our independent registered public accounting firm is unable to provide an unqualified attestation report on, the effectiveness of our internal control over financial reporting, investor confidence in the reliability of our financial reports may be adversely affected, which could have a material adverse effect on our stock price.

ITEM 6.

EXHIBITS.

See the Exhibit List which follows the signature page of this Quarterly Report on Form 10-Q, which is incorporated by reference here.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 5, 2016	MEDIVATION, INC.

	By:	/s/ Jennifer Jarrett
	Name:	Jennifer Jarrett
	Title:	Chief Financial Officer
		(Duly Authorized and Principal Financial Officer)

Incorporated By Reference

Exhibit

Number

Exhibit Description

Form

File No.

Exhibit

Filing Date

Filed
Herewith

2.1**

Asset Purchase Agreement, dated August 21, 2015, by and between Medivation, Inc. and BioMarin Pharmaceutical, Inc.

8-K

001-32836

2.1

10/7/2015

2.2**

License Agreement between Medivation, Inc. and CureTech Ltd., dated as of October 23, 2014

8-K

001-32836

2.1

11/6/2015

3.1

Restated Certificate of Incorporation.

8-K

001-32836

3.4

10/17/2013

3.2

Certificate of Amendment to Amended and Restated Certificate of Designation of Series C Junior Participating Preferred Stock of Medivation, Inc.

8-K

001-32836

3.1

2/13/2015

3.3

Certificate of Amendment of Restated Certificate of Incorporation

8-K

001-32836

3.1

6/19/2015

3.4

Amended and Restated Bylaws of Medivation, Inc.

8-K

001-32836

3.1

5/02/2016

4.1

Common Stock Certificate.

10-Q

001-32836

4.1

5/9/2012

4.2

Rights Agreement, dated as of December 4, 2006, between Medivation, Inc. and American Stock Transfer & Trust Company, as Rights Agent, which includes the form of Certificate of Designations of the Series C Junior Participating Preferred Stock of Medivation, Inc. as Exhibit A, the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C.

8-K

001-32836

4.1

12/4/2006

10.1

Form of indemnity agreement between Medivation and Executive Officers and Directors

10.2**

Amendment No. 6 to Collaboration Agreement dated January 6, 2016, by and among Medivation, Inc., Astellas Pharma Inc., and Astellas US LLC

10-K

001-32836

10.23

2/26/2016

10.3

Offer Letter, dated January 6, 2016, by and between Medivation, Inc. and Marion McCourt

10-K

001-32836

10.50

2/26/2016

10.4

Compensation Arrangements with Named Executive Officers

8-K/A

001-32836

Item 5.02

3/10/2016

10.5

Separation Agreement between Medivation, Inc. and Richard A. Bierly dated March 25, 2016.

10.6

Offer Letter between Medivation, Inc. and Jennifer Jarrett dated March 25, 2016.

10.7

Offer Letter between Medivation, Inc. and Mohammad Hirmand dated March 28, 2016

31.1

Certification pursuant to Rule 13a-14(a)/15d-14(a).

31.2

Certification pursuant to Rule 13a-14(a)/15d-14(a).

32.1†

Certifications of Chief Executive Officer and Chief Financial Officer.

101.INS

XBRL Instance Document.

101.SCH

XBRL Taxonomy Extension Schema Document.

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document.

Incorporated By Reference

Exhibit

Number

Exhibit Description

Form

File No.

Exhibit

Filing Date

Filed
Herewith

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB

XBRL Taxonomy Extension Labels Linkbase Document.

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document.

†

The certifications attached as Exhibit 32.1 accompanying this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Medivation, Inc., under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

**	Confidential treatment has been requested with respect to certain portions of this exhibit.

EX-10.1 2 mdvn-ex101_336.htm EX-10.1 mdvn-ex101_336.htm

Exhibit 10.1

INDEMNIFICATION AGREEMENT

This Indemnification Agreement (“Agreement”) is made as of [____], 20[__] (the “Effective Date”) by and between Medivation, Inc., a Delaware corporation (the “Company”), and [__________], who serves as a director and/or an officer or agent of the Company (“Indemnitee”).

RECITALS

WHEREAS, the Company desires to attract and retain the services of highly qualified individuals as directors, officers and agents; and

WHEREAS, the Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) and the By-Laws (the “By-Laws”) of the Company require indemnification of the officers and directors of the Company, and permit the indemnification of agents, and Indemnitee may also be entitled to indemnification pursuant to the Delaware General Corporation Law (“DGCL”); and

WHEREAS, the Certificate of Incorporation, the By-Laws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the Board with respect to indemnification and the advancement of defense costs; and

WHEREAS, the Board has determined that, in order to help attract and retain qualified individuals as directors, officers and in other capacities, the best interests of the Company and its investors will be served by assuring such individuals that the Company will indemnify them to the maximum extent permitted by law; and

WHEREAS, the Board has determined that it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance defense costs on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; and

WHEREAS, the Board recognizes that the Indemnitee does not regard the protection available under the Company’s Certificate of Incorporation, the By-Laws and insurance program as adequate in the present circumstances, and may not be willing to serve or continue to serve as a director, officer and/or in such other capacity as the Company may request without adequate protection, and the Company desires Indemnitee to serve in such capacity; and

WHEREAS, Indemnitee is willing to serve, and continue to serve, as a member of the Board of Directors (and any committee thereof) and/or an officer or agent of the Company, on the condition that he or she be indemnified as provided for herein; and

WHEREAS, this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, By-Laws and any resolutions adopted pursuant thereto, and shall not be

deemed a substitute therefor, nor shall it be deemed to diminish or abrogate any rights of Indemnitee thereunder;

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

1.Services to the Company. Indemnitee will serve or continue to serve, at the will of the Company, as a director, officer or agent of the Company for so long as Indemnitee is duly elected or appointed or until Indemnitee tenders his or her resignation. This Agreement shall not serve as a binding commitment on the part of Indemnitee to continue to serve in such capacity, or on the part of the Company to cause him to continue as such.

The Company acknowledges that it has entered into this Agreement and assumes the obligations imposed on it hereby, in addition to and separate from its obligations to Indemnitee under the Bylaws, to induce Indemnitee to serve, or continue to serve, as a director and/or officer or agent of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director and/or an officer or agent of the Company.

2.Definitions. As used in this Agreement:

(a)The term “agent” of the Company means any person who: (i) is or was a director, officer, employee or other fiduciary of the Company or a subsidiary of the Company; or (ii) is or was serving at the request or for the convenience of, or representing the interests of, the Company or a subsidiary of the Company, as a director, officer, employee or other fiduciary of a foreign or domestic corporation, partnership, joint venture, trust or other enterprise.

(b)A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:

(i)Any Person (excluding any employee benefit plan of the Company or any subsidiary of the Company) is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company’s outstanding securities then entitled ordinarily to vote for the election of directors; or

(ii)During any period of two (2) consecutive years commencing on or after the Effective Date, the individuals who at the beginning of such period constitute the Board or any individuals who would be Continuing Directors (as defined below) cease for any reason to constitute at least a majority thereof; or

(iii)The Board shall approve a sale of all or substantially all of the assets of the Company; or

(iv)The Board shall approve any merger, consolidation, or like business combination or reorganization of the Company, the consummation of which would result in the occurrence of any event described in clause (i) or (ii), above.

(c)“Continuing Directors” shall mean the directors of the Company in office on the Effective Date and any successor to any such director and any additional director who after the Effective Date (i) was nominated or selected by a majority of the Continuing Directors in office at the time of his or her nomination or selection and (ii) who is not an “affiliate” or “associate” (as defined in Regulation 12B promulgated under the Exchange Act) of any person who is the beneficial owner, directly or indirectly, of securities representing ten percent (10%) or more of the combined voting power of the Company’s outstanding securities then entitled ordinarily to vote for the election of directors.

(d)“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

(e)“Person” shall have the meaning set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however, that Person shall exclude (i) the Company and (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company or a subsidiary of the Company.

(f)“Beneficial Owner” shall have the meaning given to such term in Rule 13d-3 issued under the Exchange Act; provided, however, that Beneficial Owner shall exclude any Person becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity,

(g)“Corporate Status” shall describe the status of a person who is or was a director, officer, trustee, partner, member, fiduciary, employee or agent of the Company or of any other Enterprise (as defined below), which such person is or was serving at the request of the Company.

(h)“Disinterested Director” shall mean a director of the Company who is not and was not a party to the Proceeding (as defined below) in respect of which indemnification is sought by Indemnitee.

(i)“Enterprise” shall mean any corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, administrator, partner, member, fiduciary, employee or agent.

(j)“Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts and accountants, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types and amounts customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding (as defined below). Expenses also shall include costs incurred in connection with any appeal resulting from any Proceeding (as defined below), including, without limitation, the premium, security for, and other costs relating to any bond, supersedeas bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of _.judgments or fines against Indemnitee.

(k)References to “fines” shall include any excise tax assessed on a person with respect to any employee benefit plan pursuant to applicable law.

(l)References to “serving at the request of the Company” shall include any service provided at the request of the Company as a director, officer, trustee, administrator, partner, member, fiduciary, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, trustee, administrator, partner, member, fiduciary, employee or agent with respect to an employee benefit plan, its participants or beneficiaries.

(m)Any action taken or omitted to be taken by a person for a purpose which he or she reasonably believed to be in the interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have been taken in “good faith” and for a purpose which is “not opposed to the best interests of the Company”, as such terms are referred to in this Agreement and used in the DGCL.

(n)The term. “Proceeding” shall include any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative or investigative nature, including any related appeal, in which Indemnitee was, is or will be involved as a party or witness or otherwise by reason of the fact that Indemnitee is or was a director, officer, trustee, administrator, partner, member, fiduciary, employee or agent of the Company, by reason of any action taken or not taken by him or her while acting as director, officer, trustee, administrator, partner, member, fiduciary, employee or agent of the Company, or by reason of the fact that he or she is or was serving at the request of the Company as a director, officer, trustee, administrator, partner, member, fiduciary, employee or agent of any other Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement, or advancement of expenses can be provided under this Agreement.

(o)“Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five (5) years has been, retained to represent: (i) the Company or Indemnitee in any matter _.material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement.

3.Indemnity in Third-Party Proceedings. To the fullest extent permitted by the DGCL, the Company shall indemnify and hold harmless Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is made, or is threatened to be made, a party to or a participant in (as a witness or otherwise) any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified and held harmless against all judgments, fines, penalties,

amounts paid in settlement (if such settlement is approved in writing in advance by the Company, which approval shall not be unreasonably withheld) (including, without limitation, all interest, assessments and other charges paid or payable in connection with or in respect of any of the foregoing) (collectively, “Losses”) and Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any action, discovery event, claim, issue or matter therein or related thereto, if Indemnitee acted in good faith, for a purpose which he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding, in addition, had no reasonable cause to believe that his or her conduct was unlawful.

4.Indemnity in Proceedings by or in the Right of the Company. To the fullest extent permitted by the DGCL, the Company shall indemnify Indemnitee in accordance with the provisions of this Section 4 if Indemnitee is made, or is threatened to be made, a party to or a participant in (as a witness or otherwise) any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 4, Indemnitee shall be indemnified and held harmless against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with the defense or settlement of such Proceeding or any action, discovery event, claim, issue or matter therein or related thereto, if Indemnitee acted in good faith, for a purpose which he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification, however, shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged to be liable to the Company, unless and only to the extent that the court in which the Proceeding was brought or, if no Proceeding was brought in a court, any court of competent jurisdiction, determines upon application that, in view of all the circumstances of the case, Indemnitee fairly and reasonably is entitled to indemnification for such portion of the Expenses as the court deems proper.

5.Indemnification for Expenses Where Indemnitee is Wholly or Partly Successful. Notwithstanding and in addition to any other provisions of this Agreement, to the extent that Indemnitee is a party to a Proceeding and is successful, on the merits or otherwise, in the defense of any claim, issue or matter therein, the Company shall indemnify and hold harmless Indemnitee against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with such successful defense. For the avoidance of doubt, if Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with each successfully resolved claim, issue or matter. For purposes of this Section 5 and, without limitation, the termination of any claim, issue or matter in such a Proceeding by withdrawal or dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

6.Indemnification for Expenses of a Witness. Notwithstanding and in addition to any other provision of this Agreement, to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness in or otherwise incurs Expenses in connection with any Proceeding to which Indemnitee is not a party, he or she shall be indemnified and held harmless by the Company against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith.

7.Additional Indemnification. Notwithstanding any limitation in Sections 3, 4, or 5 _.hereof or in Section 145 of the DGCL or other applicable statutory provision, the Company shall indemnify Indemnitee to the fullest extent permitted by law if Indemnitee is made, or is threatened to be made, a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Losses and Expenses actually and reasonably incurred by Indemnitee in connection with the Proceeding. No indemnification shall be made under this Section 7(a) on account of Indemnitee’s conduct which constitutes a breach of Indemnitee’s duty of loyalty to the Company or its investors or is an act or omission not in good faith or which involves intentional misconduct or a knowing violation of the law.

(a)For purposes of Sections 7(a), the meaning of the phrase “to the fullest extent permitted by law” shall include, but not be limited to:

(i)to the fullest extent authorized or permitted by the then applicable provisions of the DGCL or other applicable statutory provision, that authorize or contemplate indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL or other applicable statutory provision, and

(ii)to the fullest extent authorized or permitted by any amendments to or replacements of the DGCL or other applicable statutory provision, adopted after the date of this Agreement that increase the extent to which a corporation limited liability company or partnership, as applicable may indemnify its officers, directors or persons holding similar fiduciary responsibilities.

(b)Indemnitee shall be entitled to the prompt payment of all Expenses reasonably incurred in enforcing successfully (fully or partially) this Agreement.

8.Assumption of Defense. In the event the Company shall be requested by Indemnitee to pay the Expenses of any Proceeding, the Company, if appropriate, shall be entitled to assume the defense of such proceeding, or to participate to the extent permissible in such proceeding, with counsel reasonably acceptable to Indemnitee. Upon assumption of the defense by the Company and the retention of such counsel by the Company, the Company shall not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same proceeding, provided that Indemnitee shall have the right to employ separate counsel in such proceeding at Indemnitee’s sole cost and expense. Notwithstanding the foregoing, if Indemnitee’s counsel delivers a written notice to the Company stating that such counsel has reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of any such defense or the Company shall not, in fact, have employed counsel or otherwise actively pursued the defense of such proceeding within a reasonable time, then in any such event the fees and expenses of Indemnitee’s counsel to defend such proceeding shall be subject to the indemnification and advancement of expenses provisions of this Agreement.

9.Exclusions. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee:

(a)for which payment actually has been received by or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount actually received under such insurance policy or other indemnity provision; or

(b)for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company or any subsidiary of the Company within the meaning of Section 16(b) of the Exchange Act, as amended, or similar provisions of state blue sky law, state statutory law or common law; or

(c)prior to a Change in Control, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company (other than any Proceeding referred to in Sections 14(d) or (e) below or any other Proceeding commenced to recover any Expenses referred to in Section 7(c) above) or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law;

(d)for remuneration paid to Indemnitee if it is determined by final judgment or other final adjudication that such remuneration was in violation of law (and, in this respect, both the Company and Indemnitee have been advised that the Securities and Exchange Commission believes that indemnification for liabilities arising under the federal securities laws is against public policy and is, therefore, unenforceable and that claims for indemnification should be submitted to appropriate courts for adjudication);

(e)a final judgment or other final adjudication that Indemnitee’s conduct was in bad faith, knowingly fraudulent or deliberately dishonest or constituted willful misconduct (but only to the extent of such specific determination); or

(f)on account of conduct that is established by a final judgment as constituting a breach of Indemnitee’s duty of loyalty to the Company or resulting in any personal profit or advantage to which Indemnitee is not legally entitled; or

(g)for any amounts paid in settlement of a proceeding effected without the Company’s written consent. Neither the Company nor Indemnitee shall unreasonably withhold consent to any proposed settlement; provided, however, that the Company may in any event decline to consent to (or to otherwise admit or agree to any liability for indemnification hereunder in respect of) any proposed settlement if the Company is also a party in such proceeding and determines in good faith that such settlement is not in the best interests of the Company and its stockholders; or

(h)if the funds at issue were paid pursuant to a settlement approved by a court and indemnification would be inconsistent with any condition with respect to indemnification expressly imposed by the court in approving the settlement.

For purposes of the foregoing sentence, a final judgment or other adjudication may be reached in either the underlying proceeding or action in connection with which indemnification is sought or a separate proceeding or action to establish rights and liabilities under this Agreement.

10.Advances of Expenses; Defense of Claim.

(a)Notwithstanding any provision of this Agreement to the contrary, the Indemnitee shall be entitled to advances of Expenses incurred by him or her or on his or her behalf in connection with a Proceeding that Indemnitee claims is covered by Sections 3 and 4 hereof, prior to a final determination of eligibility for indemnification and prior to the final disposition of the Proceeding, upon the execution and delivery to the Company of an undertaking by or on behalf of the Indemnitee providing that the Indemnitee will repay such advances to the extent that it ultimately is determined that Indemnitee is not entitled to be indemnified by the Company. This Section 10(a) shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 9.

(i)The Company shall advance pursuant to Section 10(a) the Expenses incurred by Indemnitee in connection with any Proceeding within thirty (30) days after the receipt by the Company of a written statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee’s ability to repay such advances. Advances shall include any and all reasonable Expenses incurred pursuing an action to enforce such right to receive advances.

(ii)The Company will be entitled to participate in the Proceeding at its own expense.

(iii)The Company shall not settle any action, claim or Proceeding (in whole or in part) which would impose any Expense, judgment, fine, penalty or limitation on the Indemnitee without the Indemnitee’s prior written consent, which consent shall not be unreasonably withheld.

11.Procedure for Notification and Application for Indemnification. Within sixty (60) days after the actual receipt by Indemnitee of notice that he or she is a party to or is requested to be a participant in (as a witness or otherwise) any Proceeding, Indemnitee shall submit to the Company a written notice identifying the Proceeding. The failure by the Indemnitee to notify the Company within such 60-day period will not relieve the Company from any liability which it may have to Indemnitee (i) otherwise than under this Agreement, and (ii) under this Agreement, provided that if the Company can establish that such failure to notify the Company in a timely manner resulted in actual prejudice to the Company, then the Company will be relieved from liability under this Agreement only to the extent of such actual prejudice.

(a)Indemnitee shall at the time of giving such notice pursuant to Section 11(a) or thereafter deliver to the Company a written application for indemnification. Such application may be delivered at such time as Indemnitee deems appropriate in his or her sole discretion. Following delivery of such a written application for indemnification by Indemnitee, the Indemnitee’s entitlement to indemnification shall be determined promptly

according to Section 12(a) of this Agreement and the outcome of such determination shall be reported to Indemnitee in writing within forty-five (45) days of the submission of such application.

12.Procedure Upon Application for Indemnification.

(a)Upon written application by Indemnitee for indemnification pursuant to Section 11(b) or written statement by Indemnitee for advances of Expenses pursuant to Section 10(b), a determination with respect to Indemnitee’s entitlement thereto pursuant to the mandatory terms of this Agreement, pursuant to statute, or pursuant to other sources of right to indemnity, and pursuant to Section 13 of this Agreement shall be made in the specific case: (i) by a majority vote of the Disinterested Directors, whether or not such directors otherwise would constitute a quorum of the Board; (ii) by a committee of Disinterested Directors designated by a majority vote of such directors, whether or not such directors would otherwise constitute a quorum of the Board, (iii) if there are no Disinterested Directors or if so requested by (x) the Indemnitee in his or her sole discretion or (y) the Disinterested Directors, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (iv) by the stockholders of the Company. Indemnitee shall reasonably cooperate with the person, persons or entity making the determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby jointly and severally indemnify and agree to hold Indemnitee harmless from any such costs and expenses.

(b)If it is determined that Indemnitee is entitled to indemnification requested by the Indemnitee in a written application submitted to the Company pursuant to Section 11(b), payment to Indemnitee shall be made within ten (10) days after such determination. All advances of Expenses requested in a written statement by Indemnitee pursuant to Section 10(b) prior to a final determination of eligibility for indemnification shall be paid in accordance with Section 10.

(c)In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) hereof, the Independent Counsel shall be selected as provided in this Section 12(c). If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee advising him or her of the identity of the Independent Counsel so selected. If a Change in Control shall have occur^red, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been received, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection;

provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If a written objection is made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court of competent jurisdiction has determined that such objection is without merit.

(d)If, within twenty (20) days after submission by Indemnitee of a written request for indemnification pursuant to Section 10(b) or 11(b) hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition a court of competent jurisdiction for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Court or by such other person as the Court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 12(a) hereof.

(e)The Company shall pay the reasonable fees and expenses of the Independent Counsel and to fully indemnify such Independent Counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

(f)Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14(a) of this Agreement, any Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

13.Presumptions and Effect of Certain Proceedings.

(a)Presumption in Favor of Indemnitee. In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted an application for indemnification in accordance with Section 11(a) of this Agreement, and the Company shall have the burden of proof to overcome that presumption.

(b)No Presumption Against Indemnitee. Neither the failure of the Company (including by its Directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement nor an actual determination by the Company (including by its Directors or Independent Counsel) that Indemnitee has not met the applicable standard of conduct for indemnification shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.

(c)Sixty Day Period for Determination. If the person, persons or entity empowered or selected under Section 11 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after

receipt by the Company of an application therefor, a determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the application for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto.

(d)No Presumption from Termination of a Proceeding. The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere, or its equivalent, shall not of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and for a purpose which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.

(e)Reliance as Safe Harbor. For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action or failure to act is based on the records or books of account of the Company or any Enterprise other than the Company, including financial statements, or on information supplied to Indemnitee by the officers of the Company or any Enterprise other than the Company in the course of their duties, or on the advice of legal counsel for the Company or any Enterprise other than the Company or on information or records given or reports made to the Company or any Enterprise other than the Company by an independent certified public accountant or by an appraiser or other expert selected by the Company or any Enterprise other than the Company, except if the Indemnitee knew or had reason to know that such records or books of account of the Company, information supplied by the officers of the Company, advice of legal counsel or information or records given or reports made by an independent certified public accountant or by an appraiser or other expert were materially false or materially inaccurate. The provisions of this Section 13(e) shall not be deemed to be exclusive or to limit in any way the other circumstances in which the Indemnitee may be deemed or found to have met any applicable standard of conduct.

(f)Actions of Others. The knowledge and/or actions, or failure to act, of any other director, officer, trustee, administrator, partner, member, fiduciary, employee or agent of the Company or any Enterprise other than the Company shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.

14.Remedies of Indemnitee.

(a)Adjudication/Arbitration. In the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 10 of this Agreement, (iii) subject to Section 13(c), no determination of entitlement to indemnification shall have been made pursuant to Section 12(a) of this Agreement within 60

days after receipt by the Company of the application for indemnification, or (iv) payment of indemnification is not made pursuant to Sections 3, 4, 5, 6, 7 and 12(b) of this Agreement within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or after receipt by the Company of a written request for any additional monies owed with respect to a Proceeding as to which it already has been determined that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication by a court of his or her entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration.

(b)Indemnitee Not Prejudiced by Prior Adverse Determination. In the event that a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 14 shall be conducted in all respects as a de novo trial, or arbitration, on the merits, and Indemnitee shall not be prejudiced by reason of the prior adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 14, the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.

(c)Company Bound by Prior Determination. If a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 14, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the application for indemnification, or (ii) a prohibition of such indemnification under applicable law.

(d)Expenses. In the event that Indemnitee, pursuant to this Section 14, seeks a judicial adjudication of or an award in arbitration to enforce his or her rights under, or to recover damages for breach of, this Agreement, Indemnitee shall be entitled to recover from the Company, and shall be jointly and severally indemnified by the Company against, any and all Expenses actually and reasonably incurred by him or her in such judicial adjudication or arbitration if it shall be determined in such judicial adjudication or arbitration that Indemnitee is entitled to receive all or part of the indemnification or advancement of Expenses sought which the Company had disputed prior to the commencement of the judicial proceeding or arbitration.

(e)Advances of Expenses. If requested by Indemnitee, the Company shall (within ten (10) days after receipt by the Company of a written request therefore) advance to Indemnitee the Expenses which are incurred by Indemnitee in connection with any judicial proceeding or arbitration brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company, if the Indemnitee has submitted an undertaking to repay such Expenses if Indemnitee ultimately is determined to not be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be.

The Indemnitee’s financial ability to repay any such advances shall not be a basis for the Company to decline to make such advances.

(f)Precluded Assertions by the Company. The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.

15.Non-exclusivity; Survival of Rights; Insurance; Subrogation.

(a)Rights of Indemnitee Not Exclusive. The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, or the By-Laws, any agreement, vote of investors or a resolution of directors, members, partners, or otherwise. No right or remedy herein conferred by this Agreement is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent or subsequent assertion or employment of any other right or remedy.

(b)Survival of Rights. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal.

(c)Change of Law. To the extent that a change in Delaware law, or where applicable California law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Certificate of Incorporation or the By-Laws, or this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy and be conferred by this Agreement the greater benefits so afforded by such change.

(d)Insurance. To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, trustees, administrators partners, members, fiduciaries, employees, or agents of the Company or of any other Enterprise which such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, trustee, partner, member, fiduciary, officer, employee or agent under such policy or policies. If, at the time the Company receives notice from any source of a Proceeding as to which Indemnitee is a party or a participant (as a witness or otherwise) the Company has director and officer liability insurance in effect that covers Indemnitee, the Company shall give prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.

(e)Subrogation. In the event of any payment under this Agreement, the Company, shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

(f)Other Payments. The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.

(g)Other Indemnification, The Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, trustee, administrator partner, member, fiduciary, employee or agent of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of expenses from such Enterprise.

16.Duration of Agreement. This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as any of the following: a director, officer, agent or employee of the Company or as a director, officer, trustee, administrator partner, member, fiduciary, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other Enterprise which Indemnitee served at the request of the Company; or (b) one (1) year after the final termination of any Proceeding (including after the expiration of any rights of appeal) then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 14 of this Agreement (including any rights of appeal of any Proceeding commenced pursuant to Section 14). This Agreement shall be binding upon the Company and its respective successors and assigns and shall inure to the benefit of Indemnitee and his or her heirs, executors and administrators.

17.Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.

18.Enforcement.

(a)The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce

Indemnitee to serve, or to continue to serve, as a director and/or officer or agent, of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving or continuing to serve as a director and/or officer or agent of the Company.

(b)This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof.

19.Modification and Waiver. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by each of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.

20.Successors and Binding Agreement.

(a)The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise) and any acquirer of all or substantially all of the business or assets of the Company by agreement in form and substance reasonably satisfactory to Indemnitee and/or his or her counsel, expressly to assume and agree to perform this Agreement in the same manner and to the same extent the Company would be required to perform it if no such succession had taken place.

(b)This Agreement will be binding upon and inure to the benefit of the Company and any successor to the Company, including, without limitation, any person acquiring directly or indirectly all or substantially all of the business or assets of the Company whether by purchase, merger, consolidation, reorganization or otherwise (and such successor will thereafter be deemed the “Company” for purposes of this Agreement), but will not otherwise be assignable or delegatable by the Company.

(c)This Agreement will inure to the benefit of and be enforceable by the Indemnitee’s personal or legal representatives, executors, administrators, successors, heirs, distributees, legatees and other successors.

(d)This Agreement is personal in nature and neither of the parties hereto will, without the consent of the other, assign or delegate this Agreement or any rights or obligations hereunder except as expressly provided in Sections 20(a), (b) and (c). Without limiting the generality or effect of the foregoing, Indemnitee’s right to receive payments hereunder will not be assignable, whether by pledge, creation of a security interest or otherwise, other than by a transfer by the Indemnitee’s will, devise, a grantor’s trust instrument under which the Indemnitee or his estate is the sole beneficiary, or by the laws of descent and distribution, and, in the event of any attempted assignment or transfer contrary to this Section 20(d), the Company will have no liability to pay any amount so attempted to be assigned or transferred.

21.Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if: (i) delivered by hand and receipted for by the party to whom said notice or other communication shall have

been directed, on the date of such receipt, or (ii) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed:

(a)If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee subsequently shall provide in writing to the Company.

(b)If to the Company to:

Medivation, Inc.

525 Market Street, 36th Floor

San Francisco, California 94105

Attention: General Counsel

or to any other address as may have been furnished to Indemnitee in writing by the Company.

22.Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company, on the one hand, and Indemnitee , on the other, as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company, on the one hand (and its directors, officers, employees and agents) and Indemnitee, on the other, in connection with such event(s) and/or transaction(s).

23.Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws, principles or rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 14 of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the “Delaware Court”), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) irrevocably appoint, to the extent such party is not a resident of the State of Delaware, The Prentice-Hall Corporation System, Inc., 32 Lockerman Square, Suite L-100, Dover, County of Kent, Delaware 19901 as its agent in the State of Delaware as such party’s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.

24.Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

25.Miscellaneous. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

[The remainder of this page is intentionally left, blank.]

IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written,

MEDIVATION, INC.		INDEMNITEE

By:
	Name:	Name:
	Title:

		Address for Notices to Indemnitee:

[Signature Page to Indemnification Agreement]

EX-10.5 3 mdvn-ex105_335.htm EX-10.5 mdvn-ex105_335.htm

Exhibit 10.5

March 25, 2016

Sent Via Email

Rick Bierly

Re: Separation Agreement

Dear Rick:

This letter sets forth the terms of the separation agreement (the “Agreement”) between you and Medivation, Inc. (the “Company”) regarding your employment transition.

1.Separation Date; Final Pay. As discussed, your last day of employment and your employment termination date will be July 15, 2016, (the “Separation Date”). On the Separation Date or within the timing required by law, the Company shall pay you all accrued salary earned by you through the Separation Date, less standard payroll deductions and withholdings. You are entitled to this payment by law and will receive it regardless of whether or not you sign this Agreement. As you know, due to your level in the Company, you did not accrue vacation or other Paid Time Off (“PTO”) and instead were permitted to take time off, with pay, within your discretion; thus, no payment for accrued or unused vacation or PTO is owed or will be provided.

2.Severance Benefits. If: (i) you sign, date and return this Agreement to the Company, and you do not subsequently revoke it; (ii) you comply with all of your obligations to the Company as set forth herein; and (iii) on or within 21 days after the Separation Date, you sign, return, and do not revoke the Separation Date Release set forth as Exhibit A hereto (the “Separation Date Release”); then the Company will provide you with the following severance benefits (the “Severance Benefits”):

(a)Cash Severance Payment. Subject to standard payroll deductions and withholdings, the Company will pay you a single lump sum severance amount equal to $437,180. This amount is the sum of: (i) $280,758, which is seven (7) months of your Base Salary; and (ii) $156,422, which is equal to a pro-rata share of your 2016 annual target bonus from January 1 through July 15, 2016, (collectively, the “Severance Amount”). Such lump sum payment shall be made in the first payroll cycle following the Effective Date of the Separation Date Release (as set forth therein).

(b)Health Insurance. To the extent provided by the federal COBRA law or, if applicable, state insurance laws (collectively, “COBRA”), and by the Company’s current group health insurance policies, you will be eligible to continue your group health insurance benefits after the Separation Date. Later, you may be able to convert to an individual policy through the provider of the Company’s health insurance, if you wish. You will be provided with

a separate notice describing your rights and obligations under COBRA laws on or after the Separation Date. As an additional Severance Benefit, if you timely elect continued group health insurance coverage under COBRA, the Company will reimburse your COBRA premium payments sufficient to continue your group coverage at its current level including costs of dependent coverage, if applicable, through the earlier of either of the following provided that you remain eligible for COBRA coverage (such applicable time period, the “COBRA Payment Period”): (i) February 28, 2017 or (ii) the date that you become eligible for group health insurance coverage through a new employer. You must promptly notify Maya Thaw, in Benefits Administration in writing if you become eligible for group health insurance coverage through a new employer prior to February 28, 2017. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA payments without a substantial risk of violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company instead shall provide you with taxable monthly payments in an amount equal to the premium amount for the first month of your COBRA coverage, and such monthly installments shall be made through the remainder of the COBRA Payment Period.

(c)Earlier Termination of Severance Benefits. As a condition of your receipt of the Severance Benefits, you must continue to comply with your continuing obligations to the Company, including but not limited to your full continued compliance with this Agreement. For example, in the event of any material breach of this Agreement, the Company’s obligation to provide the Severance Benefits immediately shall terminate and you will receive no further Severance Benefits.

(d)Section 409A Compliance. It is intended that the Severance Payments be exempt from Section 409A of the Internal Revenue Code under Treasury Regulations Sections 1.409A-1(b)(4) and 1.409A-1(b)(9)(iii) and will be implemented and construed in accordance therewith to the greatest extent permitted under applicable law.

3.Consulting Period. You and the Company have agreed that the Company will retain you as a consultant under the terms specified below. The consulting relationship commences on the Separation Date and continues through September 15, 2016, unless terminated earlier as provided herein (the “Consulting Period”). Your agreement to provide consulting services is in further consideration of the benefits to be provided to you under this Agreement. There is no separate compensation specifically attributable to your consulting services.

(a)Consulting Services. During the Consulting Period, you will use your best efforts to provide consulting services, as may be requested by the Company, in the areas of your experience and expertise, including but not limited to your expertise in financial and investor matters (the “Consulting Services”). You will report to David Hung M.D, President and CEO (or his designee) during this consultancy period. You agree to exercise the highest degree of professionalism and utilize your expertise and creative talents in performing these services. You have agreed to make yourself available to provide the Consulting Services for up to 20 hours per week for the first four weeks of the Consulting Period, and 10 hours per week for the remainder of the Consulting Period, respectively, from July 15, 2016 through September 15, 2016. During the Consulting Period, you shall abide by the Company’s applicable policies and procedures.

(b)Equity Awards. Since your service as an employee and a consultant will be continuous, your termination of employment will not constitute a termination of service for purposes of the Company’s Amended and Restated 2004 Equity Incentive Award Plan (the “Plan”). Thus, vesting of your outstanding stock options and other equity awards (including but not limited to Restricted Stock Unit awards) (the “Equity Awards”) will not cease as of the Separation Date and will continue for the duration of the Consulting Period. Your Equity Awards shall continue to be governed by the Plan and all applicable grant notices and agreements.

(c)Independent Contractor Relationship. During the Consulting Period, your relationship with the Company will be that of an independent contractor, and nothing in this Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship after the Separation Date. Except as expressly provided in this Agreement, you will not be entitled to, and will not receive, any benefits which the Company may make available to its employees, including but not limited to, group health or life insurance, profit-sharing or retirement benefits.

(d)Limitations on Authority. During the Consulting Period, you will have no responsibilities or authority as a consultant to the Company other than as provided above. You will have no authority to bind the Company to any contractual obligations, whether written, oral or implied, except with the prior written authorization of an officer of the Company. You agree not to represent or purport to represent the Company in any manner whatsoever to any third party unless authorized in advance by the Company, in writing, to do so.

(e)Proprietary Information and Inventions. You agree that, during the Consulting Period and thereafter, you will not use or disclose, in any manner that is not authorized by the Company or essential to your performance of specifically requested Consulting Services, any confidential or proprietary information or materials of the Company that you obtain or develop in the course of performing the Consulting Services. Any and all work product you create in the course of performing the Consulting Services will be the sole and exclusive property of the Company. As set forth in your Proprietary Information and Inventions Agreement with the Company, and subject to the limitations set forth herein, you hereby assign to the Company all right, title, and interest in all inventions, techniques, processes, materials, and other intellectual property developed in the course of performing the Consulting Services. You further acknowledge and reaffirm your continuing obligations, both during the Consulting Period and thereafter (as applicable), under the Proprietary Information and Inventions Agreement entered into between you and the Company, a copy of which is attached hereto as Exhibit A and incorporated herein by reference.

(f)Other Work Activities. Throughout the Consulting Period, you shall have the right to engage in employment, consulting, or other work relationships in addition to your work for the Company. The Company will make arrangements to enable you to perform your work for the Company at such times and in such a manner so that it will not unreasonably interfere with other activities in which you may engage. In order to protect the trade secrets and confidential and proprietary information of the Company, you agree that, during the Consulting Period, you will notify the Company, in writing, and obtain the Company’s written consent before you obtain employment with, or perform competitive work for, any business entity that is

competitive with the Company, or engage in any other work activity, or preparation for work activity, competitive with the Company.

(g)Termination of Consulting Period. Without waiving any other rights or remedies, the Company may immediately terminate the Consulting Period if you breach your obligations under this Agreement and, in such event, your continued vesting of your Equity Awards shall cease immediately. The Company also may immediately terminate the Consulting Period upon written notice to you even if you do not breach your obligations hereunder but, in such an event, vesting of your Equity Awards shall accelerate such that you will receive any vesting which would have occurred through September 15, 2016.

4.No Other Compensation or Benefits. You acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive from the Company any additional compensation, severance, or benefits on or after the Separation Date, with the exception of any vested benefits you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account). By way of example, you acknowledge that you have not earned and are not owed any sales commissions and will not be granted any new equity awards or earn any bonus or other compensation for 2016. You acknowledge and agree that this is an individual agreement with the Company for Severance Benefits and therefore you shall not receive any benefits pursuant to Section 5 of the Medivation, Inc. 2015 Employee Severance Plan. You further agree that you shall not be entitled to any additional compensation or benefits pursuant to your Change of Control Severance Benefits Agreement (the “Severance Benefits Agreement”); provided, however, that if a Change of Control (as defined therein) is consummated prior to your Separation Date of July 15, 2016, then you shall receive the Severance Benefits set forth in Section 4 of the Severance Benefits Agreement (and pursuant to the terms of that Agreement) in lieu of, and not in addition to, any benefits set forth in this Agreement.

5.Expense Reimbursement. You agree that, within thirty (30) days of the Separation Date, you will submit your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement. The Company will reimburse you for such expenses pursuant to its regular business practice and policies.

6.Return of Company Property. By no later than thirty (30) days after the close of business on the Separation Date, you shall return to the Company all non-public Company documents (and all copies thereof) and other property of the Company in your possession or control, including, but not limited to, Company files, notes, correspondence, memoranda, notebooks, drawings, records, reports, lists, compilations of data, proposals, agreements, drafts, minutes, studies, plans, forecasts, purchase orders, financial and operational information, product and training information, research and development information, clinical trial information, sales and marketing information, personnel and compensation information, vendor information, promotional literature and instructions, product specifications and manufacturing information, computer-recorded information, electronic information (including e-mail and correspondence), other tangible property and equipment (including, but not limited to, computer equipment, PDAs, facsimile machines, and cellular telephones), credit cards, entry cards, identification badges and keys; and any materials of any kind that contain or embody any proprietary or confidential

information of the Company (and all reproductions thereof in whole or in part). You agree that you will make a diligent search to locate any such documents, property and information within the timeframe referenced above. In addition, if you have used any personally owned computer, server, e-mail system, mobile phone, or portable electronic device (e.g., BlackBerry), (collectively, “Personal Systems”) to receive, store, prepare or transmit any Company confidential or proprietary data, materials or information, then by no later than thirty (30) days after the Separation Date, you will provide the Company with a computer-useable copy of all such information and then permanently delete and expunge all such Company confidential or proprietary information from such Personal Systems without retaining any copy or reproduction in any form and, if the Company requests, will provide a written certificate to that effect. Your timely compliance with the provisions of this Section 6 is a condition of your receipt of the Severance Benefits hereunder.

7.Proprietary Information Obligations. You hereby acknowledge and agree to comply with your continuing obligations with respect to protection of the Company’s confidential and proprietary information pursuant to your confidentiality agreement with the Company (attached hereto and incorporated herein by reference).

8.Nondisparagement. You agree not to disparage or subvert, verbally or in writing, the Company, its collaboration partners, and its and their current and former officers, directors, employees, shareholders and agents, in any manner likely to be harmful to them or their business, business reputations or personal reputations, and the Company agrees to direct its officers and directors not to disparage you in any manner likely to be harmful to your business, business reputation or personal reputation; provided, however, that both you and the Company must respond accurately and truthfully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation.

9.No Voluntary Adverse Action; and Cooperation. You agree that you will not voluntarily provide assistance, information or advice, directly or indirectly (including through agents or attorneys), to any person or entity in connection with any proposed or pending litigation, arbitration, administrative claim, cause of action, or other formal proceeding of any kind brought against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or agents, nor shall you induce or encourage any person or entity to bring any such claims; provided, however, that you must respond accurately and truthfully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation. In addition, you agree to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during the period of your employment by the Company. Such cooperation includes, without limitation, making yourself available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony. Subject to the terms of the indemnity agreement between you and the Company, the Company generally will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding forgone wages, salary, or other compensation) and will make reasonable

efforts to accommodate your scheduling needs. In addition, you agree to execute all documents (if any) necessary to carry out the terms of this Agreement.

10.Nonsolicitation of Employees, Contractors or Consultants. You agree, for one (1) year after the Separation Date, not to solicit, induce, or attempt to solicit or induce, any employees, independent contractors or consultants of the Company to reduce or terminate his, her or its employment or other relationship with the Company.

11.No Admissions. Nothing contained in this Agreement shall be construed as an admission by you or the Company of any liability, obligation, wrongdoing or violation of law.

12.Release of Claims.

(a)General Release. In exchange for the Severance Benefits under this Agreement, and except as otherwise set forth in this Agreement, you hereby generally and completely release the Company, its parent and subsidiary entities, and its and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, insurers, affiliates, and assigns (collectively, the “Released Parties”) of and from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the “Released Claims”).

(b)Scope of Release. The Released Claims include, but are not limited to: (i) all claims arising out of or in any way related to your employment with the Company, or the termination of that employment; (ii) all claims related to your compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (iii) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (iv) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (v) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (the “ADEA”), the federal Family and Medical Leave Act (as amended) (“FMLA”), the California Family Rights Act (as amended), the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended).

(c)Excluded Claims. Notwithstanding the foregoing, the following are not included in the Released Claims (the “Excluded Claims”): (i) any rights or claims for indemnification you may have pursuant your indemnification agreement with the Company; the charter, bylaws, or operating agreements of the Company; or under applicable law; (ii) any rights or claims which are not waivable as a matter of law; and (iii) any claims for breach of this Agreement. In addition, nothing in this Agreement prevents you from filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, the California Department of Fair Employment and Housing, or any other government agency, except that you acknowledge and agree that you are hereby waiving your right to any monetary benefits in connection with any such claim, charge or proceeding. You

hereby represent and warrant that, other than the Excluded Claims, you are not aware of any claims you have or might have against any of the Released Parties that are not included in the Released Claims.

(d)ADEA Waiver. You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you have under the ADEA, and that the consideration given for the waiver and release you have given in this Agreement is in addition to anything of value to which you were already entitled. You further acknowledge that you have been advised, as required by the ADEA, that: (i) your waiver and release does not apply to any rights or claims that arise after the date you sign this Agreement; (ii) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so); (iii) you have twenty-one (21) days to consider this Agreement (although you may choose voluntarily to sign it sooner); (iv) you have seven (7) days following the date you sign this Agreement to revoke this Agreement (in a written revocation delivered to me); and (v) this Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after you sign this Agreement provided that you do not revoke it (the “Effective Date”).

(e)Section 1542 Waiver. In giving the releases set forth in this Agreement, which include claims which may be unknown to you at present, you acknowledge that you have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” You hereby expressly waive and relinquish all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to the releases granted herein, including but not limited to the release of unknown and unsuspected claims granted in this Agreement.

13.Job Reference Inquiries. The Company agrees to respond to job reference inquiries consistent with its standard practice by providing your job title, dates of employment, and salary amount (if you authorize disclosure of your salary amount in advance). You agree to direct prospective employers to the Company’s Human Resources department for such references.

14.Representations. You hereby represent and warrant that (a) you have been paid all compensation owed and for all time worked, (b) you have received all the leave and leave benefits and protections for which you are eligible pursuant to FMLA, any applicable law or Company policy, and (c) you have not suffered any on-the-job injury or illness for which you have not already filed a workers’ compensation claim.

15.Arbitration.

(a)Agreement to Arbitrate. To ensure the rapid and economical resolution of disputes that may arise under this Agreement, you and the Company both agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment from

the Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted in San Francisco, California by JAMS, Inc. (“JAMS”) or its successors. Both you and the Company acknowledge that by agreeing to this arbitration procedure, you each waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding.

(b)Governing Rules.

(i)Any such arbitration proceeding will be governed by JAMS’ then applicable rules and procedures for employment disputes, which can be found at www.jamsadr.com/rules-employment-arbitration/, and which will be provided to you upon request.

(ii)In any such proceeding, the Arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii) issue a written arbitration decision including the arbitrator’s essential findings and conclusions and a statement of the award.

(iii)You and the Company each shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law; provided, however, that in no event shall the Arbitrator be empowered to hear or determine any class or collective claim of any type. This paragraph shall not apply to an action or claim brought pursuant to the California Private Attorneys General Act of 2004.

(iv)Nothing in this Agreement is intended to prevent either the Company or Executive from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration pursuant to applicable law.

(c)Arbitration Fees. The Company shall pay all filing fees in excess of those which would be required if the dispute were decided in a court of law, and shall pay the arbitrator’s fees and any other fees or costs unique to arbitration.

16.Miscellaneous. This Agreement and any documents incorporated herein by reference constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This Agreement may not be modified or amended except in a written agreement signed by both you and a duly authorized officer of the Company. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, and their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question shall be deemed modified so as to be rendered enforceable in a manner consistent with the intent of the parties, insofar as possible under applicable law. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or

rights hereunder. This Agreement shall be deemed to have been entered into, and shall be construed and enforced, in accordance with the laws of the State of California without regard to conflicts of law principles. This Agreement may be executed in counterparts, each of which shall be deemed to be part of one original, and facsimile signatures shall be equivalent to original signatures.

If this Agreement is acceptable to you, please sign below on the Separation Date, and return it to me. If you do not sign and return it to the Company within the aforementioned timeframe, the Company’s offer to enter into this Agreement and provide the Severance Benefits will expire.

We wish you the best in your future endeavors.

Sincerely,

Medivation, Inc.

By:	/s/ Sandy Cooper
	Sandy Cooper
	Senior Vice President, Human Resources

Understood and Agreed:

/s/ Rick Bierly		3/27/16
Rick Bierly		Date

EXHIBIT A

Separation Date Release

(To be signed on or within 21 days after the Separation Date)

In exchange for the Severance Benefits under this Agreement, and except as otherwise set forth in this Agreement, I hereby generally and completely release the Company, its parent and subsidiary entities, and its and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, insurers, affiliates, and assigns (collectively, the “Released Parties”) of and from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date I sign this Agreement (collectively, the “Released Claims”).

The Released Claims include, but are not limited to: (i) all claims arising out of or in any way related to my employment with the Company, or the termination of that employment; (ii) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (iii) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (iv) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (v) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (the “ADEA”), the federal Family and Medical Leave Act (as amended) (“FMLA”), the California Family Rights Act (as amended), the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended).

Notwithstanding the foregoing, the following are not included in the Released Claims (the “Excluded Claims”): (i) any rights or claims for indemnification I may have pursuant to my indemnification agreement with the Company; the charter, bylaws, or operating agreements of the Company; or under applicable law; (ii) any rights or claims which are not waivable as a matter of law; and (iii) any claims for breach of this Agreement. In addition, nothing in this Agreement prevents me from filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, the California Department of Fair Employment and Housing, or any other government agency, except that I acknowledge and agree that I am hereby waiving your right to any monetary benefits in connection with any such claim, charge or proceeding. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or might have against any of the Released Parties that are not included in the Released Claims.

I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I have under the ADEA, and that the consideration given for the waiver and release I have given in this Agreement is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised, as required by the ADEA, that: (i) my waiver and release does not apply to any rights or claims that arise after the date I sign this Agreement; (ii) I should consult with an attorney prior to signing this Agreement (although I may choose voluntarily not

to do so); (iii) I have twenty-one (21) days to consider this Agreement (although I may choose voluntarily to sign it sooner); (iv) I have seven (7) days following the date I sign this Agreement to revoke this Agreement (in a written revocation); and (v) this Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after you sign this Agreement provided that I do not revoke it (the “Effective Date”).

In giving the releases set forth in this Agreement, which include claims which may be unknown to me at present, I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to the releases granted herein, including but not limited to the release of unknown and unsuspected claims granted in this Agreement.

I hereby represent and warrant that: (i) I have been paid all compensation owed and for all time worked; (ii) I have received all the leave and leave benefits and protections for which I am eligible pursuant to FMLA, any applicable law or Company policy; and (iii) I have not suffered any on-the-job injury or illness for which I have not already filed a workers’ compensation claim.

Understood and Agreed:

Rick Bierly

Date

EX-10.6 4 mdvn-ex106_334.htm EX-10.6 mdvn-ex106_334.htm

Exhibit 10.6

March 25, 2016 Revised

Jennifer Jarrett

Email Delivery

Dear Jennifer:

It is my great pleasure to offer you the position of Chief Financial Officer, reporting to David Hung, President, and Chief Executive Officer. We are very excited about the possibility of you joining our team, and we look forward to the prospect of working with you in our innovative company!

As an employee of Medivation Inc., (the Company) you will be eligible to participate in our benefits and compensation programs. The following outlines the terms of our offer:

Your annualized base salary will be $498,300 payable on the 15^th and last day of each month.

Employees who join the Company between January 1 and September 30^th will be eligible for a prorated bonus for their first year of employment. Bonuses are generally paid in the first quarter, following year that the bonus was earned. As such, you will be eligible for the 2016 corporate bonus paid out in the first quarter of 2017. The target bonus opportunity for your position is 50% of your base salary. The actual payout can vary based on your individual and company performance. The Board of Directors makes an assessment of company achievement against goals for purposes of annual bonus payouts generally in the first quarter of the following year.

We will recommend to Medivation’s Board of Directors or their designee that you be granted an option to purchase 119,885 shares of Medivation common stock, 29,971 restricted stock units (RSUs) and 29,971 performance stock units (PSUs). Upon vesting, each RSU will entitle you to receive one share of Medivation common stock.

Your options will have an exercise price equal to the fair market value of the shares, on the date the option is granted (as determined in accordance with Medivation’s Stock Option Grant Date Policy). The terms of your options will be governed in all respects by the terms of our 2004 Equity Incentive Award Plan and the stock option agreements. Your options will vest over a four-year period – 25% at the end of the first year, then 1/48^th monthly thereafter over the ensuing three years. Your RSUs will vest over a three year period – one third on each of approximately the first, second and third anniversaries of the grant date. In the event there is a change of control of Medivation, your options would fully vest and become exercisable, and your RSUs and PSUs would also fully vest, automatically upon the occurrence of that event.

The Board of Directors or their designee generally considers and approves new hire grants according to Medivation, Inc. policy. Your options and RSUs will be submitted for Board approval following your first date of employment. A stock option agreement will be provided to you, after the Board of Directors has approved your grant. In addition, you may be eligible for future annual equity grants under the Plan based on the level of your position and your performance. Annual grants are typically made in the first quarter, of the year following a performance evaluation. Employees must be on board by September 30^th, in order to be eligible for an annual grant.

As an employee of the Company you will be eligible to enroll in our comprehensive benefits program that includes health, dental, vision, basic life and basic personal accident insurance. Details

of our benefits plans will be provided during your onboarding process and in the new hire orientation. I am also pleased to respond to any questions you may have regarding Medivation benefits as you consider our offer. All Medivation benefits are re-evaluated on an annual basis and are subject to change.

Paid Time Off (PTO) is an important benefit for all of our employees. For your position and subject to the timely completion of your job responsibilities, PTO may be utilized at your discretion, with supervisory approval.

The Company offers a 401(k) plan with an employer match that provides you with the opportunity for pre- or post-tax, long-term savings. You may contribute up to the federal maximum, which is currently $18,000.

In addition, the Company offers an Employee Stock Purchase Plan (ESPP) - ESPP is a voluntary benefit that allows eligible employees to purchase shares of Medivation common stock at a discount through after tax payroll deductions. Eligible employees must enroll during the designated enrollment period. Additional information including a Prospectus and online enrollment instructions will be provided after your date of employment.

As a result of the 1986 Immigration Reform and Control Act, we are required to verify the identity and work authorization of all new employees. You will therefore be required to sign the Employment Eligibility Verification (Form I-9). We will need to examine original documents that satisfy these verification requirements, within 24 hours of your employment start date. This offer of employment is contingent upon your providing the necessary documentation within that period.

You will abide by the Company’s strict policy that prohibits any new employee from using or bringing with him/her all prior employers’ proprietary information, trade secrets, proprietary materials, and/or processes. Upon starting employment with Medivation Inc., you will be required to sign an Employee Confidentiality and Invention Assignment Agreement indicating, among other things, your agreement with this policy.

Employees are expected to devote all professional work time to the Company. If you would like to request an exception for special circumstances, you will need to obtain written permission from your manager.

By signing below you are indicating your understanding that should you accept a position at Medivation the employment relationship is based on the mutual consent of the employee and the Company. Accordingly, either you or the Company can terminate the employment relationship at will, at any time, with or without cause or advance notice.

This offer of employment is effective for 3 business days from the date of this letter and is contingent upon satisfactory completion of references and a background check. If all of the foregoing is satisfactory, please sign, date, and return the letter, within 3 business days. Please label the envelope attention Human Resources and mail it to Medivation, 525 Market Street 36^th Floor, and San Francisco, CA 94105. If you prefer, you may scan and email your signed offer letter to sandy.cooper@medivation.com

Jennifer, we are all enthusiastic about welcoming you to the Company and look forward to you joining our team.

Sincerely,

/s/ Sandy Cooper

Sandy Cooper

Senior Vice President, Human Resources

I accept employment with the Company on the foregoing terms.


/s/ Jennifer Jarrett
Jennifer Jarrett

3/26/16		4/23/16
Date Signed		Anticipated Start Date

EX-10.7 5 mdvn-ex107_333.htm EX-10.7 mdvn-ex107_333.htm

Exhibit 10.7

March 28, 2016

HAND DELIVERY

Dear Mohammad,

I am pleased to extend your role as Interim Chief Medical Officer. This extension will be from April 1, 2016 through June 30, 2016. Your role and duties will remain as communicated during the original interim assignment. During this period you will continue to report to me. We will meet regularly to discuss and plan your priorities and goals.

To recognize and compensate you for assuming these additional responsibilities, Medivation will provide you with the following compensation for the duration of the interim role period:

***In addition to your regular base pay you will receive an additional $4,400 per month ($2,200 per pay period) in cash compensation. This is a total of an additional $13,200 for the three month period.

***You will also be eligible to receive, at my discretion if goals are met, an additional $13,000 in the form of a lump sum payment. This payment will be made, if earned, at the conclusion of the interim role period, on June 30, 2016.

***In further recognition of your contributions and leadership during this period we will recommend to the Board of Directors that you be granted an option to purchase 1,120 Medivation options and 560 (RSUs) restricted stock units. The Stock options will be granted with an exercise price equal to the fair market value of Medivation’s common stock on the date the option is granted (as determined in accordance with Medivation’s Stock Option and RSU Grant Date and Vesting Policy.)

The stock options and restricted stock units will vest on a four and three year schedule respectively (as determined in accordance with Medivation’s Stock Option and RSU Grant Date and Vesting Policy) and will be subject to accelerated vesting upon a change of control of Medivation, as provided in the 2004 Equity Incentive Award Plan (the “Plan”). Except as set forth in this letter, the terms of your stock options and restricted stock units are governed in all other respects by the terms of the Plan, Stock Option Agreement, and Restricted Stock Unit Agreement.

Mohammad, I am enthusiastic about the opportunity to continue to work with you closely in this interim role.

Sincerely,

/s/ David T. Hung, MD

David T. Hung MD

President and Chief Executive Officer

EX-31.1 6 mdvn-ex311_98.htm EX-31.1 mdvn-ex311_98.htm

Exhibit 31.1

CERTIFICATIONS

I, David T. Hung, M.D., certify that:

1. I have reviewed this Form 10-Q of Medivation, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2016

/s/ David T. Hung, M.D.
Name:	David T. Hung, M.D.
Title:	President and Chief Executive Officer

EX-31.2 7 mdvn-ex312_97.htm EX-31.2 mdvn-ex312_97.htm

Exhibit 31.2

CERTIFICATIONS

I, Jennifer Jarrett, certify that:

1. I have reviewed this Form 10-Q of Medivation, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2016

/s/ Jennifer Jarrett
Name:	Jennifer Jarrett
Title:	Chief Financial Officer

EX-32.1 8 mdvn-ex321_96.htm EX-32.1 mdvn-ex321_96.htm

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), David T. Hung, M.D., President and Chief Executive Officer of Medivation, Inc. (the “Company”), and Jennifer Jarrett, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

(1) The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2016, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

(2) The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In Witness Whereof, each of the undersigned has set his or her hand hereto as of the 5th day of May, 2016.

/s/ David T. Hung, M.D.		/s/ Jennifer Jarrett
Name:	David T. Hung, M.D.	Name:	Jennifer Jarrett
Title:	President and Chief Executive Officer	Title:	Chief Financial Officer

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Medivation, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.INS 9 mdvn-20160331.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares mdvn:Product mdvn:Segment pure mdvn:DerivativeContract utr:sqft 0001011835 2016-01-01 2016-03-31 0001011835 2016-04-29 0001011835 2016-03-31 0001011835 2015-12-31 0001011835 us-gaap:RevolvingCreditFacilityMember 2015-12-31 0001011835 2015-01-01 2015-03-31 0001011835 2014-12-31 0001011835 2015-03-31 0001011835 us-gaap:CollaborativeArrangementProductAgreementMember 2016-03-31 0001011835 us-gaap:CollaborativeArrangementMember mdvn:AstellasPharmaIncMember 2016-01-01 2016-03-31 0001011835 us-gaap:PerformanceSharesMember us-gaap:MinimumMember mdvn:RevenueGoalsMember 2016-03-31 0001011835 us-gaap:PerformanceSharesMember us-gaap:MaximumMember mdvn:RevenueGoalsMember 2016-03-31 0001011835 us-gaap:PerformanceSharesMember mdvn:ClinicalDevelopmentMilestonesMember 2016-03-31 0001011835 us-gaap:CollaborativeArrangementMember 2016-01-01 2016-03-31 0001011835 mdvn:AstellasPharmaIncMember us-gaap:UpFrontPaymentArrangementMember 2009-10-01 2009-12-31 0001011835 mdvn:AstellasPharmaIncMember mdvn:DevelopmentMilestonePaymentsMember 2016-01-01 2016-03-31 0001011835 mdvn:AstellasPharmaIncMember mdvn:SalesMilestonePaymentsMember 2016-01-01 2016-03-31 0001011835 mdvn:AstellasPharmaIncMember us-gaap:CollaborativeArrangementMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0001011835 mdvn:XTANDIMember country:US us-gaap:CollaborativeArrangementMember 2016-01-01 2016-03-31 0001011835 mdvn:XTANDIMember country:US us-gaap:CollaborativeArrangementMember 2015-01-01 2015-03-31 0001011835 mdvn:XTANDIMember us-gaap:NonUsMember us-gaap:CollaborativeArrangementMember 2016-01-01 2016-03-31 0001011835 mdvn:XTANDIMember us-gaap:NonUsMember us-gaap:CollaborativeArrangementMember 2015-01-01 2015-03-31 0001011835 mdvn:DevelopmentCostSharingPaymentsMember us-gaap:CollaborativeArrangementMember us-gaap:ParentMember country:US 2016-01-01 2016-03-31 0001011835 mdvn:CommercialCostSharingPaymentsMember us-gaap:CollaborativeArrangementMember mdvn:AstellasPharmaIncMember country:US 2016-01-01 2016-03-31 0001011835 mdvn:DevelopmentCostSharingPaymentsMember us-gaap:CollaborativeArrangementMember us-gaap:ParentMember us-gaap:NonUsMember 2016-01-01 2016-03-31 0001011835 mdvn:CommercialCostSharingPaymentsMember us-gaap:CollaborativeArrangementMember mdvn:AstellasPharmaIncMember us-gaap:NonUsMember 2016-01-01 2016-03-31 0001011835 country:US mdvn:XTANDIMember us-gaap:CollaborativeArrangementMember mdvn:AstellasPharmaIncMember 2016-01-01 2016-03-31 0001011835 country:US mdvn:XTANDIMember us-gaap:CollaborativeArrangementMember mdvn:AstellasPharmaIncMember 2015-01-01 2015-03-31 0001011835 country:US mdvn:XTANDIMember us-gaap:CollaborativeArrangementMember us-gaap:ParentCompanyMember 2016-01-01 2016-03-31 0001011835 country:US mdvn:XTANDIMember us-gaap:CollaborativeArrangementMember us-gaap:ParentCompanyMember 2015-01-01 2015-03-31 0001011835 mdvn:AstellasPharmaIncMember mdvn:AmortizationOfDeferredUpfrontAndDevelopmentMilestonesMember 2015-01-01 2015-03-31 0001011835 mdvn:AstellasPharmaIncMember 2016-01-01 2016-03-31 0001011835 mdvn:AstellasPharmaIncMember 2015-01-01 2015-03-31 0001011835 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-01-01 2016-03-31 0001011835 us-gaap:ForeignExchangeContractMember 2016-03-31 0001011835 us-gaap:ForeignExchangeForwardMember 2016-03-31 0001011835 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-03-31 0001011835 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-03-31 0001011835 us-gaap:DesignatedAsHedgingInstrumentMember 2016-03-31 0001011835 mdvn:MDVThreeThousandEightHundredMember 2016-03-31 0001011835 mdvn:MDVNineThousandThreeHundredMember 2016-03-31 0001011835 mdvn:MDVThreeThousandEightHundredMember 2015-12-31 0001011835 mdvn:MDVNineThousandThreeHundredMember 2015-12-31 0001011835 mdvn:LaboratorySpaceMember 2015-06-30 0001011835 mdvn:LaboratorySpaceMember 2013-12-31 0001011835 mdvn:LaboratorySpaceMember 2016-01-01 2016-03-31 0001011835 mdvn:LaboratorySpaceMember 2015-04-01 2015-06-30 0001011835 mdvn:BuildToSuitLeasePropertyAndEquipmentMember 2015-01-01 2015-12-31 0001011835 mdvn:TenantImprovementsMember 2015-01-01 2015-12-31 0001011835 mdvn:CapitalizedInterestCostMember 2015-01-01 2015-12-31 0001011835 2015-01-01 2015-12-31 0001011835 us-gaap:LeaseholdImprovementsMember 2016-03-31 0001011835 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001011835 mdvn:BuildToSuitPropertyMember 2016-03-31 0001011835 mdvn:BuildToSuitPropertyMember 2015-12-31 0001011835 mdvn:ComputerEquipmentAndSoftwareMember 2016-03-31 0001011835 mdvn:ComputerEquipmentAndSoftwareMember 2015-12-31 0001011835 us-gaap:FurnitureAndFixturesMember 2016-03-31 0001011835 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001011835 us-gaap:ConstructionInProgressMember 2016-03-31 0001011835 us-gaap:ConstructionInProgressMember 2015-12-31 0001011835 mdvn:LaboratoryEquipmentMember 2016-03-31 0001011835 mdvn:LaboratoryEquipmentMember 2015-12-31 0001011835 us-gaap:RevolvingCreditFacilityMember 2015-10-01 2015-10-31 0001011835 us-gaap:RevolvingCreditFacilityMember 2015-10-31 0001011835 us-gaap:RevolvingCreditFacilityMember mdvn:MultiCurrencySubFacilityMember 2015-10-31 0001011835 us-gaap:RevolvingCreditFacilityMember us-gaap:LetterOfCreditMember 2015-10-31 0001011835 us-gaap:RevolvingCreditFacilityMember mdvn:SwingLineLoanSubFacilityMember 2015-10-31 0001011835 us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:MinimumMember 2015-10-01 2015-10-31 0001011835 us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:MaximumMember 2015-10-01 2015-10-31 0001011835 us-gaap:RevolvingCreditFacilityMember us-gaap:PrimeRateMember us-gaap:MinimumMember 2015-10-01 2015-10-31 0001011835 us-gaap:RevolvingCreditFacilityMember us-gaap:PrimeRateMember us-gaap:MaximumMember 2015-10-01 2015-10-31 0001011835 us-gaap:RevolvingCreditFacilityMember 2016-01-01 2016-01-31 0001011835 us-gaap:RevolvingCreditFacilityMember 2016-01-01 2016-03-31 0001011835 us-gaap:RevolvingCreditFacilityMember 2016-03-31 0001011835 mdvn:CreditAgreementMember 2016-01-01 2016-03-31 0001011835 mdvn:ConvertibleSeniorNotesDueTwoThousandSeventeenMember us-gaap:SeniorNotesMember 2012-03-31 0001011835 mdvn:ConvertibleSeniorNotesDueTwoThousandSeventeenMember us-gaap:SeniorNotesMember 2016-01-01 2016-03-31 0001011835 mdvn:ConvertibleSeniorNotesDueTwoThousandSeventeenMember us-gaap:SeniorNotesMember 2015-06-30 0001011835 mdvn:ConvertibleSeniorNotesDueTwoThousandSeventeenMember us-gaap:SeniorNotesMember 2015-09-30 0001011835 mdvn:ConvertibleSeniorNotesDueTwoThousandSeventeenMember us-gaap:SeniorNotesMember 2015-04-01 2015-06-30 0001011835 mdvn:ConvertibleSeniorNotesDueTwoThousandSeventeenMember us-gaap:SeniorNotesMember 2015-07-01 2015-09-30 0001011835 mdvn:ConvertibleSeniorNotesDueTwoThousandSeventeenMember us-gaap:SeniorNotesMember 2015-01-01 2015-12-31 0001011835 2006-12-04 0001011835 mdvn:EquityIncentivePlanMember 2015-03-31 0001011835 mdvn:EquityIncentivePlanMember 2015-06-16 0001011835 us-gaap:PerformanceSharesMember 2016-01-01 2016-03-31 0001011835 mdvn:EmployeeStockPurchasePlanMember 2016-03-31 0001011835 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001011835 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 0001011835 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-03-31 0001011835 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-03-31 0001011835 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherCurrentLiabilitiesMember 2016-03-31 0001011835 us-gaap:FairValueInputsLevel2Member us-gaap:OtherCurrentLiabilitiesMember 2016-03-31 0001011835 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-03-31 0001011835 us-gaap:FairValueInputsLevel3Member 2016-03-31 0001011835 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherNoncurrentLiabilitiesMember 2016-03-31 0001011835 us-gaap:FairValueInputsLevel2Member us-gaap:OtherNoncurrentLiabilitiesMember 2016-03-31 0001011835 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-12-31 0001011835 us-gaap:FairValueInputsLevel3Member 2015-12-31 0001011835 mdvn:MDVThreeThousandEightHundredMember us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001011835 mdvn:MDVThreeThousandEightHundredMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-03-31 0001011835 mdvn:MDVNineThousandThreeHundredMember us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001011835 mdvn:MDVNineThousandThreeHundredMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-03-31 0001011835 mdvn:MDVNineThousandThreeHundredMember us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 0001011835 mdvn:MDVNineThousandThreeHundredMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-03-31 0001011835 mdvn:MDVNineThousandThreeHundredMember mdvn:DevelopmentMilestonesMember 2016-03-31 0001011835 mdvn:MDVNineThousandThreeHundredMember mdvn:SalesMilestonesMember 2016-03-31 0001011835 us-gaap:MinimumMember mdvn:MDVNineThousandThreeHundredMember 2016-03-31 0001011835 us-gaap:MaximumMember mdvn:MDVNineThousandThreeHundredMember 2016-03-31 0001011835 mdvn:MDVNineThousandThreeHundredMember 2016-01-01 2016-03-31 0001011835 mdvn:MDVThreeThousandEightHundredMember mdvn:DefinedRegulatoryAndSalesBasedMilestonesMember 2016-03-31 0001011835 us-gaap:FairValueInputsLevel3Member 2016-01-01 2016-03-31 0001011835 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2016-03-31 0001011835 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2016-03-31 0001011835 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2015-12-31 0001011835 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2015-12-31 0001011835 us-gaap:RevolvingCreditFacilityMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2015-12-31 0001011835 us-gaap:RevolvingCreditFacilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2015-12-31 0001011835 mdvn:CorporateHeadquartersMember 2016-03-31 0001011835 mdvn:CorporateHeadquartersMember 2016-01-01 2016-03-31 0001011835 mdvn:DevelopmentMilestonePaymentsMember 2016-03-31 0001011835 mdvn:DevelopmentMilestonePaymentsMember 2016-01-01 2016-03-31 0001011835 mdvn:MDVNineThousandThreeHundredMember 2014-10-01 2014-12-31 0001011835 mdvn:MDVNineThousandThreeHundredMember 2015-04-01 2015-06-30 0001011835 mdvn:MDVNineThousandThreeHundredMember 2015-07-01 2015-09-30 0001011835 2014-10-01 2014-12-31 0001011835 us-gaap:SubsequentEventMember mdvn:SanofiMember 2016-04-28 10-Q false 2016-03-31 2016 Q1 MDVN MEDIVATION, INC. 0001011835 --12-31 Large Accelerated Filer 164624777

317361000

225853000

186593000 391558000

24416000

15877000

1140000

930000

529510000

634218000

59849000

58142000

644299000

53148000

57011000

11996000

12206000

18643000

8037000

7072000

1325482000

1431591000

121995000

186203000

75000000

4924000

4900000

110000

127029000

266103000

268303000

262368000

17278000 17406000

12658000

13035000

425268000

558912000

1646000

1639000

707870000

684841000

-317000

191015000

186199000

900214000

872679000

1325482000

1431591000

0.01

1000000

0.01

340000000

164581922

163905342

164581922

163905342

182497000 129188000

77587000

44676000

96827000

83939000

174414000

128615000

8083000

573000

680000

5608000

-209000

137000

-889000

-5471000

7194000

-4898000

2378000

-1780000

4816000

-3118000

0.03

-0.02

0.03

-0.02

164247000

156637000

168397000

156637000

-317000

4499000

-3118000

-175000

14211000

13372000

5959000

4000000

2416000

1531000

-2696000

1402000

85000

3910000

2490000

1411000

73000

-204965000 -58124000

6050000

520000

1049000

1335000

-26869000

-17587000

1698000

-32565000

-438000

-113000

165687000

57222000

9328000

956000

1574000

-9328000

-2530000

75000000

7677000

11502000

2490000

18000 227000

8000

-64851000

11267000

91508000

65959000

502677000

568636000

964000

918000

527000

<div> NOTE 12. FAIR VALUE DISCLOSURES The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements Using:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2016:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency derivative contracts</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,924</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,924</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency derivative contracts</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268,303</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268,303</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2015:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,900</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,900</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,368</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,368</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The Company estimates the fair values of Level 2 assets or liabilities, including foreign currency derivative contracts, by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly, or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar assets, issuer credit spreads, benchmark yields, foreign currency rates, London Interbank Offered Rates (LIBOR), and other observable inputs. The Company validates the prices provided by its third-party pricing sources by understanding the models used, obtaining market values from other pricing sources, and/or analyzing pricing data in certain instances. For additional information regarding the Company’s foreign currency derivative transactions, see Note 4, “Derivative Financial Instruments.” In connection with the acquisitions of MDV3800 and MDV9300, the Company recorded contingent consideration liabilities pertaining to amounts potentially payable to BioMarin and CureTech, respectively. The fair value of contingent consideration is considered a Level 3 liability and was estimated utilizing a model with key assumptions that included estimated revenues or completion of certain development, regulatory and sales milestone targets during the earn-out period, volatility, and estimated discount rates corresponding to the periods of expected payments. The estimated fair value of the contingent consideration liability is measured at each reporting date based on significant inputs not observable in the market. The Company assesses these estimates on an ongoing basis as additional data impacting the assumptions is obtained. Changes in the estimated fair value of contingent consideration are reflected as non-cash adjustments to operating expenses in the unaudited condensed consolidated statements of operations. During the three months ended March 31, 2016, the Company recorded fair value adjustments of $0.5 million and $2.5 million as increases to R&D and SG&A expenses, respectively, related to the BioMarin contingent consideration liability. During the three months ended March 31, 2016, the Company also recorded fair value adjustments of $0.6 million and $2.3 million as increases to R&D and SG&A expenses, respectively, related to the CureTech contingent consideration liability. During the three months ended March 31, 2015, the Company recorded fair value adjustments of $1.0 million and $3.0 million as increases to R&D and SG&A expenses, respectively, related to the CureTech contingent consideration liability. All of these adjustments were primarily due to the time value of money. BioMarin is entitled to contingent payments totaling up to $160.0 million upon the achievement of defined regulatory and sales-based milestones, and mid-single digit royalties on net sales of products that contain MDV3800 during the royalty term specified in the related purchase agreement. CureTech is entitled to contingent payments totaling up to $85.0 million upon attainment of certain development and regulatory milestones, up to $245.0 million upon the achievement of certain annual worldwide net sales thresholds, and tiered royalties ranging from 5% to 11% on annual worldwide net sales. CureTech is also entitled to a $5.0 million milestone payment upon completion of the Manufacturing Technology Transfer as described in Note 13, “Commitments and Contingencies.” Contingent consideration may change significantly as development progresses and additional data is obtained that will affect the Company’s assumptions regarding probabilities of successful achievement of related milestones used to estimate the fair value of the liability and the timing in which they are expected to be achieved. Updates to these assumptions could have a significant impact on our results of operations. For example, a significant increase in the probability of achieving a milestone would result in a significantly higher fair value measurement, while a significant increase in the expected timing of achieving a milestone would result in a significantly lower fair value measurement. Considerable judgment is required to interpret the market data used to develop the assumptions. The estimates of fair value may not be indicative of amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques could result in materially different fair value estimates. There were no transfers between Level 1 and Level 2 financial instruments during the three months ended March 31, 2016. The following table includes a roll-forward of the fair value of Level 3 financial instruments for the period presented:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2016</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration (current and non-current):</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267,268</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts acquired or issued</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in fair value</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,959</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfers in and/or out of Level 3</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273,227</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The following table presents the total balance of the Company’s other financial instruments that are not measured at fair value on a recurring basis:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements Using:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Balance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2016:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bank deposits (included in “Cash and cash <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   equivalents”)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317,361</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317,361</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2015:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bank deposits (included in “Cash and cash <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   equivalents”)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225,853</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225,853</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings under Revolving Credit Facility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to their short-term maturities, the Company believes that the fair value of its bank deposits, receivable from collaboration partner, accounts payable and accrued expenses, short-term borrowings under the Revolving Credit Facility, and other current assets and liabilities approximate their carrying value.</div>

<div> (a) Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of the Company’s financial condition, results of operations and cash flows for the periods presented, have been included. The results of operations for any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2015, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, or the Annual Report, filed with the U.S. Securities and Exchange Commission, or SEC, on February 26, 2016. The consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company operates in one business segment. All tabular disclosures of dollar and share amounts are presented in thousands unless otherwise indicated. All per share amounts are presented at their actual amounts. The number of shares issuable under the Amended and Restated 2004 Equity Incentive Award Plan, or the Medivation Equity Incentive Plan, and the Medivation, Inc. 2013 Employee Stock Purchase Plan, or ESPP, disclosed in Note 10, “Stockholders’ Equity,” are presented at their actual amounts unless otherwise indicated. Amounts presented herein may not calculate or sum precisely due to rounding.</div>

<div> (f) New Accounting Pronouncements In March 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-09, “Compensation--Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions. Changes that may impact public companies include changes in the accounting for income taxes, specifically excess tax benefits and tax deficiencies; the classification of excess tax benefits on the statement of cash flows as an operating activity; the option for companies to make an entity-wide accounting policy election to either estimate the number of share-based payment awards that are expected to vest (current GAAP) or account for forfeitures when they occur; and the classification of employee taxes paid when an employer withholds shares for tax withholding purposes as a financing activity on the statement of cash flows. Depending on the specific item to be changed, ASU 2016-09 requires certain changes to be applied either prospectively, retrospectively, or under a modified retrospective transition method to all periods presented. The amended guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period, and early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures. In March 2016, the FASB issued ASU 2016-05, “Derivatives and Hedging (Topic 815): Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships.” ASU 2016-05 clarifies that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument under Topic 815 does not, in and of itself, require dedesignation of that hedging relationship provided that all other hedge accounting criteria continue to be met. The amended guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period, with the option to apply the amended guidance on either a prospective basis or a modified retrospective basis, and early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” ASU 2016-02 includes a lessee accounting model that recognizes two types of leases - finance leases and operating leases. The standard requires that a lessee recognize on the balance sheet a right-to-use asset and a lease liability for all leases with lease terms of more than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as either a finance or operating lease. ASU 2016-02 also requires new qualitative and quantitative disclosures for the amount, timing, and uncertainty of cash flows arising from leases. The amended guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that reporting period, and early adoption is permitted. ASU 2016-02 requires modified retrospective transition, which requires application of the guidance at the beginning of the earliest comparative period presented in the year of adoption; however, for all leases that commenced before the effective date, companies can elect not to reassess certain elements, including their lease classification or whether contracts are or contain embedded leases. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.   In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, a comprehensive new revenue recognition standard that will supersede the existing revenue recognition guidance. The new accounting guidance creates a framework by which an entity will allocate the transaction price to separate performance obligations and recognize revenue when (or as) each performance obligation is satisfied. Under the new standard, entities will be required to use judgment and make estimates, including identifying performance obligations in a contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each separate performance obligation and determining when an entity satisfies its performance obligations. The standard allows for either “full retrospective” adoption, meaning that the standard is applied to all of the periods presented with a cumulative catch-up as of the earliest period presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements with a cumulative catch-up as of the current period. In August 2015, the effective date of the new revenue standard was delayed by one year to December 15, 2017 for annual reporting periods beginning after that date. The FASB also agreed to permit early adoption of the standard, but not before the original effective date of December 15, 2016. In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” to clarify ASU 2014-09 implementation guidance on principal versus agent considerations. The Company has not yet selected a transition method and is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.</div>

<div> Intangible assets consist of in-process research and development, or IPR&D, acquired from business acquisitions. The Company accounts for IPR&D as indefinite-lived intangible assets until regulatory approval or discontinuation of the related R&D efforts. Upon obtaining regulatory approval, the Company reclassifies the IPR&D as a definite-lived intangible asset and determines the economic life for amortization purposes. The Company assesses the impairment of indefinite-lived intangible assets and goodwill on an annual basis or more frequently whenever events or changes in circumstances may indicate that the carrying value might not be recoverable. </div>

<div> The computation of basic net income (loss) per common share is based on the weighted-average number of common shares outstanding during each period. The computation of diluted net income (loss) per common share is based on the weighted-average number of common shares outstanding during the period plus, when their effect is dilutive, incremental shares consisting of shares subject to stock options, restricted stock units, performance share units, stock appreciation rights, ESPP shares, warrants, and shares issuable upon conversion of convertible debt. In periods where the Company reports a net loss, all common stock equivalents are deemed anti-dilutive such that basic net loss per common share and diluted net loss per common share are equal.</div>

<div> The Company calculates its quarterly income tax provision in accordance with the guidance provided by ASC 740-270, “Interim Income Tax Accounting,” whereby the Company forecasts its estimated annual effective tax rate and then applies that rate to its year-to-date pre-tax book income (loss). Income tax expense for the three months ended March 31, 2016 was $2.4 million. The provision for income taxes was lower than the tax computed at the U.S. federal statutory rate due primarily to the Federal research and development credit, partially offset by state income taxes, non-deductible officers’ compensation and non-deductible stock-based compensation. Income tax benefit for the three months ended March 31, 2015 was $1.8 million. The effective tax rate was 33.1% and 36.3% for the three months ended March 31, 2016 and 2015, respectively. The decrease in the effective tax rate for the three months ended March 31, 2016 as compared to the prior year period was due to the Federal research and development tax credit which was permanently reinstated in the fourth quarter of 2015. For the three months ended March 31, 2016, the Company reduced its current Federal and state taxes payable by $2.5 million related to excess tax benefits from stock-based compensation, increasing additional paid-in capital. The Company records a valuation allowance to reduce deferred tax assets to reflect the net amount that is more likely than not to be realized. Based upon the weight of available evidence at December 31, 2014, the Company determined that it was more likely than not that a portion of its deferred tax assets would be realizable and consequently released the valuation allowance against Federal and certain state net deferred tax assets during the fourth quarter of 2014. The decision to reverse a portion of the valuation allowance was made after management considered all available evidence, both positive and negative, including but not limited to the historical operating results, income or loss in recent periods, cumulative income in recent years, forecasted earnings, forecasted future taxable income, and significant risk and uncertainty related to forecasts. The release of the valuation allowance resulted in the recognition of certain deferred net tax assets and a decrease to income tax expense. The future effective tax rate is subject to volatility and may be materially impacted by various internal and external factors. These factors may include, but are not limited to, the amount of income tax benefits and charges from: interpretations of existing tax laws; changes in tax laws and rates; future levels of research and development expenditures; changes in the mix of earnings in countries with differing statutory tax rates in which the Company may conduct business; changes in the valuation of deferred tax assets and liabilities; state income taxes; the tax impact of stock-based compensation; accounting for uncertain tax positions; closure of statute of limitations or settlement of tax audits; changes in estimates of prior years’ items; tax costs for acquisition-related items; changes in accounting standards; non-deductible officers’ compensation; limitations on the utilization of net operating losses and tax credits due to changes in ownership; and overall levels of income before taxes.</div>

<div> The Company is party to legal proceedings, investigations, and claims in the ordinary course of its business, including the matters described below. The Company records accruals for outstanding legal matters when it believes that it is both probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in significant legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. To the extent new information is obtained and the Company’s views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company’s accrued liabilities would be recorded in the period in which such determination is made. In addition, in accordance with the relevant authoritative guidance, for matters for which the likelihood of material loss is at least reasonably possible, the Company provides disclosure of the possible loss or range of loss; however, if a reasonable estimate cannot be made, the Company will provide disclosure to that effect. Gain contingencies, if any, are recorded when they are realized.</div>

<div> Collaboration revenue was as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related to U.S. XTANDI net sales</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,793</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,010</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related to ex-U.S. XTANDI net sales</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,704</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,767</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related to upfront and milestone payments</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,411</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,497</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129,188</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> Collaboration revenue related to U.S. XTANDI net sales was as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. XTANDI net sales (as reported by Astellas)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">307,586</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shared U.S. development and commercialization costs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(130,583</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110,313</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-tax U.S. profit</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177,003</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,707</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medivation’s share of pre-tax U.S. profit</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,501</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,853</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement of Medivation’s share of shared U.S. costs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,292</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,157</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue related to U.S. XTANDI net sales</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,793</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,010</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table summarizes the classification and fair values of derivative instruments on the Company’s unaudited condensed consolidated balance sheet:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="4" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset Derivatives</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="4" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability Derivatives</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Classification</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Classification</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivatives designated as hedges:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency exchange contracts</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(431</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency exchange contracts</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total derivatives</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.56%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.56%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(492</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>  </div>

<div> The following table reconciles the numerator and denominator used to calculate diluted net income (loss) per common share:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,816</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,118</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares, basic</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,247</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,637</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dilutive effect of common stock equivalents</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,150</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares, diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,397</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,637</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Property and equipment, net, consisted of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,615</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,074</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Build-to-suit property</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,371</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,371</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,300</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,083</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,014</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,714</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,806</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,440</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,447</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,553</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,430</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,704</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,288</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,849</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,142</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Accounts payable, accrued expenses and other current liabilities consisted of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical and preclinical</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,635</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,975</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,791</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,696</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and payroll-related</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,988</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,215</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties payable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,665</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional services and other current liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,566</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,282</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes payable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,565</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other payable to licensor</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,500</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest payable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">305</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,995</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,203</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Stock-based compensation expense was as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recognized as:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&D expense</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,037</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,811</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SG&A expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,174</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,561</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,211</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,372</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements Using:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2016:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency derivative contracts</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,924</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,924</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency derivative contracts</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268,303</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268,303</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2015:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,900</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,900</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,368</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,368</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table presents the total balance of the Company’s other financial instruments that are not measured at fair value on a recurring basis:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements Using:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Balance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2016:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bank deposits (included in “Cash and cash <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   equivalents”)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317,361</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317,361</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2015:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bank deposits (included in “Cash and cash <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   equivalents”)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225,853</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225,853</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings under Revolving Credit Facility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Future operating lease obligations as of March 31, 2016 are as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ending December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,028</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,542</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,743</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,065</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 and thereafter</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,378</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Expected future lease payments under the build-to-suit lease as of March 31, 2016 are as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ending December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expected Cash <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Under Build- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">To-Suit Lease <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Obligation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,639</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,244</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,311</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,380</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,452</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 and thereafter</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,627</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,653</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> 1 Low teens to the low twenties

0.50 1.50 1.00 0.50

110000000

335000000 320000000 0.05 153793000 112010000 28704000 15767000 0.50 0.50 0.3333 0.6667 0.50 0.50 307586000 224020000 130583000 110313000 177003000 113707000 88501000 56853000

65292000

55157000

1400000

13300000 13800000 18700000 20100000

have maturity dates of 15 months or less

5400000

500000

431000

61000

492000

-492000

492000

573299000

71000000

573299000

71000000

4200000

22800000

4150000

44000

52000

August 2024 P5Y

14500000

3600000

3500000

8000 3200000 3200000 18400000 17400000

22615000

19074000

18371000

17300000

16083000

6014000

5714000

12806000

14440000

1447000

748000

78553000

74430000

18704000

16288000

45635000 48975000

23791000

22696000

15988000

29215000

21015000

20665000

15566000

14282000

32565000

17500000

305000

P5Y

300000000

50000000

20000000

10000000

0.0175

0.0250

0.0075

0.0150

75000000

0.021250

The interest rate for this borrowing was 2.1250% and was applied on an actual/360 day basis.

75000000

(a) the LIBOR rate, plus an applicable margin ranging from 1.75% to 2.50% per annum, based upon the secured leverage ratio (as defined in the Credit Agreement) or (b) the prime lending rate, plus an applicable margin ranging from 0.75% to 1.50% per annum, based upon the senior secured net leverage ratio (as defined in the Credit Agreement).

(i) all tangible and intangible assets of the Loan Parties, except for certain customary excluded assets, and (ii) all of the capital stock owned by the Loan Parties thereunder (limited, in the case of the stock of certain non-U.S. subsidiaries of the Company and Domestic Foreign Holding Companies, to 65% of the capital stock of such subsidiaries).

0.65

1700000

P5Y

258800000

The Company was required to pay interest semi-annually in arrears on April 1 and October 1 of each year.

91000000

167800000

92100000

167800000

2099358

3539218

-7900000

-13200000

1700000 0.20

42300000

47700000

5700000

129150

P1Y 0.85 0.85 25000

397536

6000000

6037000

5811000

8174000

7561000

0.331

0.363

431000

4924000

61000

268303000

4900000

262368000

500000

2500000

600000

2300000

1000000

3000000

85000000

245000000

0.05 0.11 5000000

160000000

267268000

5959000

273227000

317361000

225853000

75000000

158000

143000

2019-12 P5Y

7028000

9542000

9743000

5065000

31378000

1639000 2244000 2311000 2380000 2452000 9627000 20653000 2800000 0.10 0.04 P3Y

3000000

200000

100000

19300000 P3Y 9000000 15200000 6200000 52.50

EX-101.SCH 10 mdvn-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Description of Business link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Collaboration Agreement link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Derivative Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Intangible Assets and Goodwill link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Net Income (Loss) Per Common Share link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Build-to-Suit Lease Obligation link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Other Balance Sheet Items link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Fair Value Disclosures link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Subsequent Event link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Collaboration Agreement (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Derivative Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Intangible Assets and Goodwill (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Net Income (Loss) Per Common Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Other Balance Sheet Items (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Fair Value Disclosures (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Description of Business - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Collaboration Agreement - Collaboration Agreements with Astellas - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Collaboration Agreement - Schedule of Collaboration Revenue (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Collaboration Agreement - Collaboration Revenue and Collaboration Receivables - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Collaboration Agreement - Schedule of Collaboration Revenue Related to U.S. XTANDI Net Sales (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Derivative Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Derivative Financial Instruments - Summary of Classification and Fair values of Derivative Instruments on Unaudited Condensed Consolidated Balance Sheet (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Derivative Financial Instruments - Summary of the Effect of Foreign Currency Exchange Contracts on Condensed Consolidated Financial Statements (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives by Type of Financial Instrument on Unaudited Condensed Consolidated Balance Sheets (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Intangible Assets and Goodwill - Summary of Indefinite-lived Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Intangible Assets and Goodwill - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Net Income (Loss) Per Common Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Net Income (Loss) Per Common Share - Calculation of Diluted Net Income (Loss) Per Common Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Build-to-Suit Lease Obligation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Other Balance Sheet Items - Schedule of Property and Equipment, Net (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Other Balance Sheet Items - Components of Accounts Payable, Accrued Expenses and Other Current Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Fair Value Disclosures - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Fair Value Disclosures - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Fair Value Disclosures - Schedule of Roll-forward of Fair Value of Level 3 Instruments (Detail) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Fair Value Disclosures - Fair Value of Other Financial Instruments Not Measured on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Commitments and Contingencies - Schedule of Future Operating Lease Obligations (Detail) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Commitments and Contingencies - Schedule of Future Lease Cash Payments under the Build to Suit Lease (Detail) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Subsequent Event - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 11 mdvn-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 12 mdvn-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 13 mdvn-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document and Entity Information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Net amount due from collaboration partner. Amount of build-to-suit lease obligation due within one year or the normal operating cycle, if longer. Amount of build-to-suit lease obligation due to be paid more than one year (or one operating cycle if longer) after the balance sheet date. Statement Of Financial Position [Abstract] Statement [Table] Statement [Table] Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] Revolving Credit Facility [Member] Revolving Credit Facility [Member] Statement [Line Items] Statement [Line Items] ASSETS Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Receivable from collaboration partner Receivable From Collaboration Partner Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Restricted cash Restricted Cash And Investments Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Intangible assets Indefinite Lived Intangible Assets Excluding Goodwill Deferred income tax assets Deferred Tax Assets Liabilities Net Noncurrent Restricted cash, net of current Restricted Cash And Cash Equivalents Noncurrent Goodwill Goodwill Other non-current assets Other Assets Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable, accrued expenses and other current liabilities Accounts Payable And Other Accrued Liabilities Current Borrowings under Credit Facility Short Term Borrowings Contingent consideration Business Combination Contingent Consideration Liability Current Current portion of build-to-suit lease obligation Build To Suit Lease Obligation Current Total current liabilities Liabilities Current Contingent consideration Business Combination Contingent Consideration Liability Noncurrent Build-to-suit lease obligation, excluding current portion Build To Suit Lease Obligation Non Current Other non-current liabilities Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 13) Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.01 par value per share; 1,000,000 shares authorized; no shares issued and outstanding Preferred Stock Value Common stock, $0.01 par value per share; 340,000,000 shares authorized; 164,581,922 and 163,905,342 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Retained earnings Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Revenues earned from collaboration partners under collaboration agreements. Income Statement [Abstract] Collaboration revenue Collaboration Revenue Operating expenses: Operating Expenses [Abstract] Research and development expenses Research And Development Expense Selling, general and administrative expenses Selling General And Administrative Expense Total operating expenses Operating Expenses Income from operations Operating Income Loss Other income (expense), net: Nonoperating Income Expense [Abstract] Interest expense Interest Expense Debt Other, net Other Nonoperating Income Expense Total other income (expense), net Nonoperating Income Expense Income (loss) before income tax (expense) benefit Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax (expense) benefit Income Tax Expense Benefit Net income (loss) Net Income Loss Basic net income (loss) per common share Earnings Per Share Basic Diluted net income (loss) per common share Earnings Per Share Diluted Weighted average common shares used in the calculation of basic net income (loss) per common share Weighted Average Number Of Shares Outstanding Basic Weighted average common shares used in the calculation of diluted net income (loss) per common share Weighted Average Number Of Diluted Shares Outstanding Statement Of Income And Comprehensive Income [Abstract] Net income (loss) Other comprehensive loss: Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Unrealized losses on cash flow hedges, net of tax impact of $175 and $-- for the three months ended March 31, 2016 and 2015, respectively Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax Other comprehensive loss Other Comprehensive Income Loss Net Of Tax Comprehensive income (loss) Comprehensive Income Net Of Tax Unrealized losses on cash flow hedges, tax Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax The net change during the reporting period in amount due within one year (or one business cycle) from collaboration partner under collaboration agreements. Lease payments applied to reduce build to suit obligation. Interest capitalized during construction period for build-to-suit transactions. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Net income (loss) Adjustments for non-cash operating items: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Stock-based compensation Share Based Compensation Change in fair value of contingent purchase consideration Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 Depreciation on property and equipment Depreciation Depletion And Amortization Change in deferred income taxes Increase Decrease In Deferred Income Taxes Amortization of debt discount and debt issuance costs Amortization Of Financing Costs And Discounts Excess tax benefits from stock-based compensation Excess Tax Benefit From Share Based Compensation Operating Activities Amortization of deferred revenue Recognition Of Deferred Revenue Other non-cash items Other Operating Activities Cash Flow Statement Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Receivable from collaboration partner Increase Decrease In Receivable From Collaboration Partner Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Other non-current assets Increase Decrease In Other Noncurrent Assets Accounts payable, accrued expenses and other current liabilities Increase Decrease In Other Accounts Payable And Accrued Liabilities Interest payable Increase Decrease In Interest Payable Net Current taxes payable Increase Decrease In Accrued Taxes Payable Other non-current liabilities Increase Decrease In Other Noncurrent Liabilities Net cash provided by operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash flows from investing activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Change in restricted cash Increase Decrease In Restricted Cash Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash flows from financing activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Principal repayment of borrowings under Revolving Credit Facility Repayments Of Lines Of Credit Proceeds from issuance of common stock under equity incentive and stock purchase plans Proceeds From Stock Plans Excess tax benefits from stock-based compensation Excess Tax Benefit From Share Based Compensation Financing Activities Reduction of build-to-suit lease obligation Lease Payments Applied To Reduce Build To Suit Obligation Principal repayment of Convertible Notes Repayments Of Convertible Debt Net cash (used in) provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Net increase in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Non-cash investing and financing activities: Noncash Investing And Financing Items [Abstract] Property and equipment expenditures incurred but not yet paid Capital Expenditures Incurred But Not Yet Paid Interest capitalized during construction period for build-to-suit lease transactions Interest Capitalized For Build To Suit Transactions Organization Consolidation And Presentation Of Financial Statements [Abstract] Description of Business Nature Of Operations Summary of Significant Accounting Policies Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block] Collaboration Agreement Collaborative Arrangement Disclosure [Text Block] Derivative Instruments And Hedging Activities Disclosure [Abstract] Derivative Financial Instruments Derivative Instruments And Hedging Activities Disclosure [Text Block] Goodwill And Intangible Assets Disclosure [Abstract] Intangible Assets and Goodwill Goodwill And Intangible Assets Disclosure [Text Block] Earnings Per Share [Abstract] Net Income (Loss) Per Common Share Earnings Per Share [Text Block] Leases [Abstract] Build-to-Suit Lease Obligation Leases Of Lessee Disclosure [Text Block] Balance Sheet Related Disclosures [Abstract] Other Balance sheet Items Supplemental Balance Sheet Disclosures [Text Block] Debt Disclosure [Abstract] Debt Debt Disclosure [Text Block] Equity [Abstract] Stockholders' Equity Shareholders Equity And Share Based Payments [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures Fair Value Disclosures [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Event Subsequent Events [Text Block] Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS) and principles of consolidation. Basis of Presentation and Principles of Consolidation Basis Of Presentation And Principles Of Consolidation Policy [Text Block] Use of Estimates Use Of Estimates Significant Accounting Policies Significant Accounting Policies [Text Block] Derivative Financial Instruments Derivatives Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy New Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Intangible Assets Goodwill And Intangible Assets Policy [Text Block] Earnings Per Share Earnings Per Share Policy [Text Block] Income Taxes Income Tax Policy [Text Block] Litigation Policy Commitments And Contingencies Policy [Text Block] Tabular disclosure of collaboration revenue. Schedule of Collaboration Revenue Schedule Of Collaboration Revenue Table [Text Block] Tabular disclosure of collaboration revenue related to US XTANDI net sales. Schedule of Collaboration Revenue Related to U.S. XTANDI Net Sales Schedule Of Collaboration Revenue Related To Us Xtandi Net Sales Table [Text Block] Summary of Classification and Fair values of Derivative Instruments on Unaudited Condensed Consolidated Balance Sheet Schedule Of Derivative Instruments In Statement Of Financial Position Fair Value [Text Block] Summary of the Effect of Foreign Currency Exchange Contracts on Unaudited Condensed Consolidated Financial Statements Schedule Of Derivative Instruments Gain Loss In Statement Of Financial Performance [Text Block] Tabular disclosure of potential effect of offsetting derivatives by type of financial instrument. Summary of Potential Effect of Offsetting Derivatives by Type of Financial Instrument on Unaudited Condensed Consolidated Balance Sheets Derivatives Off Setting Table [Text Block] Summary of Indefinite-lived Intangible Assets Schedule Of Indefinite Lived Intangible Assets Table [Text Block] Calculation of Diluted Net Income (Loss) Per Common Share Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Schedule of Property and Equipment, Net Property Plant And Equipment [Text Block] Components of Accounts Payable, Accrued Expenses and Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block] Schedule of Stock-Based Compensation Expense Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block] Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Schedule of Roll-forward of Fair Value of Level 3 Instruments Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Fair Value of Other Financial Instruments Not Measured on Recurring Basis Fair Value Assets Measured On Nonrecurring Basis [Text Block] Schedule of Future Operating Lease Obligations Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block] Tabular disclosure of expected future cash payments under build-to-suit lease in the aggregate and for each of the five succeeding fiscal years as of the balance sheet date. Schedule of Future Lease Cash Payments under Build to Suit Lease Schedule Of Future Minimum Payments For Build To Suit Leases Table [Text Block] Number of commercial products. Range of percentage rates for royalties received on ex-U.S. net sales, as defined by collaboration agreement. Organization and description of business. Organization and description of business. Organization And Description Of Business [Table] Organization And Description Of Business [Table] Type of Arrangement and Non-arrangement Transactions Type Of Arrangement [Axis] Arrangements and Non-arrangement Transactions Arrangements And Nonarrangement Transactions [Member] XTANDI [Member] Collaborative Arrangement Product Agreement [Member] Collaborative agreement [Member] Collaborative Arrangement [Member] Legal Entity Legal Entity [Axis] Entity Entity [Domain] Astellas Pharma Inc. Astellas Pharma Inc. [Member] Astellas Pharma Inc [Member] Organization And Description Of Business [Line Items] Organization And Description Of Business [Line Items] Number of commercial products Number Of Commercial Products Range of percentage rates for royalties received on ex-U.S. net sales, as defined by collaboration agreement Royalties Received At Percentage Rate Ranging Accounting Policies [Abstract] Schedule of summary of significant accounting policies. Schedule of summary of significant accounting policies. Schedule Of Summary Of Significant Accounting Policies [Table] Schedule Of Summary Of Significant Accounting Policies [Table] Scenario Statement Scenario [Axis] Scenario, Unspecified Scenario Unspecified [Domain] Revenue goals. Revenue Goals [Member] Revenue Goals [Member] Clinical development milestones. Clinical Development Milestones [Member] Clinical Development Milestones [Member] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] EX-101.PRE 14 mdvn-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 15 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	Apr. 29, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Trading Symbol	MDVN
Entity Registrant Name	MEDIVATION, INC.
Entity Central Index Key	0001011835
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		164,624,777

XML 16 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 317,361	$ 225,853
Receivable from collaboration partner	186,593	391,558
Prepaid expenses and other current assets	24,416	15,877
Restricted cash	1,140	930
Total current assets	529,510	634,218
Property and equipment, net	59,849	58,142
Intangible assets	644,299	644,299
Deferred income tax assets	53,148	57,011
Restricted cash, net of current	11,996	12,206
Goodwill	18,643	18,643
Other non-current assets	8,037	7,072
Total assets	1,325,482	1,431,591
Current liabilities:
Accounts payable, accrued expenses and other current liabilities	121,995	186,203
Contingent consideration	4,924	4,900
Current portion of build-to-suit lease obligation	110
Total current liabilities	127,029	266,103
Contingent consideration	268,303	262,368
Build-to-suit lease obligation, excluding current portion	17,278	17,406
Other non-current liabilities	12,658	13,035
Total liabilities	$ 425,268	$ 558,912
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.01 par value per share; 1,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.01 par value per share; 340,000,000 shares authorized; 164,581,922 and 163,905,342 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively	$ 1,646	$ 1,639
Additional paid-in capital	707,870	684,841
Accumulated other comprehensive loss	(317)
Retained earnings	191,015	186,199
Total stockholders’ equity	900,214	872,679
Total liabilities and stockholders’ equity	$ 1,325,482	1,431,591
Revolving Credit Facility [Member]
Current liabilities:
Borrowings under Credit Facility		$ 75,000

XML 17 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	340,000,000	340,000,000
Common stock, shares issued	164,581,922	163,905,342
Common stock, shares outstanding	164,581,922	163,905,342

XML 18 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Collaboration revenue	$ 182,497	$ 129,188
Operating expenses:
Research and development expenses	77,587	44,676
Selling, general and administrative expenses	96,827	83,939
Total operating expenses	174,414	128,615
Income from operations	8,083	573
Other income (expense), net:
Interest expense	(680)	(5,608)
Other, net	(209)	137
Total other income (expense), net	(889)	(5,471)
Income (loss) before income tax (expense) benefit	7,194	(4,898)
Income tax (expense) benefit	(2,378)	1,780
Net income (loss)	$ 4,816	$ (3,118)
Basic net income (loss) per common share	$ 0.03	$ (0.02)
Diluted net income (loss) per common share	$ 0.03	$ (0.02)
Weighted average common shares used in the calculation of basic net income (loss) per common share	164,247	156,637
Weighted average common shares used in the calculation of diluted net income (loss) per common share	168,397	156,637

XML 19 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 4,816	$ (3,118)
Other comprehensive loss:
Unrealized losses on cash flow hedges, net of tax impact of $175 and $-- for the three months ended March 31, 2016 and 2015, respectively	(317)
Other comprehensive loss	(317)
Comprehensive income (loss)	$ 4,499	$ (3,118)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 20 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2016 USD ($)
Statement Of Income And Comprehensive Income [Abstract]
Unrealized losses on cash flow hedges, tax	$ 175

XML 21 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net income (loss)	$ 4,816	$ (3,118)
Adjustments for non-cash operating items:
Stock-based compensation	14,211	13,372
Change in fair value of contingent purchase consideration	5,959	4,000
Depreciation on property and equipment	2,416	1,531
Change in deferred income taxes	2,696	(1,402)
Amortization of debt discount and debt issuance costs	85	3,910
Excess tax benefits from stock-based compensation	(2,490)
Amortization of deferred revenue		(1,411)
Other non-cash items		73
Changes in operating assets and liabilities:
Receivable from collaboration partner	204,965	58,124
Prepaid expenses and other current assets	(6,050)	(520)
Other non-current assets	(1,049)	(1,335)
Accounts payable, accrued expenses and other current liabilities	(26,869)	(17,587)
Interest payable		1,698
Current taxes payable	(32,565)
Other non-current liabilities	(438)	(113)
Net cash provided by operating activities	165,687	57,222
Cash flows from investing activities:
Purchases of property and equipment	(9,328)	(956)
Change in restricted cash		(1,574)
Net cash used in investing activities	(9,328)	(2,530)
Cash flows from financing activities:
Principal repayment of borrowings under Revolving Credit Facility	(75,000)
Proceeds from issuance of common stock under equity incentive and stock purchase plans	7,677	11,502
Excess tax benefits from stock-based compensation	2,490
Reduction of build-to-suit lease obligation	(18)	(227)
Principal repayment of Convertible Notes		(8)
Net cash (used in) provided by financing activities	(64,851)	11,267
Net increase in cash and cash equivalents	91,508	65,959
Cash and cash equivalents at beginning of period	225,853	502,677
Cash and cash equivalents at end of period	317,361	568,636
Non-cash investing and financing activities:
Property and equipment expenditures incurred but not yet paid	$ 964	918
Interest capitalized during construction period for build-to-suit lease transactions		$ 527

XML 22 R8.htm IDEA: XBRL DOCUMENT

Description of Business	3 Months Ended
Description of Business	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	NOTE 1. DESCRIPTION OF BUSINESS Medivation, Inc. (the “Company” or “Medivation”) is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. It has one commercial product, XTANDI® (enzalutamide) capsules, or XTANDI, through the Company’s collaboration with Astellas Pharma, Inc., or Astellas. XTANDI has received marketing approval in the United States, Europe and numerous other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer, or mCRPC, and in Japan for the treatment of patients with castration-resistant prostate cancer, or CRPC. The Company and Astellas are also conducting investigational studies of enzalutamide in prostate cancer, advanced breast cancer, and hepatocellular carcinoma. Under the Company’s collaboration agreement with Astellas, it shares equally with Astellas all profits (losses) related to U.S. net sales of XTANDI. The Company also receives royalties ranging from the low teens to the low twenties as a percentage of ex-U.S. XTANDI net sales. The Company seeks to become a more fully-integrated biopharmaceutical company through the continued commercialization of XTANDI, the acquisition or in-license and development and commercialization of other product opportunities, and through the advancement of its own proprietary research and development programs. The Company expects that its future growth may come from both its internal research efforts, focused in oncology, neurology and other areas, and third-party business development activities, such as its acquisition of all worldwide rights to talazoparib (which is referred to as MDV3800) from BioMarin Pharmaceutical Inc., or BioMarin, in the fourth quarter of 2015 and its license of exclusive worldwide rights to pidilizumab (which is referred to as MDV9300) from CureTech, Ltd., or CureTech, in the fourth quarter of 2014.

XML 23 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of the Company’s financial condition, results of operations and cash flows for the periods presented, have been included. The results of operations for any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2015, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, or the Annual Report, filed with the U.S. Securities and Exchange Commission, or SEC, on February 26, 2016. The consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company operates in one business segment. All tabular disclosures of dollar and share amounts are presented in thousands unless otherwise indicated. All per share amounts are presented at their actual amounts. The number of shares issuable under the Amended and Restated 2004 Equity Incentive Award Plan, or the Medivation Equity Incentive Plan, and the Medivation, Inc. 2013 Employee Stock Purchase Plan, or ESPP, disclosed in Note 10, “Stockholders’ Equity,” are presented at their actual amounts unless otherwise indicated. Amounts presented herein may not calculate or sum precisely due to rounding. (b) Use of Estimates The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that management make estimates and assumptions in certain circumstances that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Although management believes that these estimates are reasonable, actual future results could differ materially from those estimates. In addition, had different estimates and assumptions been used, the unaudited condensed consolidated financial statements could have differed materially from what is presented. Significant estimates and assumptions used by management principally relate to revenue recognition, including reliance on third-party information, estimating the performance periods of the Company’s deliverables under collaboration agreements, and estimating the various deductions from gross sales to calculate net sales of XTANDI. Additionally, significant estimates and assumptions used by management include those related to contingent purchase consideration, intangible assets, goodwill, convertible notes, determining whether the Company is the primary beneficiary of any variable interest entities, leases, taxes, research and development and other accruals, share-based compensation, derivatives and hedging, and the calculation of diluted net income per common share. (c) Significant Accounting Policies Reference is made to Note 2, “Summary of Significant Accounting Policies,” included in the notes to the Company’s audited consolidated financial statements included in its Annual Report. As of the date of the filing of this Quarterly Report on Form 10-Q, or Quarterly Report, there were no significant changes to the significant accounting policies described in the Company’s Annual Report, except for the addition of the Company’s accounting policies with respect to derivative instruments related to its cash flow hedging program, which commenced during the first quarter of 2016 as discussed in Note 4, “Derivative Financial Instruments,” and performance share units. (d) Derivative Financial Instruments The Company uses forward foreign currency exchange contracts to hedge a portion of its gross collaboration revenue exposure from royalties related to the Euro and the Japanese Yen. These derivative instruments are designated as cash flow hedges and are recognized as either assets or liabilities at fair value in the Company’s unaudited condensed consolidated balance sheets. The effective portion of changes in the fair value of these instruments is initially recorded as a component of accumulated other comprehensive income (loss) in stockholders’ equity, and subsequently reclassified into earnings when the underlying exposure is reflected in earnings. Ineffectiveness, if any, is recorded immediately in earnings as other income (expense), net. The Company classifies the cash flows from these instruments in the same category as the cash flows from the hedged items, within net cash provided by operating activities in the unaudited condensed consolidated statement of cash flows. The Company assesses, both at inception and on an ongoing basis, whether its cash flow hedge derivative instruments are highly effective in offsetting the changes in cash flows of the hedged items. At inception and on a quarterly basis, the Company documents and asserts that the critical terms of its derivatives (i.e. notional amounts, currency rate mechanisms, and timing) match the critical terms of the hedged items for the risk being hedged. As such, the Company will assume no ineffectiveness in the hedge relationship because all of the critical terms of the hedge and hedged item are matched. If the Company determines that a forecasted transaction is no longer probable of occurring, hedge accounting will be discontinued for the affected portion of the hedge instrument. If the hedged item becomes probable of not occurring, any related gain or loss on the contract will be recognized immediately in earnings as other income (expense), net. In assessing hedge effectiveness, the Company also considers the risk of counterparty default under the hedge contract. The Company seeks to limit its counterparty credit risk by working only with counterparties that have certain financial credit ratings. The Company does not enter into derivative contracts for speculative or trading purposes. (e) Stock-Based Compensation Performance Share Units In the first quarter of 2016, the Company granted performance share units, or PSUs, to certain officers of the Company pursuant to the terms of the Medivation Equity Incentive Plan. The terms of the PSUs provide for target and maximum numbers of shares eligible to be earned based on the level of achievement of certain pre-determined revenue goals and clinical development milestones. For the PSUs tied to revenue goals, the actual number of shares of common stock that may ultimately be issued upon vest is calculated by multiplying the number of PSUs by a payout percentage ranging from 50% to 150%. For the PSUs tied to clinical development milestones, the actual number of shares of common stock that may ultimately be issued upon vest is calculated by multiplying the number of PSUs by a payout percentage of 100%. The PSUs will vest, if at all, upon certification by the Compensation Committee of the Company’s Board of Directors of the actual achievement of the performance objectives, subject to specified change of control exceptions. Stock-based compensation expense associated with PSUs is based on the fair value of the Company’s common stock on the grant date, which equals the closing market price of the Company’s common stock on the grant date. The Company recognizes compensation expense over the vesting period of the awards that are ultimately expected to vest. (f) New Accounting Pronouncements In March 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-09, “Compensation--Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions. Changes that may impact public companies include changes in the accounting for income taxes, specifically excess tax benefits and tax deficiencies; the classification of excess tax benefits on the statement of cash flows as an operating activity; the option for companies to make an entity-wide accounting policy election to either estimate the number of share-based payment awards that are expected to vest (current GAAP) or account for forfeitures when they occur; and the classification of employee taxes paid when an employer withholds shares for tax withholding purposes as a financing activity on the statement of cash flows. Depending on the specific item to be changed, ASU 2016-09 requires certain changes to be applied either prospectively, retrospectively, or under a modified retrospective transition method to all periods presented. The amended guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period, and early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures. In March 2016, the FASB issued ASU 2016-05, “Derivatives and Hedging (Topic 815): Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships.” ASU 2016-05 clarifies that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument under Topic 815 does not, in and of itself, require dedesignation of that hedging relationship provided that all other hedge accounting criteria continue to be met. The amended guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period, with the option to apply the amended guidance on either a prospective basis or a modified retrospective basis, and early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” ASU 2016-02 includes a lessee accounting model that recognizes two types of leases - finance leases and operating leases. The standard requires that a lessee recognize on the balance sheet a right-to-use asset and a lease liability for all leases with lease terms of more than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as either a finance or operating lease. ASU 2016-02 also requires new qualitative and quantitative disclosures for the amount, timing, and uncertainty of cash flows arising from leases. The amended guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that reporting period, and early adoption is permitted. ASU 2016-02 requires modified retrospective transition, which requires application of the guidance at the beginning of the earliest comparative period presented in the year of adoption; however, for all leases that commenced before the effective date, companies can elect not to reassess certain elements, including their lease classification or whether contracts are or contain embedded leases. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, a comprehensive new revenue recognition standard that will supersede the existing revenue recognition guidance. The new accounting guidance creates a framework by which an entity will allocate the transaction price to separate performance obligations and recognize revenue when (or as) each performance obligation is satisfied. Under the new standard, entities will be required to use judgment and make estimates, including identifying performance obligations in a contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each separate performance obligation and determining when an entity satisfies its performance obligations. The standard allows for either “full retrospective” adoption, meaning that the standard is applied to all of the periods presented with a cumulative catch-up as of the earliest period presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements with a cumulative catch-up as of the current period. In August 2015, the effective date of the new revenue standard was delayed by one year to December 15, 2017 for annual reporting periods beginning after that date. The FASB also agreed to permit early adoption of the standard, but not before the original effective date of December 15, 2016. In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” to clarify ASU 2014-09 implementation guidance on principal versus agent considerations. The Company has not yet selected a transition method and is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.

XML 24 R10.htm IDEA: XBRL DOCUMENT

Collaboration Agreement

3 Months Ended

Mar. 31, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaboration Agreement

NOTE 3. COLLABORATION AGREEMENT

(a) Collaboration Agreement with Astellas

(b) Collaboration Revenue

Collaboration revenue was as follows:

	Three Months Ended March 31,
	2016		2015
Collaboration revenue:
Related to U.S. XTANDI net sales	$	153,793	$	112,010
Related to ex-U.S. XTANDI net sales		28,704		15,767
Related to upfront and milestone payments		—		1,411
Total	$	182,497	$	129,188

The Company is currently involved in litigation with UCLA regarding certain terms of its license agreement and other matters, which are discussed in Note 13, “Commitments and Contingencies.”

Collaboration Revenue Related to U.S. XTANDI Net Sales

Collaboration revenue related to U.S. XTANDI net sales was as follows:

	Three Months Ended March 31,
	2016			2015
U.S. XTANDI net sales (as reported by Astellas)	$	307,586		$	224,020
Shared U.S. development and commercialization costs		(130,583	)		(110,313	)
Pre-tax U.S. profit	$	177,003		$	113,707
Medivation’s share of pre-tax U.S. profit	$	88,501		$	56,853
Reimbursement of Medivation’s share of shared U.S. costs		65,292			55,157
Collaboration revenue related to U.S. XTANDI net sales	$	153,793		$	112,010

Collaboration Revenue Related to Ex-U.S. XTANDI Net Sales

Collaboration Revenue Related to Upfront and Milestone Payments

XML 25 R11.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments

3 Months Ended

Mar. 31, 2016

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

NOTE 4. DERIVATIVE FINANCIAL INSTRUMENTS

The Company receives royalties from Astellas on net sales of XTANDI outside of the United States, which are paid to the Company in U.S. dollars and calculated by converting the respective countries’ XTANDI net sales in local currency to U.S. dollars. Because a significant portion of ex-U.S. sales of XTANDI have been generated in the European Union and in Japan, the royalties received from Astellas related to such sales are dependent on the value of the U.S. dollar versus the Euro and Japanese Yen. The Company also conducts certain R&D activities outside of the United States, with expenses incurred in various currencies, including the Euro and Japanese Yen, and these expenses partially offset the currency exposure related to its collaboration revenue from royalties.

	March 31, 2016
	Asset Derivatives			Liability Derivatives
	Classification	Fair Value		Classification	Fair Value
Derivatives designated as hedges:
Foreign currency exchange contracts	Other current assets		—	Other current liabilities	$	(431	)
Foreign currency exchange contracts	Other non-current assets		—	Other non-current liabilities		(61	)
Total derivatives			—		$	(492	)

The following table summarizes the effect of the Company’s foreign currency exchange contracts on its unaudited condensed consolidated financial statements:

	Three Months Ended March 31, 2016
Derivatives designated as hedges:
Gains (losses) recognized in accumulated OCI (effective portion)	$	(492	)
Gains (losses) reclassified from accumulated OCI into collaboration revenue (effective portion)		—
Gains (losses) recognized in other income (expense), net		—

As of March 31, 2016
Offsetting of Derivative Assets/Liabilities
									Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/Liabilities			Gross Amounts Offset in the Condensed Consolidated Balance Sheet		Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet			Derivative Financial Instruments		Cash Collateral Received/Pledged		Net Amount (Legal Offset)
Derivative assets		—			—		—			—		—		—
Derivative liabilities	$	(492	)		—	$	(492	)		—		—	$	(492	)

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

XML 26 R12.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill

3 Months Ended

Mar. 31, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

NOTE 5. INTANGIBLE ASSETS AND GOODWILL

The following table summarizes the Company’s indefinite-lived intangible assets as of March 31, 2016 and December 31, 2015:

	Carrying
	Amount
Indefinite-lived intangible asset – MDV3800	$	573,299
Indefinite-lived intangible asset – MDV9300		71,000
Total	$	644,299

The carrying amount of goodwill was $18.6 million as of March 31, 2016 and December 31, 2015.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 27 R13.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Common Share

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Net Income (Loss) Per Common Share

NOTE 6. NET INCOME (LOSS) PER COMMON SHARE

In periods where the Company reports a net loss, all common stock equivalents are deemed anti-dilutive such that basic net loss per common share and diluted net loss per common share are equal.

The following table reconciles the numerator and denominator used to calculate diluted net income (loss) per common share:

	Three Months Ended March 31,
	2016		2015
Numerator:
Net income (loss)	$	4,816	$	(3,118	)
Denominator:
Weighted-average common shares, basic		164,247		156,637
Dilutive effect of common stock equivalents		4,150		—
Weighted-average common shares, diluted		168,397		156,637

XML 28 R14.htm IDEA: XBRL DOCUMENT

Build-to-Suit Lease Obligation	3 Months Ended
Build-to-Suit Lease Obligation	Mar. 31, 2016
Leases [Abstract]
Build-to-Suit Lease Obligation	NOTE 7. BUILD-TO-SUIT LEASE OBLIGATION In the fourth quarter of 2013, the Company entered into a property lease for approximately 52,000 square feet of space located in San Francisco, California. In the second quarter of 2015, the Company entered into an amended lease agreement to reduce the amount of leased space at this property to approximately 44,000 square feet. The lease agreement expires in August 2024, and the Company has an option to extend the lease term for up to an additional five years. The Company was deemed, for accounting purposes only, to be the owner of the entire project including the building shell, even though it was not the legal owner. In connection with the Company’s accounting for this transaction, the Company capitalized $14.5 million as a build-to-suit property within property and equipment, net, and recognized a corresponding build-to-suit lease obligation for the same amount. The Company also recognized, as an additional build-to-suit lease property and obligation, structural tenant improvements totaling $3.6 million for amounts paid by the landlord and $3.5 million for capitalized interest during the construction period through 2015. As a result of the amended agreement, the Company surrendered a portion of the property totaling approximately 8,000 square feet to the lessor. Accordingly, the Company derecognized a portion of the build-to-suit asset totaling $3.2 million and a portion of the build-to-suit lease obligation totaling $3.2 million during 2015 related to the portion of the property that was surrendered to the lessor. During the first quarter of 2016, construction on the property was substantially completed and the property was placed in service. As such, the Company evaluated its lease to determine whether it had met the requirements for sale-leaseback accounting, including evaluating whether all risks of ownership have been transferred back to the landlord, as evidenced by a lack of continuing involvement in the leased property. The Company determined that the construction project did not qualify for sale-leaseback accounting and will instead be accounted for as a financing lease, given the Company’s expected continuing involvement after the conclusion of the construction period. As a result, the building asset remains on the Company’s unaudited condensed consolidated balance sheets at its historical cost of $18.4 million and the Company began depreciating the asset over its estimated useful life in the first quarter of 2016. Additionally, the Company is allocating its monthly lease payments between land rent, which is recorded as an operating lease expense, interest expense, and reduction of the related lease obligation. As of March 31, 2016, the total amount of the build-to-suit lease obligation was $17.4 million, of which $17.3 million was classified as a non-current liability on the unaudited condensed consolidated balance sheets. The Company expects to derecognize the build-to-suit lease asset and lease obligation at the end of the lease term. Expected future lease payments under the build-to-suit lease as of March 31, 2016 are included in Note 13, “Commitments and Contingencies.”

XML 29 R15.htm IDEA: XBRL DOCUMENT

Other Balance Sheet Items

3 Months Ended

Mar. 31, 2016

Balance Sheet Related Disclosures [Abstract]

Other Balance sheet Items

NOTE 8. OTHER BALANCE SHEET ITEMS

(a) Property and Equipment, Net

Property and equipment, net, consisted of the following:

	March 31, 2016			December 31, 2015
Leasehold improvements	$	22,615		$	19,074
Build-to-suit property		18,371			18,371
Computer equipment and software		17,300			16,083
Furniture and fixtures		6,014			5,714
Construction in progress		12,806			14,440
Laboratory equipment		1,447			748
		78,553			74,430
Less: Accumulated depreciation		(18,704	)		(16,288	)
Total	$	59,849		$	58,142

(b) Accounts Payable, Accrued Expenses and Other Current Liabilities

Accounts payable, accrued expenses and other current liabilities consisted of the following:

	March 31, 2016		December 31, 2015
Clinical and preclinical	$	45,635	$	48,975
Accounts payable		23,791		22,696
Payroll and payroll-related		15,988		29,215
Royalties payable		21,015		20,665
Accrued professional services and other current liabilities		15,566		14,282
Taxes payable		—		32,565
Other payable to licensor		—		17,500
Interest payable		—		305
Total	$	121,995	$	186,203

XML 30 R16.htm IDEA: XBRL DOCUMENT

Debt	3 Months Ended
Debt	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt	NOTE 9. DEBT (a) Revolving Credit Facility In October 2015, the Company entered into an amendment and restatement of its original credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders from time to time party thereto (the “Lenders”), providing for: (i) a five-year $300 million revolving loan facility (the “Revolving Credit Facility”); and (ii) an uncommitted accordion facility subject to the satisfaction of certain conditions (collectively, the “Senior Secured Credit Facility”). The Revolving Credit Facility includes a $50 million multicurrency sub-facility, a $20 million letter of credit sub-facility and a $10 million swing line loan sub-facility. Loans under the Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR rate, plus an applicable margin ranging from 1.75% to 2.50% per annum, based upon the secured leverage ratio (as defined in the Credit Agreement) or (b) the prime lending rate, plus an applicable margin ranging from 0.75% to 1.50% per annum, based upon the senior secured net leverage ratio (as defined in the Credit Agreement). In October 2015, the Company borrowed $75.0 million under the Revolving Credit Facility, which the Company repaid in January 2016. The interest rate for this borrowing was 2.1250% and was applied on an actual/360 day basis. There were no balances outstanding under the Revolving Credit Facility at March 31, 2016. The obligations under the Credit Agreement and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) thereunder are and will be guaranteed by the Company and each of the Company’s existing and subsequently acquired or organized direct and indirect domestic subsidiaries (other than certain immaterial domestic subsidiaries, certain Domestic Foreign Holding Companies, and certain domestic subsidiaries whose equity interests are owned directly or indirectly by certain foreign subsidiaries) (collectively, the “Loan Parties”). The obligations under the Credit Agreement and any such swap and banking services obligations are secured, subject to customary permitted liens and other agreed upon exceptions, by a perfected security interest in (i) all tangible and intangible assets of the Loan Parties, except for certain customary excluded assets, and (ii) all of the capital stock owned by the Loan Parties thereunder (limited, in the case of the stock of certain non-U.S. subsidiaries of the Company and Domestic Foreign Holding Companies, to 65% of the capital stock of such subsidiaries). The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions. Under the terms of the Credit Agreement, the Company is required to comply with a maximum senior secured net leverage ratio and minimum interest coverage ratio covenants. At March 31, 2016, the Company was in compliance with these covenants. In accordance with ASU 2015-15, the Company deferred $1.7 million of debt issuance costs associated with the Revolving Credit Facility, including underwriting, legal and accounting fees, and is amortizing this amount ratably over the five-year access period of the facility. Amortization of the debt issuance costs is recorded as non-cash interest expense on the unaudited condensed consolidated statements of operations. (b) Convertible Notes Due 2017 In March 2012, the Company issued $258.8 million aggregate principal amount of the Convertible Notes. The Company was required to pay interest semi-annually in arrears on April 1 and October 1 of each year. The Convertible Notes were convertible upon the occurrence of certain conditions into shares of the Company’s common stock. During 2015, the Company settled all of its Convertible Notes. During the second quarter of 2015, the Company settled a total of $91.0 million aggregate principal amount of the Convertible Notes through a combination of $92.1 million in cash and 2,099,358 shares of its common stock. During the third quarter of 2015, the Company settled a total of $167.8 million aggregate principal amount of the Convertible Notes through a combination of $167.8 million in cash and 3,539,218 shares of its common stock. The Company recorded a non-cash loss on extinguishment of the Convertible Notes of $7.9 million and $13.2 million in the second and third quarters of 2015, respectively, which was included in other income (expense), net, on the condensed consolidated statements of operations. Forfeited accrued interest payable totaling $1.7 million was reclassified to additional paid-in capital during 2015. Upon settlement, the Convertible Notes were no longer outstanding, interest ceased to accrue thereon, and all rights of the holders of the Convertible Notes ceased to exist.

XML 31 R17.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

Stockholders' Equity

NOTE 10. STOCKHOLDERS’ EQUITY

(a) Stock Purchase Rights

(b) Medivation Equity Incentive Plan

Performance Share Units

(d) Stock-Based Compensation

Stock-based compensation expense was as follows:

	Three Months Ended March 31,
	2016		2015
Stock-based compensation expense recognized as:
R&D expense	$	6,037	$	5,811
SG&A expense		8,174		7,561
Total	$	14,211	$	13,372

XML 32 R18.htm IDEA: XBRL DOCUMENT

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 11. INCOME TAXES The Company calculates its quarterly income tax provision in accordance with the guidance provided by ASC 740-270, “Interim Income Tax Accounting,” whereby the Company forecasts its estimated annual effective tax rate and then applies that rate to its year-to-date pre-tax book income (loss). Income tax expense for the three months ended March 31, 2016 was $2.4 million. The provision for income taxes was lower than the tax computed at the U.S. federal statutory rate due primarily to the Federal research and development credit, partially offset by state income taxes, non-deductible officers’ compensation and non-deductible stock-based compensation. Income tax benefit for the three months ended March 31, 2015 was $1.8 million. The effective tax rate was 33.1% and 36.3% for the three months ended March 31, 2016 and 2015, respectively. The decrease in the effective tax rate for the three months ended March 31, 2016 as compared to the prior year period was due to the Federal research and development tax credit which was permanently reinstated in the fourth quarter of 2015. For the three months ended March 31, 2016, the Company reduced its current Federal and state taxes payable by $2.5 million related to excess tax benefits from stock-based compensation, increasing additional paid-in capital. The Company records a valuation allowance to reduce deferred tax assets to reflect the net amount that is more likely than not to be realized. Based upon the weight of available evidence at December 31, 2014, the Company determined that it was more likely than not that a portion of its deferred tax assets would be realizable and consequently released the valuation allowance against Federal and certain state net deferred tax assets during the fourth quarter of 2014. The decision to reverse a portion of the valuation allowance was made after management considered all available evidence, both positive and negative, including but not limited to the historical operating results, income or loss in recent periods, cumulative income in recent years, forecasted earnings, forecasted future taxable income, and significant risk and uncertainty related to forecasts. The release of the valuation allowance resulted in the recognition of certain deferred net tax assets and a decrease to income tax expense. The future effective tax rate is subject to volatility and may be materially impacted by various internal and external factors. These factors may include, but are not limited to, the amount of income tax benefits and charges from: interpretations of existing tax laws; changes in tax laws and rates; future levels of research and development expenditures; changes in the mix of earnings in countries with differing statutory tax rates in which the Company may conduct business; changes in the valuation of deferred tax assets and liabilities; state income taxes; the tax impact of stock-based compensation; accounting for uncertain tax positions; closure of statute of limitations or settlement of tax audits; changes in estimates of prior years’ items; tax costs for acquisition-related items; changes in accounting standards; non-deductible officers’ compensation; limitations on the utilization of net operating losses and tax credits due to changes in ownership; and overall levels of income before taxes.

XML 33 R19.htm IDEA: XBRL DOCUMENT

Fair Value Disclosures

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Disclosures

NOTE 12. FAIR VALUE DISCLOSURES

The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis:

			Fair Value Measurements Using:
	Fair Value		Level 1		Level 2		Level 3
March 31, 2016:
Current liabilities:
Foreign currency derivative contracts	$	431		—	$	431		—
Contingent consideration	$	4,924		—		—	$	4,924
Non-current liabilities:
Foreign currency derivative contracts	$	61		—	$	61		—
Contingent consideration	$	268,303		—		—	$	268,303
December 31, 2015:
Current liabilities:
Contingent consideration	$	4,900		—		—	$	4,900
Non-current liabilities:
Contingent consideration	$	262,368		—		—	$	262,368

	Three Months Ended March 31, 2016
Contingent consideration (current and non-current):
Balance at beginning of period	$	267,268
Amounts acquired or issued		—
Net change in fair value		5,959
Settlements		—
Transfers in and/or out of Level 3		—
Balance at end of period	$	273,227

The following table presents the total balance of the Company’s other financial instruments that are not measured at fair value on a recurring basis:

			Fair Value Measurements Using:
	Total Balance		Level 1		Level 2		Level 3
March 31, 2016:
Assets:
Bank deposits (included in “Cash and cash equivalents”)	$	317,361	$	317,361		—		—
December 31, 2015:
Assets:
Bank deposits (included in “Cash and cash equivalents”)	$	225,853	$	225,853		—		—
Liabilities:
Borrowings under Revolving Credit Facility	$	75,000	$	75,000		—		—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 34 R20.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2016

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 13. COMMITMENTS AND CONTINGENCIES

(a) Lease Obligations

Future operating lease obligations as of March 31, 2016 are as follows:

Years Ending December 31,	Operating Leases
Remainder of 2016	$	7,028
2017		9,542
2018		9,743
2019		5,065
2020		—
2021 and thereafter		—
Total minimum lease payments	$	31,378

Expected future lease payments under the build-to-suit lease as of March 31, 2016 are as follows:

Years Ending December 31,	Expected Cash Payments Under Build- To-Suit Lease Obligation
Remainder of 2016	$	1,639
2017		2,244
2018		2,311
2019		2,380
2020		2,452
2021 and thereafter		9,627
Total minimum lease payments	$	20,653

(b) License Agreement with UCLA

Manufacturing Services and Supply Agreements

Contemporaneous with the execution of the License Agreement with CureTech, the Company entered into a Manufacturing Services and Supply Agreement, or MSA, with CureTech pursuant to which CureTech will provide clinical trial supply of MDV9300 over a three-year period. In accordance with the terms of the MSA, as amended, the Company paid CureTech upfront and setup fees of $3.0 million during the fourth quarter of 2014, $0.2 million during the second quarter of 2015 and $0.1 million during the third quarter of 2015. The Company is required to pay CureTech a one-time milestone payment of $5.0 million upon the completion of the Manufacturing Technology Transfer, as defined. In accordance with the terms of the MSA, the Company is also responsible for providing Manufacturing Funding totaling up to $19.3 million for clinical trial materials of MDV9300 over the three-year term of the MSA, of which $9.0 million has been paid through March 31, 2016. The Manufacturing Funding is contingent upon the successful achievement of the requirements set forth in the Manufacturing Plan, and any such amounts may be reduced or eliminated by the Company under the terms of the MSA.

Development and Manufacturing Services Agreement

(d) Litigation

XML 35 R21.htm IDEA: XBRL DOCUMENT

Subsequent Event	3 Months Ended
Subsequent Event	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Event	NOTE 14. SUBSEQUENT EVENT On April 28, 2016, the Company confirmed that it had received an unsolicited, non-binding proposal from Sanofi to acquire all outstanding shares of Medivation common stock for $52.50 in cash, which followed a private letter received by the Company from Sanofi on April 15, 2016. On April 29, 2016, the Company announced that its Board of Directors, after consultation with its financial and legal advisors, unanimously determined that the unsolicited proposal from Sanofi to acquire Medivation for $52.50 per share in cash substantially undervalues Medivation and is not in the best interests of the Company and its stockholders.

XML 36 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	(a) Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of the Company’s financial condition, results of operations and cash flows for the periods presented, have been included. The results of operations for any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2015, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, or the Annual Report, filed with the U.S. Securities and Exchange Commission, or SEC, on February 26, 2016. The consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company operates in one business segment. All tabular disclosures of dollar and share amounts are presented in thousands unless otherwise indicated. All per share amounts are presented at their actual amounts. The number of shares issuable under the Amended and Restated 2004 Equity Incentive Award Plan, or the Medivation Equity Incentive Plan, and the Medivation, Inc. 2013 Employee Stock Purchase Plan, or ESPP, disclosed in Note 10, “Stockholders’ Equity,” are presented at their actual amounts unless otherwise indicated. Amounts presented herein may not calculate or sum precisely due to rounding.
Use of Estimates	(b) Use of Estimates The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that management make estimates and assumptions in certain circumstances that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Although management believes that these estimates are reasonable, actual future results could differ materially from those estimates. In addition, had different estimates and assumptions been used, the unaudited condensed consolidated financial statements could have differed materially from what is presented. Significant estimates and assumptions used by management principally relate to revenue recognition, including reliance on third-party information, estimating the performance periods of the Company’s deliverables under collaboration agreements, and estimating the various deductions from gross sales to calculate net sales of XTANDI. Additionally, significant estimates and assumptions used by management include those related to contingent purchase consideration, intangible assets, goodwill, convertible notes, determining whether the Company is the primary beneficiary of any variable interest entities, leases, taxes, research and development and other accruals, share-based compensation, derivatives and hedging, and the calculation of diluted net income per common share.
Significant Accounting Policies	(c) Significant Accounting Policies Reference is made to Note 2, “Summary of Significant Accounting Policies,” included in the notes to the Company’s audited consolidated financial statements included in its Annual Report. As of the date of the filing of this Quarterly Report on Form 10-Q, or Quarterly Report, there were no significant changes to the significant accounting policies described in the Company’s Annual Report, except for the addition of the Company’s accounting policies with respect to derivative instruments related to its cash flow hedging program, which commenced during the first quarter of 2016 as discussed in Note 4, “Derivative Financial Instruments,” and performance share units.
Derivative Financial Instruments	(d) Derivative Financial Instruments The Company uses forward foreign currency exchange contracts to hedge a portion of its gross collaboration revenue exposure from royalties related to the Euro and the Japanese Yen. These derivative instruments are designated as cash flow hedges and are recognized as either assets or liabilities at fair value in the Company’s unaudited condensed consolidated balance sheets. The effective portion of changes in the fair value of these instruments is initially recorded as a component of accumulated other comprehensive income (loss) in stockholders’ equity, and subsequently reclassified into earnings when the underlying exposure is reflected in earnings. Ineffectiveness, if any, is recorded immediately in earnings as other income (expense), net. The Company classifies the cash flows from these instruments in the same category as the cash flows from the hedged items, within net cash provided by operating activities in the unaudited condensed consolidated statement of cash flows. The Company assesses, both at inception and on an ongoing basis, whether its cash flow hedge derivative instruments are highly effective in offsetting the changes in cash flows of the hedged items. At inception and on a quarterly basis, the Company documents and asserts that the critical terms of its derivatives (i.e. notional amounts, currency rate mechanisms, and timing) match the critical terms of the hedged items for the risk being hedged. As such, the Company will assume no ineffectiveness in the hedge relationship because all of the critical terms of the hedge and hedged item are matched. If the Company determines that a forecasted transaction is no longer probable of occurring, hedge accounting will be discontinued for the affected portion of the hedge instrument. If the hedged item becomes probable of not occurring, any related gain or loss on the contract will be recognized immediately in earnings as other income (expense), net. In assessing hedge effectiveness, the Company also considers the risk of counterparty default under the hedge contract. The Company seeks to limit its counterparty credit risk by working only with counterparties that have certain financial credit ratings. The Company does not enter into derivative contracts for speculative or trading purposes.
Stock-Based Compensation	(e) Stock-Based Compensation Performance Share Units In the first quarter of 2016, the Company granted performance share units, or PSUs, to certain officers of the Company pursuant to the terms of the Medivation Equity Incentive Plan. The terms of the PSUs provide for target and maximum numbers of shares eligible to be earned based on the level of achievement of certain pre-determined revenue goals and clinical development milestones. For the PSUs tied to revenue goals, the actual number of shares of common stock that may ultimately be issued upon vest is calculated by multiplying the number of PSUs by a payout percentage ranging from 50% to 150%. For the PSUs tied to clinical development milestones, the actual number of shares of common stock that may ultimately be issued upon vest is calculated by multiplying the number of PSUs by a payout percentage of 100%. The PSUs will vest, if at all, upon certification by the Compensation Committee of the Company’s Board of Directors of the actual achievement of the performance objectives, subject to specified change of control exceptions. Stock-based compensation expense associated with PSUs is based on the fair value of the Company’s common stock on the grant date, which equals the closing market price of the Company’s common stock on the grant date. The Company recognizes compensation expense over the vesting period of the awards that are ultimately expected to vest.
New Accounting Pronouncements	(f) New Accounting Pronouncements In March 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-09, “Compensation--Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions. Changes that may impact public companies include changes in the accounting for income taxes, specifically excess tax benefits and tax deficiencies; the classification of excess tax benefits on the statement of cash flows as an operating activity; the option for companies to make an entity-wide accounting policy election to either estimate the number of share-based payment awards that are expected to vest (current GAAP) or account for forfeitures when they occur; and the classification of employee taxes paid when an employer withholds shares for tax withholding purposes as a financing activity on the statement of cash flows. Depending on the specific item to be changed, ASU 2016-09 requires certain changes to be applied either prospectively, retrospectively, or under a modified retrospective transition method to all periods presented. The amended guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period, and early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures. In March 2016, the FASB issued ASU 2016-05, “Derivatives and Hedging (Topic 815): Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships.” ASU 2016-05 clarifies that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument under Topic 815 does not, in and of itself, require dedesignation of that hedging relationship provided that all other hedge accounting criteria continue to be met. The amended guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period, with the option to apply the amended guidance on either a prospective basis or a modified retrospective basis, and early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” ASU 2016-02 includes a lessee accounting model that recognizes two types of leases - finance leases and operating leases. The standard requires that a lessee recognize on the balance sheet a right-to-use asset and a lease liability for all leases with lease terms of more than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as either a finance or operating lease. ASU 2016-02 also requires new qualitative and quantitative disclosures for the amount, timing, and uncertainty of cash flows arising from leases. The amended guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that reporting period, and early adoption is permitted. ASU 2016-02 requires modified retrospective transition, which requires application of the guidance at the beginning of the earliest comparative period presented in the year of adoption; however, for all leases that commenced before the effective date, companies can elect not to reassess certain elements, including their lease classification or whether contracts are or contain embedded leases. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, a comprehensive new revenue recognition standard that will supersede the existing revenue recognition guidance. The new accounting guidance creates a framework by which an entity will allocate the transaction price to separate performance obligations and recognize revenue when (or as) each performance obligation is satisfied. Under the new standard, entities will be required to use judgment and make estimates, including identifying performance obligations in a contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each separate performance obligation and determining when an entity satisfies its performance obligations. The standard allows for either “full retrospective” adoption, meaning that the standard is applied to all of the periods presented with a cumulative catch-up as of the earliest period presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements with a cumulative catch-up as of the current period. In August 2015, the effective date of the new revenue standard was delayed by one year to December 15, 2017 for annual reporting periods beginning after that date. The FASB also agreed to permit early adoption of the standard, but not before the original effective date of December 15, 2016. In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” to clarify ASU 2014-09 implementation guidance on principal versus agent considerations. The Company has not yet selected a transition method and is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.
Intangible Assets	Intangible assets consist of in-process research and development, or IPR&D, acquired from business acquisitions. The Company accounts for IPR&D as indefinite-lived intangible assets until regulatory approval or discontinuation of the related R&D efforts. Upon obtaining regulatory approval, the Company reclassifies the IPR&D as a definite-lived intangible asset and determines the economic life for amortization purposes. The Company assesses the impairment of indefinite-lived intangible assets and goodwill on an annual basis or more frequently whenever events or changes in circumstances may indicate that the carrying value might not be recoverable.
Earnings Per Share	The computation of basic net income (loss) per common share is based on the weighted-average number of common shares outstanding during each period. The computation of diluted net income (loss) per common share is based on the weighted-average number of common shares outstanding during the period plus, when their effect is dilutive, incremental shares consisting of shares subject to stock options, restricted stock units, performance share units, stock appreciation rights, ESPP shares, warrants, and shares issuable upon conversion of convertible debt. In periods where the Company reports a net loss, all common stock equivalents are deemed anti-dilutive such that basic net loss per common share and diluted net loss per common share are equal.
Income Taxes	The Company calculates its quarterly income tax provision in accordance with the guidance provided by ASC 740-270, “Interim Income Tax Accounting,” whereby the Company forecasts its estimated annual effective tax rate and then applies that rate to its year-to-date pre-tax book income (loss). Income tax expense for the three months ended March 31, 2016 was $2.4 million. The provision for income taxes was lower than the tax computed at the U.S. federal statutory rate due primarily to the Federal research and development credit, partially offset by state income taxes, non-deductible officers’ compensation and non-deductible stock-based compensation. Income tax benefit for the three months ended March 31, 2015 was $1.8 million. The effective tax rate was 33.1% and 36.3% for the three months ended March 31, 2016 and 2015, respectively. The decrease in the effective tax rate for the three months ended March 31, 2016 as compared to the prior year period was due to the Federal research and development tax credit which was permanently reinstated in the fourth quarter of 2015. For the three months ended March 31, 2016, the Company reduced its current Federal and state taxes payable by $2.5 million related to excess tax benefits from stock-based compensation, increasing additional paid-in capital. The Company records a valuation allowance to reduce deferred tax assets to reflect the net amount that is more likely than not to be realized. Based upon the weight of available evidence at December 31, 2014, the Company determined that it was more likely than not that a portion of its deferred tax assets would be realizable and consequently released the valuation allowance against Federal and certain state net deferred tax assets during the fourth quarter of 2014. The decision to reverse a portion of the valuation allowance was made after management considered all available evidence, both positive and negative, including but not limited to the historical operating results, income or loss in recent periods, cumulative income in recent years, forecasted earnings, forecasted future taxable income, and significant risk and uncertainty related to forecasts. The release of the valuation allowance resulted in the recognition of certain deferred net tax assets and a decrease to income tax expense. The future effective tax rate is subject to volatility and may be materially impacted by various internal and external factors. These factors may include, but are not limited to, the amount of income tax benefits and charges from: interpretations of existing tax laws; changes in tax laws and rates; future levels of research and development expenditures; changes in the mix of earnings in countries with differing statutory tax rates in which the Company may conduct business; changes in the valuation of deferred tax assets and liabilities; state income taxes; the tax impact of stock-based compensation; accounting for uncertain tax positions; closure of statute of limitations or settlement of tax audits; changes in estimates of prior years’ items; tax costs for acquisition-related items; changes in accounting standards; non-deductible officers’ compensation; limitations on the utilization of net operating losses and tax credits due to changes in ownership; and overall levels of income before taxes.
Litigation Policy	The Company is party to legal proceedings, investigations, and claims in the ordinary course of its business, including the matters described below. The Company records accruals for outstanding legal matters when it believes that it is both probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in significant legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. To the extent new information is obtained and the Company’s views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company’s accrued liabilities would be recorded in the period in which such determination is made. In addition, in accordance with the relevant authoritative guidance, for matters for which the likelihood of material loss is at least reasonably possible, the Company provides disclosure of the possible loss or range of loss; however, if a reasonable estimate cannot be made, the Company will provide disclosure to that effect. Gain contingencies, if any, are recorded when they are realized.

XML 37 R23.htm IDEA: XBRL DOCUMENT

Collaboration Agreement (Tables)

3 Months Ended

Mar. 31, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Collaboration Revenue

Collaboration revenue was as follows:

	Three Months Ended March 31,
	2016		2015
Collaboration revenue:
Related to U.S. XTANDI net sales	$	153,793	$	112,010
Related to ex-U.S. XTANDI net sales		28,704		15,767
Related to upfront and milestone payments		—		1,411
Total	$	182,497	$	129,188

Schedule of Collaboration Revenue Related to U.S. XTANDI Net Sales

Collaboration revenue related to U.S. XTANDI net sales was as follows:

	Three Months Ended March 31,
	2016			2015
U.S. XTANDI net sales (as reported by Astellas)	$	307,586		$	224,020
Shared U.S. development and commercialization costs		(130,583	)		(110,313	)
Pre-tax U.S. profit	$	177,003		$	113,707
Medivation’s share of pre-tax U.S. profit	$	88,501		$	56,853
Reimbursement of Medivation’s share of shared U.S. costs		65,292			55,157
Collaboration revenue related to U.S. XTANDI net sales	$	153,793		$	112,010

XML 38 R24.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2016

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Summary of Classification and Fair values of Derivative Instruments on Unaudited Condensed Consolidated Balance Sheet

The following table summarizes the classification and fair values of derivative instruments on the Company’s unaudited condensed consolidated balance sheet:

	March 31, 2016
	Asset Derivatives			Liability Derivatives
	Classification	Fair Value		Classification	Fair Value
Derivatives designated as hedges:
Foreign currency exchange contracts	Other current assets		—	Other current liabilities	$	(431	)
Foreign currency exchange contracts	Other non-current assets		—	Other non-current liabilities		(61	)
Total derivatives			—		$	(492	)

Summary of the Effect of Foreign Currency Exchange Contracts on Unaudited Condensed Consolidated Financial Statements

The following table summarizes the effect of the Company’s foreign currency exchange contracts on its unaudited condensed consolidated financial statements:

	Three Months Ended March 31, 2016
Derivatives designated as hedges:
Gains (losses) recognized in accumulated OCI (effective portion)	$	(492	)
Gains (losses) reclassified from accumulated OCI into collaboration revenue (effective portion)		—
Gains (losses) recognized in other income (expense), net		—

Summary of Potential Effect of Offsetting Derivatives by Type of Financial Instrument on Unaudited Condensed Consolidated Balance Sheets

The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on our unaudited condensed consolidated balance sheet:

As of March 31, 2016
Offsetting of Derivative Assets/Liabilities
									Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/Liabilities			Gross Amounts Offset in the Condensed Consolidated Balance Sheet		Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet			Derivative Financial Instruments		Cash Collateral Received/Pledged		Net Amount (Legal Offset)
Derivative assets		—			—		—			—		—		—
Derivative liabilities	$	(492	)		—	$	(492	)		—		—	$	(492	)

XML 39 R25.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill (Tables)

3 Months Ended

Mar. 31, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Summary of Indefinite-lived Intangible Assets

The following table summarizes the Company’s indefinite-lived intangible assets as of March 31, 2016 and December 31, 2015:

	Carrying
	Amount
Indefinite-lived intangible asset – MDV3800	$	573,299
Indefinite-lived intangible asset – MDV9300		71,000
Total	$	644,299

XML 40 R26.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Common Share (Tables)

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Calculation of Diluted Net Income (Loss) Per Common Share

The following table reconciles the numerator and denominator used to calculate diluted net income (loss) per common share:

	Three Months Ended March 31,
	2016		2015
Numerator:
Net income (loss)	$	4,816	$	(3,118	)
Denominator:
Weighted-average common shares, basic		164,247		156,637
Dilutive effect of common stock equivalents		4,150		—
Weighted-average common shares, diluted		168,397		156,637

XML 41 R27.htm IDEA: XBRL DOCUMENT

Other Balance Sheet Items (Tables)

3 Months Ended

Mar. 31, 2016

Balance Sheet Related Disclosures [Abstract]

Schedule of Property and Equipment, Net

Property and equipment, net, consisted of the following:

	March 31, 2016			December 31, 2015
Leasehold improvements	$	22,615		$	19,074
Build-to-suit property		18,371			18,371
Computer equipment and software		17,300			16,083
Furniture and fixtures		6,014			5,714
Construction in progress		12,806			14,440
Laboratory equipment		1,447			748
		78,553			74,430
Less: Accumulated depreciation		(18,704	)		(16,288	)
Total	$	59,849		$	58,142

Components of Accounts Payable, Accrued Expenses and Other Current Liabilities

Accounts payable, accrued expenses and other current liabilities consisted of the following:

	March 31, 2016		December 31, 2015
Clinical and preclinical	$	45,635	$	48,975
Accounts payable		23,791		22,696
Payroll and payroll-related		15,988		29,215
Royalties payable		21,015		20,665
Accrued professional services and other current liabilities		15,566		14,282
Taxes payable		—		32,565
Other payable to licensor		—		17,500
Interest payable		—		305
Total	$	121,995	$	186,203

XML 42 R28.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

Schedule of Stock-Based Compensation Expense

Stock-based compensation expense was as follows:

	Three Months Ended March 31,
	2016		2015
Stock-based compensation expense recognized as:
R&D expense	$	6,037	$	5,811
SG&A expense		8,174		7,561
Total	$	14,211	$	13,372

XML 43 R29.htm IDEA: XBRL DOCUMENT

Fair Value Disclosures (Tables)

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis:

			Fair Value Measurements Using:
	Fair Value		Level 1		Level 2		Level 3
March 31, 2016:
Current liabilities:
Foreign currency derivative contracts	$	431		—	$	431		—
Contingent consideration	$	4,924		—		—	$	4,924
Non-current liabilities:
Foreign currency derivative contracts	$	61		—	$	61		—
Contingent consideration	$	268,303		—		—	$	268,303
December 31, 2015:
Current liabilities:
Contingent consideration	$	4,900		—		—	$	4,900
Non-current liabilities:
Contingent consideration	$	262,368		—		—	$	262,368

Schedule of Roll-forward of Fair Value of Level 3 Instruments

The following table includes a roll-forward of the fair value of Level 3 financial instruments for the period presented:

	Three Months Ended March 31, 2016
Contingent consideration (current and non-current):
Balance at beginning of period	$	267,268
Amounts acquired or issued		—
Net change in fair value		5,959
Settlements		—
Transfers in and/or out of Level 3		—
Balance at end of period	$	273,227

Fair Value of Other Financial Instruments Not Measured on Recurring Basis

The following table presents the total balance of the Company’s other financial instruments that are not measured at fair value on a recurring basis:

			Fair Value Measurements Using:
	Total Balance		Level 1		Level 2		Level 3
March 31, 2016:
Assets:
Bank deposits (included in “Cash and cash equivalents”)	$	317,361	$	317,361		—		—
December 31, 2015:
Assets:
Bank deposits (included in “Cash and cash equivalents”)	$	225,853	$	225,853		—		—
Liabilities:
Borrowings under Revolving Credit Facility	$	75,000	$	75,000		—		—

XML 44 R30.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2016

Commitments And Contingencies Disclosure [Abstract]

Schedule of Future Operating Lease Obligations

Future operating lease obligations as of March 31, 2016 are as follows:

Years Ending December 31,	Operating Leases
Remainder of 2016	$	7,028
2017		9,542
2018		9,743
2019		5,065
2020		—
2021 and thereafter		—
Total minimum lease payments	$	31,378

Schedule of Future Lease Cash Payments under Build to Suit Lease

Expected future lease payments under the build-to-suit lease as of March 31, 2016 are as follows:

Years Ending December 31,	Expected Cash Payments Under Build- To-Suit Lease Obligation
Remainder of 2016	$	1,639
2017		2,244
2018		2,311
2019		2,380
2020		2,452
2021 and thereafter		9,627
Total minimum lease payments	$	20,653

XML 45 R31.htm IDEA: XBRL DOCUMENT

Description of Business - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016 Product
XTANDI [Member]
Organization And Description Of Business [Line Items]
Number of commercial products	1
Collaborative agreement [Member] \| Astellas Pharma Inc. [Member]
Organization And Description Of Business [Line Items]
Range of percentage rates for royalties received on ex-U.S. net sales, as defined by collaboration agreement	Low teens to the low twenties

XML 46 R32.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016 Segment
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Number of operating business segment	1
Revenue Goals [Member] \| Performance Share Units [Member] \| Minimum [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Payout percentage of PSUs	50.00%
Revenue Goals [Member] \| Performance Share Units [Member] \| Maximum [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Payout percentage of PSUs	150.00%
Clinical Development Milestones [Member] \| Performance Share Units [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Payout percentage of PSUs	100.00%

XML 47 R33.htm IDEA: XBRL DOCUMENT

Collaboration Agreement - Collaboration Agreements with Astellas - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2009
Collaborative agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Co-promotion of sales and medical affairs percentage	50.00%
Astellas Pharma Inc. [Member] \| Up-front cash payment arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable, upfront cash payment		$ 110,000,000
Astellas Pharma Inc. [Member] \| Development milestone payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Eligible to receive milestone payments	$ 335,000,000
Astellas Pharma Inc. [Member] \| Sales milestone payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Eligible to receive milestone payments	$ 320,000,000
Astellas Pharma Inc. [Member] \| Collaborative agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Range of percentage rates for royalties received on ex-U.S. net sales, as defined by collaboration agreement	Low teens to the low twenties
Astellas Pharma Inc. [Member] \| Collaborative agreement [Member] \| Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Beneficial ownership percentage of voting securities	5.00%

XML 48 R34.htm IDEA: XBRL DOCUMENT

Collaboration Agreement - Schedule of Collaboration Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Related to upfront and milestone payments		$ 1,411
Collaboration revenue	$ 182,497	129,188
Collaborative agreement [Member] \| XTANDI [Member] \| U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Related to XTANDI net sales	153,793	112,010
Collaborative agreement [Member] \| XTANDI [Member] \| ex-U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Related to XTANDI net sales	$ 28,704	$ 15,767

XML 49 R35.htm IDEA: XBRL DOCUMENT

Collaboration Agreement - Collaboration Revenue and Collaboration Receivables - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue percentage of U.S. XTANDI net sales	50.00%	50.00%
Amortization of deferred upfront and development milestones		$ 1,411
Astellas Pharma Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development cost-sharing payments	$ 13,300	13,800
Commercialization cost-sharing payments	$ 18,700	20,100
Astellas Pharma Inc. [Member] \| Amortization of deferred upfront and development milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amortization of deferred upfront and development milestones		$ 1,400
Development cost-sharing payments [Member] \| Collaborative agreement [Member] \| Medivation Inc [Member] \| U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of XTANDI development and commercialization costs	50.00%
Development cost-sharing payments [Member] \| Collaborative agreement [Member] \| Medivation Inc [Member] \| ex-U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of XTANDI development and commercialization costs	33.33%
Commercial cost sharing-payments [Member] \| Astellas Pharma Inc. [Member] \| Collaborative agreement [Member] \| U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of XTANDI development and commercialization costs	50.00%
Commercial cost sharing-payments [Member] \| Astellas Pharma Inc. [Member] \| Collaborative agreement [Member] \| ex-U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of XTANDI development and commercialization costs	66.67%

XML 50 R36.htm IDEA: XBRL DOCUMENT

Collaboration Agreement - Schedule of Collaboration Revenue Related to U.S. XTANDI Net Sales (Detail) - U.S. [Member] - XTANDI [Member] - Collaborative agreement [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue related to U.S. XTANDI net sales	$ 153,793	$ 112,010
Astellas Pharma Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
U.S. XTANDI net sales (as reported by Astellas)	307,586	224,020
Shared U.S. development and commercialization costs	(130,583)	(110,313)
Pre-tax U.S. profit	177,003	113,707
Medivation [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Medivation’s share of pre-tax U.S. profit	88,501	56,853
Reimbursement of Medivation’s share of shared U.S. costs	$ 65,292	$ 55,157

XML 51 R37.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016 USD ($) DerivativeContract
Derivatives Fair Value [Line Items]
Gains (losses) recognized in other income (expense) ineffectiveness	$ 0
Foreign currency exchange contracts [Member]
Derivatives Fair Value [Line Items]
Notional amounts	5,400,000
Credit risk derivative liabilities, at fair value	$ 500,000
Number of financial instrument \| DerivativeContract	1
Foreign currency exchange contracts [Member] \| Derivatives designated as hedges [Member]
Derivatives Fair Value [Line Items]
Derivative instrument maturity	have maturity dates of 15 months or less
Foreign currency forward contracts [Member]
Derivatives Fair Value [Line Items]
Number of contract per quarter \| DerivativeContract	8

XML 52 R38.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Summary of Classification and Fair values of Derivative Instruments on Unaudited Condensed Consolidated Balance Sheet (Detail) $ in Thousands	Mar. 31, 2016 USD ($)
Foreign currency exchange contracts [Member]
Derivatives Fair Value [Line Items]
Liability Derivatives, Fair Value	$ (492)
Derivatives designated as hedges [Member]
Derivatives Fair Value [Line Items]
Liability Derivatives, Fair Value	(492)
Derivatives designated as hedges [Member] \| Foreign currency exchange contracts [Member] \| Other current liabilities [Member]
Derivatives Fair Value [Line Items]
Liability Derivatives, Fair Value	(431)
Derivatives designated as hedges [Member] \| Foreign currency exchange contracts [Member] \| Other non-current liabilities [Member]
Derivatives Fair Value [Line Items]
Liability Derivatives, Fair Value	$ (61)

XML 53 R39.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Summary of the Effect of Foreign Currency Exchange Contracts on Condensed Consolidated Financial Statements (Detail)	3 Months Ended
	Mar. 31, 2016 USD ($)
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in other income (expense), net	$ 0
Derivatives designated as hedges [Member] \| Foreign currency exchange contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in accumulated OCI (effective portion)	$ (492,000)

XML 54 R40.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives by Type of Financial Instrument on Unaudited Condensed Consolidated Balance Sheets (Detail) - Foreign currency exchange contracts [Member] $ in Thousands	Mar. 31, 2016 USD ($)
Offsetting Assets And Liabilities [Line Items]
Gross amounts of recognized liabilities, Derivative liabilities	$ (492)
Amounts of assets/liabilities presented in the condensed consolidated balance sheet, Derivative liabilities	(492)
Net amount (legal offset), Derivative liabilities	$ (492)

XML 55 R41.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Summary of Indefinite-lived Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Acquired Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Carrying Amount	$ 644,299	$ 644,299
MDV3800 [Member]
Acquired Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Carrying Amount	573,299	573,299
MDV9300 [Member]
Acquired Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Carrying Amount	$ 71,000	$ 71,000

XML 56 R42.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Carrying amount of goodwill	$ 18,643	$ 18,643

XML 57 R43.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Common Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Earnings Per Share [Abstract]
Dilutive common shares excluded from net loss per common share computations	4.2	22.8

XML 58 R44.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Common Share - Calculation of Diluted Net Income (Loss) Per Common Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Numerator:
Net income (loss)	$ 4,816	$ (3,118)
Denominator:
Weighted-average common shares, basic	164,247	156,637
Dilutive effect of common stock equivalents	4,150
Weighted-average common shares, diluted	168,397	156,637

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 59 R45.htm IDEA: XBRL DOCUMENT

Build-to-Suit Lease Obligation - Additional Information (Detail) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016 USD ($) ft²	Jun. 30, 2015 ft²	Dec. 31, 2015 USD ($) ft²	Dec. 31, 2013 ft²
Build To Suit Lease Obligation [Line Items]
Build to suit lease \| ft²	158,000
Area of property surrendered \| ft²			8,000
Derecognized portion of build-to-suit asset			$ 3,200
Derecognized portion of build-to-suit lease obligation			3,200
Build-to-suit building, historical cost	$ 18,400
Total build-to-suit lease obligation, including current and non-current portions	17,400
Build-to-suit lease obligation, excluding current portion	$ 17,278		17,406
Laboratory Space [Member]
Build To Suit Lease Obligation [Line Items]
Build to suit lease \| ft²		44,000		52,000
Lease expiry period	August 2024
Build to suit lease extension term		5 years
Build-to-suit Lease Property and Equipment [Member]
Build To Suit Lease Obligation [Line Items]
Amounts capitalized under build-to-suit lease transactions			14,500
Tenant Improvements [Member]
Build To Suit Lease Obligation [Line Items]
Amounts capitalized under build-to-suit lease transactions			3,600
Capitalized Interest Cost [Member]
Build To Suit Lease Obligation [Line Items]
Amounts capitalized under build-to-suit lease transactions			$ 3,500

XML 60 R46.htm IDEA: XBRL DOCUMENT

Other Balance Sheet Items - Schedule of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 78,553	$ 74,430
Less: Accumulated depreciation	(18,704)	(16,288)
Total	59,849	58,142
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	22,615	19,074
Build-to-suit property [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	18,371	18,371
Computer equipment and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	17,300	16,083
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	6,014	5,714
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	12,806	14,440
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,447	$ 748

XML 61 R47.htm IDEA: XBRL DOCUMENT

Other Balance Sheet Items - Components of Accounts Payable, Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Clinical and preclinical	$ 45,635	$ 48,975
Accounts payable	23,791	22,696
Payroll and payroll-related	15,988	29,215
Royalties payable	21,015	20,665
Accrued professional services and other current liabilities	15,566	14,282
Taxes payable		32,565
Other payable to licensor		17,500
Interest payable		305
Total	$ 121,995	$ 186,203

XML 62 R48.htm IDEA: XBRL DOCUMENT

Debt - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended				12 Months Ended
Debt - Additional Information (Detail) - USD ($)	Jan. 31, 2016	Oct. 31, 2015	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2015	Mar. 31, 2012
Debt Instrument [Line Items]
Debt instrument term			5 years
Line of credit facility, interest rate description			The interest rate for this borrowing was 2.1250% and was applied on an actual/360 day basis.
Repayment of outstanding credit facility			$ 75,000,000
Debt issuance costs			$ 1,700,000
Principal settlement amount						$ 8,000
Convertible Notes Due 2017 [Member] \| Senior Notes [Member]
Debt Instrument [Line Items]
Convertible Notes, aggregate principal amount								$ 258,800,000
Convertible Notes, payment terms			The Company was required to pay interest semi-annually in arrears on April 1 and October 1 of each year.
Aggregate principal amount of convertible notes settled				$ 167,800,000	$ 91,000,000
Principal settlement amount				$ 167,800,000	$ 92,100,000
Common stock, shares issued on redemption of convertible notes				3,539,218	2,099,358
Non-cash loss on extinguishment of Convertible Notes				$ 13,200,000	$ 7,900,000
Forfeited accrued interest payable reclassified to additional paid-in capital							$ 1,700,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument term		5 years
Line of credit facility, maximum borrowing capacity		$ 300,000,000
Proceeds from borrowings under Revolving Credit Facility		$ 75,000,000
Line of credit facility, interest rate		2.125%
Repayment of outstanding credit facility	$ 75,000,000
Interest rate spread on base rate, description			(a) the LIBOR rate, plus an applicable margin ranging from 1.75% to 2.50% per annum, based upon the secured leverage ratio (as defined in the Credit Agreement) or (b) the prime lending rate, plus an applicable margin ranging from 0.75% to 1.50% per annum, based upon the senior secured net leverage ratio (as defined in the Credit Agreement).
Amount outstanding under Revolving Credit Facility			$ 0
Revolving Credit Facility [Member] \| LIBOR [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Interest rate spread on base rate		1.75%
Revolving Credit Facility [Member] \| LIBOR [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Interest rate spread on base rate		2.50%
Revolving Credit Facility [Member] \| Prime Rate [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Interest rate spread on base rate		0.75%
Revolving Credit Facility [Member] \| Prime Rate [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Interest rate spread on base rate		1.50%
Revolving Credit Facility [Member] \| Multicurrency Sub-facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		$ 50,000,000
Revolving Credit Facility [Member] \| Letter of Credit Sub-Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		20,000,000
Revolving Credit Facility [Member] \| Swing Line Loan Sub-facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		$ 10,000,000
Credit Agreement [Member]
Debt Instrument [Line Items]
Obligations under credit agreement, description			(i) all tangible and intangible assets of the Loan Parties, except for certain customary excluded assets, and (ii) all of the capital stock owned by the Loan Parties thereunder (limited, in the case of the stock of certain non-U.S. subsidiaries of the Company and Domestic Foreign Holding Companies, to 65% of the capital stock of such subsidiaries).
Percentage of capital stock			65.00%

XML 63 R49.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Jun. 16, 2015	Mar. 31, 2015	Dec. 04, 2006
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum percentage before exercise				20.00%
Number of shares available for issuance	5,700,000
Employee share purchase plan, percentage of fair market value of common stock at beginning of offering period	85.00%
Employee share purchase plan, percentage of fair market value of common stock on purchase date	85.00%
Eligible employee contributions	$ 25,000
Shares issued in period	397,536
Performance Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of PSU's granted	129,150
Period after performance is achieved to earn portion of eligible shares under award	1 year
Revenue Goals [Member] \| Performance Share Units [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payout percentage of PSUs	50.00%
Revenue Goals [Member] \| Performance Share Units [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payout percentage of PSUs	150.00%
Clinical Development Milestones [Member] \| Performance Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payout percentage of PSUs	100.00%
Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance		47,700,000	42,300,000
ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance	6,000,000

XML 64 R50.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation	$ 14,211	$ 13,372
R&D expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation	6,037	5,811
SG&A expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation	$ 8,174	$ 7,561

XML 65 R51.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income tax (expense) benefit	$ (2,378)	$ 1,780
Effective tax rate	33.10%	36.30%
Excess tax benefits from stock-based compensation	$ 2,490

XML 66 R52.htm IDEA: XBRL DOCUMENT

Fair Value Disclosures - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, current liabilities	$ 4,924	$ 4,900
Contingent consideration, long-term liabilities	268,303	262,368
Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, current liabilities	4,924	4,900
Contingent consideration, long-term liabilities	268,303	262,368
Other current liabilities [Member] \| Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency derivative contracts	431
Other non-current liabilities [Member] \| Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency derivative contracts	61
Level 2 [Member] \| Other current liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency derivative contracts	431
Level 2 [Member] \| Other non-current liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency derivative contracts	61
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, current liabilities	4,924	4,900
Contingent consideration, long-term liabilities	$ 268,303	$ 262,368

XML 67 R53.htm IDEA: XBRL DOCUMENT

Fair Value Disclosures - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Change in fair value of contingent consideration liability	$ 5,959,000	$ 4,000,000
Fair value of liabilities transferred from Level 1 to Level 2	0
Fair value of liabilities transferred from Level 2 to Level 1	0
Fair value of assets transferred from Level 1 to Level 2	0
Fair value of assets transferred from Level 2 to Level 1	0
MDV3800 [Member] \| Defined Regulatory and Sales-Based Milestones [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business acquisition maximum contingent consideration	160,000,000
MDV3800 [Member] \| R&D expense [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Change in fair value of contingent consideration liability	500,000
MDV3800 [Member] \| SG&A expense [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Change in fair value of contingent consideration liability	2,500,000
MDV9300 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Milestone payment	5,000,000
MDV9300 [Member] \| Development Milestones [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business acquisition maximum contingent consideration	85,000,000
MDV9300 [Member] \| Sales Milestones [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business acquisition maximum contingent consideration	$ 245,000,000
MDV9300 [Member] \| Minimum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Percentage of royalty	5.00%
MDV9300 [Member] \| Maximum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Percentage of royalty	11.00%
MDV9300 [Member] \| R&D expense [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Change in fair value of contingent consideration liability	$ 600,000	1,000,000
MDV9300 [Member] \| SG&A expense [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Change in fair value of contingent consideration liability	$ 2,300,000	$ 3,000,000

XML 68 R54.htm IDEA: XBRL DOCUMENT

Fair Value Disclosures - Schedule of Roll-forward of Fair Value of Level 3 Instruments (Detail) - Level 3 [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2016 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	$ 267,268
Amounts acquired or issued	0
Net change in fair value	5,959
Settlements	0
Transfers in and/or out of Level 3	0
Balance at end of period	$ 273,227

XML 69 R55.htm IDEA: XBRL DOCUMENT

Fair Value Disclosures - Fair Value of Other Financial Instruments Not Measured on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair value, measurements, nonrecurring [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Bank deposits (included in “Cash and cash equivalents”)	$ 317,361	$ 225,853
Fair value, measurements, nonrecurring [Member] \| Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Bank deposits (included in “Cash and cash equivalents”)	$ 317,361	225,853
Revolving Credit Facility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Borrowings under Revolving Credit Facility		75,000
Revolving Credit Facility [Member] \| Fair value, measurements, nonrecurring [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Borrowings under Revolving Credit Facility		75,000
Revolving Credit Facility [Member] \| Fair value, measurements, nonrecurring [Member] \| Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Borrowings under Revolving Credit Facility		$ 75,000

XML 70 R56.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016 USD ($) ft²	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2014 USD ($)
Commitments And Contingencies [Line Items]
Operating lease office space, in square feet \| ft²	158,000
Lease expiry period	2019-12
Total consideration under current statement of work				$ 15,200,000
Partial payment consideration under current statement of work	$ 6,200,000
MDV9300 [Member]
Commitments And Contingencies [Line Items]
Manufacturing services and supply agreement period	3 years
Upfront and setup fees		$ 100,000	$ 200,000	$ 3,000,000
Potential payment upon completion of Manufacturing Technology Transfer	$ 5,000,000
Funding for clinical trial materials	$ 19,300,000
Funding period for clinical materials	3 years
Clinical trial materials amount paid	$ 9,000,000
Development milestone payments [Member]
Commitments And Contingencies [Line Items]
Aggregate milestone payments upon achievement of certain development and regulatory milestone events	$ 2,800,000
Percentage of sublicensing income	10.00%
Royalty percentage on sales	4.00%
Corporate Headquarters [Member]
Commitments And Contingencies [Line Items]
Operating lease office space, in square feet \| ft²	143,000
Optional lease extension term	5 years

XML 71 R57.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Future Operating Lease Obligations (Detail) $ in Thousands	Mar. 31, 2016 USD ($)
Commitments And Contingencies Disclosure [Abstract]
Operating Leases, Remainder of 2016	$ 7,028
Operating Leases, 2017	9,542
Operating Leases, 2018	9,743
Operating Leases, 2019	5,065
Operating Leases, Future Minimum Lease Payments	$ 31,378

XML 72 R58.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Future Lease Cash Payments under the Build to Suit Lease (Detail) $ in Thousands	Mar. 31, 2016 USD ($)
Commitments And Contingencies Disclosure [Abstract]
Build-To-Suit Lease, Remainder of 2016	$ 1,639
Build-To-Suit Lease, 2017	2,244
Build-To-Suit Lease, 2018	2,311
Build-To-Suit Lease, 2019	2,380
Build-To-Suit Lease, 2020	2,452
Build-To-Suit Lease, 2021 and thereafter	9,627
Build-To-Suit Lease, Future Minimum Payments	$ 20,653

XML 73 R59.htm IDEA: XBRL DOCUMENT

Subsequent Event - Additional Information (Detail)	Apr. 28, 2016 $ / shares
Subsequent Event [Member] \| Sanofi [Member]
Subsequent Event [Line Items]
Proposal price of common stock	$ 52.50

EXCEL 74 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 76 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 128 249 1 false 61 0 false 8 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.medivation.com/20160331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.medivation.com/20160331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.medivation.com/20160331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.medivation.com/20160331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.medivation.com/20160331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss Condensed Consolidated Statements of Comprehensive Income (Loss) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) Sheet http://www.medivation.com/20160331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.medivation.com/20160331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 100070 - Disclosure - Description of Business Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureDescriptionOfBusiness Description of Business Notes 8 false false R9.htm 100080 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Collaboration Agreement Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureCollaborationAgreement Collaboration Agreement Notes 10 false false R11.htm 100100 - Disclosure - Derivative Financial Instruments Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureDerivativeFinancialInstruments Derivative Financial Instruments Notes 11 false false R12.htm 100110 - Disclosure - Intangible Assets and Goodwill Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 12 false false R13.htm 100120 - Disclosure - Net Income (Loss) Per Common Share Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureNetIncomeLossPerCommonShare Net Income (Loss) Per Common Share Notes 13 false false R14.htm 100130 - Disclosure - Build-to-Suit Lease Obligation Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureBuildToSuitLeaseObligation Build-to-Suit Lease Obligation Notes 14 false false R15.htm 100140 - Disclosure - Other Balance Sheet Items Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureOtherBalanceSheetItems Other Balance Sheet Items Notes 15 false false R16.htm 100150 - Disclosure - Debt Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureDebt Debt Notes 16 false false R17.htm 100160 - Disclosure - Stockholders' Equity Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 17 false false R18.htm 100170 - Disclosure - Income Taxes Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 100180 - Disclosure - Fair Value Disclosures Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureFairValueDisclosures Fair Value Disclosures Notes 19 false false R20.htm 100190 - Disclosure - Commitments and Contingencies Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 100200 - Disclosure - Subsequent Event Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureSubsequentEvent Subsequent Event Notes 21 false false R22.htm 100210 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.medivation.com/20160331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 100220 - Disclosure - Collaboration Agreement (Tables) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureCollaborationAgreementTables Collaboration Agreement (Tables) Tables http://www.medivation.com/20160331/taxonomy/role/DisclosureCollaborationAgreement 23 false false R24.htm 100230 - Disclosure - Derivative Financial Instruments (Tables) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureDerivativeFinancialInstrumentsTables Derivative Financial Instruments (Tables) Tables http://www.medivation.com/20160331/taxonomy/role/DisclosureDerivativeFinancialInstruments 24 false false R25.htm 100240 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://www.medivation.com/20160331/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill 25 false false R26.htm 100250 - Disclosure - Net Income (Loss) Per Common Share (Tables) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureNetIncomeLossPerCommonShareTables Net Income (Loss) Per Common Share (Tables) Tables http://www.medivation.com/20160331/taxonomy/role/DisclosureNetIncomeLossPerCommonShare 26 false false R27.htm 100260 - Disclosure - Other Balance Sheet Items (Tables) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureOtherBalanceSheetItemsTables Other Balance Sheet Items (Tables) Tables http://www.medivation.com/20160331/taxonomy/role/DisclosureOtherBalanceSheetItems 27 false false R28.htm 100270 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.medivation.com/20160331/taxonomy/role/DisclosureStockholdersEquity 28 false false R29.htm 100280 - Disclosure - Fair Value Disclosures (Tables) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureFairValueDisclosuresTables Fair Value Disclosures (Tables) Tables http://www.medivation.com/20160331/taxonomy/role/DisclosureFairValueDisclosures 29 false false R30.htm 100290 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.medivation.com/20160331/taxonomy/role/DisclosureCommitmentsAndContingencies 30 false false R31.htm 100300 - Disclosure - Description of Business - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail Description of Business - Additional Information (Detail) Details 31 false false R32.htm 100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 32 false false R33.htm 100320 - Disclosure - Collaboration Agreement - Collaboration Agreements with Astellas - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureCollaborationAgreementCollaborationAgreementsWithAstellasAdditionalInformationDetail Collaboration Agreement - Collaboration Agreements with Astellas - Additional Information (Detail) Details 33 false false R34.htm 100330 - Disclosure - Collaboration Agreement - Schedule of Collaboration Revenue (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureCollaborationAgreementScheduleOfCollaborationRevenueDetail Collaboration Agreement - Schedule of Collaboration Revenue (Detail) Details 34 false false R35.htm 100340 - Disclosure - Collaboration Agreement - Collaboration Revenue and Collaboration Receivables - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureCollaborationAgreementCollaborationRevenueAndCollaborationReceivablesAdditionalInformationDetail Collaboration Agreement - Collaboration Revenue and Collaboration Receivables - Additional Information (Detail) Details 35 false false R36.htm 100350 - Disclosure - Collaboration Agreement - Schedule of Collaboration Revenue Related to U.S. XTANDI Net Sales (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureCollaborationAgreementScheduleOfCollaborationRevenueRelatedToUSXTANDINetSalesDetail Collaboration Agreement - Schedule of Collaboration Revenue Related to U.S. XTANDI Net Sales (Detail) Details 36 false false R37.htm 100360 - Disclosure - Derivative Financial Instruments - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureDerivativeFinancialInstrumentsAdditionalInformationDetail Derivative Financial Instruments - Additional Information (Detail) Details 37 false false R38.htm 100370 - Disclosure - Derivative Financial Instruments - Summary of Classification and Fair values of Derivative Instruments on Unaudited Condensed Consolidated Balance Sheet (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureDerivativeFinancialInstrumentsSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsOnUnauditedCondensedConsolidatedBalanceSheetDetail Derivative Financial Instruments - Summary of Classification and Fair values of Derivative Instruments on Unaudited Condensed Consolidated Balance Sheet (Detail) Details 38 false false R39.htm 100380 - Disclosure - Derivative Financial Instruments - Summary of the Effect of Foreign Currency Exchange Contracts on Condensed Consolidated Financial Statements (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureDerivativeFinancialInstrumentsSummaryOfEffectOfForeignCurrencyExchangeContractsOnCondensedConsolidatedFinancialStatementsDetail Derivative Financial Instruments - Summary of the Effect of Foreign Currency Exchange Contracts on Condensed Consolidated Financial Statements (Detail) Details 39 false false R40.htm 100390 - Disclosure - Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives by Type of Financial Instrument on Unaudited Condensed Consolidated Balance Sheets (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureDerivativeFinancialInstrumentsSummaryOfPotentialEffectOfOffsettingDerivativesByTypeOfFinancialInstrumentOnUnauditedCondensedConsolidatedBalanceSheetsDetail Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives by Type of Financial Instrument on Unaudited Condensed Consolidated Balance Sheets (Detail) Details 40 false false R41.htm 100400 - Disclosure - Intangible Assets and Goodwill - Summary of Indefinite-lived Intangible Assets (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillSummaryOfIndefiniteLivedIntangibleAssetsDetail Intangible Assets and Goodwill - Summary of Indefinite-lived Intangible Assets (Detail) Details 41 false false R42.htm 100410 - Disclosure - Intangible Assets and Goodwill - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetail Intangible Assets and Goodwill - Additional Information (Detail) Details 42 false false R43.htm 100420 - Disclosure - Net Income (Loss) Per Common Share - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformationDetail Net Income (Loss) Per Common Share - Additional Information (Detail) Details http://www.medivation.com/20160331/taxonomy/role/DisclosureNetIncomeLossPerCommonShareTables 43 false false R44.htm 100430 - Disclosure - Net Income (Loss) Per Common Share - Calculation of Diluted Net Income (Loss) Per Common Share (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureNetIncomeLossPerCommonShareCalculationOfDilutedNetIncomeLossPerCommonShareDetail Net Income (Loss) Per Common Share - Calculation of Diluted Net Income (Loss) Per Common Share (Detail) Details http://www.medivation.com/20160331/taxonomy/role/DisclosureNetIncomeLossPerCommonShareTables 44 false false R45.htm 100440 - Disclosure - Build-to-Suit Lease Obligation - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureBuildToSuitLeaseObligationAdditionalInformationDetail Build-to-Suit Lease Obligation - Additional Information (Detail) Details 45 false false R46.htm 100450 - Disclosure - Other Balance Sheet Items - Schedule of Property and Equipment, Net (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureOtherBalanceSheetItemsScheduleOfPropertyAndEquipmentNetDetail Other Balance Sheet Items - Schedule of Property and Equipment, Net (Detail) Details 46 false false R47.htm 100460 - Disclosure - Other Balance Sheet Items - Components of Accounts Payable, Accrued Expenses and Other Current Liabilities (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureOtherBalanceSheetItemsComponentsOfAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetail Other Balance Sheet Items - Components of Accounts Payable, Accrued Expenses and Other Current Liabilities (Detail) Details 47 false false R48.htm 100470 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureDebtAdditionalInformationDetail Debt - Additional Information (Detail) Details 48 false false R49.htm 100480 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 49 false false R50.htm 100490 - Disclosure - Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetail Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Detail) Details 50 false false R51.htm 100500 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 51 false false R52.htm 100510 - Disclosure - Fair Value Disclosures - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail Fair Value Disclosures - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Details 52 false false R53.htm 100520 - Disclosure - Fair Value Disclosures - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureFairValueDisclosuresAdditionalInformationDetail Fair Value Disclosures - Additional Information (Detail) Details 53 false false R54.htm 100530 - Disclosure - Fair Value Disclosures - Schedule of Roll-forward of Fair Value of Level 3 Instruments (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureFairValueDisclosuresScheduleOfRollForwardOfFairValueOfLevel3InstrumentsDetail Fair Value Disclosures - Schedule of Roll-forward of Fair Value of Level 3 Instruments (Detail) Details 54 false false R55.htm 100540 - Disclosure - Fair Value Disclosures - Fair Value of Other Financial Instruments Not Measured on Recurring Basis (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureFairValueDisclosuresFairValueOfOtherFinancialInstrumentsNotMeasuredOnRecurringBasisDetail Fair Value Disclosures - Fair Value of Other Financial Instruments Not Measured on Recurring Basis (Detail) Details 55 false false R56.htm 100550 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 56 false false R57.htm 100560 - Disclosure - Commitments and Contingencies - Schedule of Future Operating Lease Obligations (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureOperatingLeaseObligationsDetail Commitments and Contingencies - Schedule of Future Operating Lease Obligations (Detail) Details 57 false false R58.htm 100570 - Disclosure - Commitments and Contingencies - Schedule of Future Lease Cash Payments under the Build to Suit Lease (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureLeaseCashPaymentsUnderBuildToSuitLeaseDetail Commitments and Contingencies - Schedule of Future Lease Cash Payments under the Build to Suit Lease (Detail) Details 58 false false R59.htm 100580 - Disclosure - Subsequent Event - Additional Information (Detail) Sheet http://www.medivation.com/20160331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail Subsequent Event - Additional Information (Detail) Details 59 false false All Reports Book All Reports mdvn-20160331.xml mdvn-20160331.xsd mdvn-20160331_cal.xml mdvn-20160331_def.xml mdvn-20160331_lab.xml mdvn-20160331_pre.xml true true ZIP 80 0001564590-16-018012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-16-018012-xbrl.zip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Ε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end